Antibody drug conjugate targeting trophoblast cell surface glycoprotein antigen 2

By developing anti-Trop-2 antibody drug conjugates and combining cytotoxic drugs, the problem of limited selection of Trop-2 targets in the prior art has been solved, and efficient treatment of a variety of epithelial-derived cancers has been achieved.

CN119074948APending Publication Date: 2024-12-06CHIA TAI TIANQING PHARMA GRP CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410721959.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-06-06
Filing Date
2024-06-05
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

Existing anti-tumor drug conjugates have limited choices for Trop-2 targets, making it difficult to effectively target a variety of epithelial-derived cancers.

Method used

An antibody drug conjugate is developed that contains the coupling of an anti-Trop-2 antibody or an antigen-binding fragment thereof to a cytotoxic drug by specifically binding and releasing a cytotoxic drug to kill tumor cells.

Benefits of technology

It improves the therapeutic effect on a variety of epithelial-derived cancers, provides more target selection, and enhances the killing activity against Trop-2 overexpressing tumors.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119074948A_ABST
    Figure CN119074948A_ABST
Patent Text Reader

Abstract

Belongs to the field of biological medicine, and provides an antibody drug conjugate targeting a trophoblast cell surface glycoprotein antigen 2, which comprises an antibody or an antigen binding fragment thereof, a linker and a cytotoxic drug which are connected with each other. Pharmaceutical compositions comprising the antibody drug conjugates and uses thereof are also provided. The antibody drug conjugate provided by the invention realizes excellent anti-tumor activity or / and relatively good safety. The provided antibody drug conjugate can be used for tumor treatment.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present disclosure belongs to the field of biomedicine and relates to an antibody-drug conjugate targeting trophoblast cell surface glycoprotein antigen 2, which comprises a connected antibody or antigen-binding fragment thereof, a linker and a cytotoxic drug. The present disclosure also relates to the use of the antibody-drug conjugate in the preparation of a drug for treating tumors. Background Art

[0002] Trop-2 stands for trophoblast cell surface glycoprotein antigen 2, also known as tumor-associated calcium signal transducer 2 (TACSTD2), epidermal glycoprotein 1 (EGP-1), gastrointestinal tumor-associated antigen (GA733-1), and surface marker 1 (M1S1). It is a transmembrane cell surface glycoprotein encoded and expressed by the Tacstd2 gene in the chromosome 1p32 region. It belongs to the GA733 protein family and has a high structural sequence similarity with the epithelial cell adhesion molecule (EpCAM, also known as Trop-1, TACSTD1), with a homology of 49%.

[0003] The human Trop-2 protein has a molecular weight of about 36 kD and includes a hydrophilic signal peptide (amino acids at positions 1-26), an extracellular domain (amino acids at positions 27-274), a cell transmembrane domain (amino acids at positions 275-297) and an intracellular domain (amino acids at positions 298-323). The extracellular domain is generally considered to be related to the proliferation, infiltration and metastasis of cancer cells.

[0004] Trop-2 transmits calcium signals in tumor cells, and because the serine residue at position 303 in Trop-2 cells is 2+ The phosphorylation of PKC and the intracellular domain of PKC have a PIP2 binding sequence, indicating that it has a signal transduction function in tumor cells.

[0005] It has been reported that human Trop-2 is overexpressed in a variety of epithelial cancers, including gastric cancer, lung cancer, colorectal cancer, ovarian cancer, breast cancer, and prostate cancer. In contrast, its expression in normal tissues is limited to cells in the epithelial area, and the expression level is also lower than that in tumor cells. This indicates that it is related to tumor formation. Therefore, the research on anti-tumor drugs targeting Trop-2 is of great significance.

[0006] Antibody-Drug Conjugate (ADC) is a class of drugs that combines the high specificity of therapeutic antibodies and the high killing activity of cytotoxic drugs, in which the therapeutic antibody part and the cytotoxic drug part are connected by an intermediate linker part. For the Trop-2 target, there have been reports on the development of antibody-drug conjugates for anti-tumor research, but they are limited, and more available options are still needed. Summary of the invention

[0007] Antibody Drug Conjugates (ADC)

[0008] The present disclosure provides an antibody-drug conjugate, which comprises an anti-Trop-2 antibody or an antigen-binding fragment thereof and a cytotoxic drug, wherein the anti-Trop-2 antibody or the antigen-binding fragment thereof is conjugated to the cytotoxic drug.

[0009] The present disclosure provides an antibody-drug conjugate, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a solvate of the antibody-drug conjugate, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, which comprises an anti-Trop-2 antibody or an antigen-binding fragment thereof.

[0010] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof can specifically bind to Trop-2.

[0011] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof binds to human Trop-2. In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof binds to monkey Trop-2.

[0012] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof is a murine antibody, a chimeric antibody, a humanized antibody or a human antibody. In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof is a monoclonal antibody, a monospecific antibody, a multispecific antibody, a Fab fragment, a F(ab')2 fragment, a Fd fragment, a Fv fragment, a dAb, a single-chain Fv (scFv) molecule, a single-chain Fab (scFab) or a nanobody.

[0013] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof comprises: a heavy chain CDR (HCDR) 1 comprising the amino acid sequence of SEQ ID NO: 17, 5, 11 or 48, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 18, 6, 12, 31, 32, 49 or 62, a HCDR3 comprising the amino acid sequence of SEQ ID NO: 19, 7 or 13, a light chain CDR (LCDR) 1 comprising the amino acid sequence of SEQ ID NO: 20, 8, 14 or 33, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 21, 9, 15 or 34, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 22, 10, 16 or 35.

[0014] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof comprises: a HCDR1 comprising the amino acid sequence shown in SEQ ID NO:5, a HCDR2 comprising the amino acid sequence shown in SEQ ID NO:6, a HCDR3 comprising the amino acid sequence shown in SEQ ID NO:7, a LCDR1 comprising the amino acid sequence shown in SEQ ID NO:8, a LCDR2 comprising the amino acid sequence shown in SEQ ID NO:9, and a LCDR3 comprising the amino acid sequence shown in SEQ ID NO:10.

[0015] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof comprises: a HCDR1 comprising the amino acid sequence shown in SEQ ID NO:5, a HCDR2 comprising the amino acid sequence shown in SEQ ID NO:31, a HCDR3 comprising the amino acid sequence shown in SEQ ID NO:7, a LCDR1 comprising the amino acid sequence shown in SEQ ID NO:8, a LCDR2 comprising the amino acid sequence shown in SEQ ID NO:34, and a LCDR3 comprising the amino acid sequence shown in SEQ ID NO:10.

[0016] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof comprises: a HCDR1 comprising the amino acid sequence of SEQ ID NO:5, a HCDR2 comprising the amino acid sequence of SEQ ID NO:32, a HCDR3 comprising the amino acid sequence of SEQ ID NO:7, a LCDR1 comprising the amino acid sequence of SEQ ID NO:8, a LCDR2 comprising the amino acid sequence of SEQ ID NO:34, and a LCDR3 comprising the amino acid sequence of SEQ ID NO:10.

[0017] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof comprises: a HCDR1 comprising the amino acid sequence shown in SEQ ID NO:5, a HCDR2 comprising the amino acid sequence shown in SEQ ID NO:31, a HCDR3 comprising the amino acid sequence shown in SEQ ID NO:7, a LCDR1 comprising the amino acid sequence shown in SEQ ID NO:33, a LCDR2 comprising the amino acid sequence shown in SEQ ID NO:34, and a LCDR3 comprising the amino acid sequence shown in SEQ ID NO:35.

[0018] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof comprises: a HCDR1 comprising the amino acid sequence of SEQ ID NO:5, a HCDR2 comprising the amino acid sequence of SEQ ID NO:32, a HCDR3 comprising the amino acid sequence of SEQ ID NO:7, a LCDR1 comprising the amino acid sequence of SEQ ID NO:33, a LCDR2 comprising the amino acid sequence of SEQ ID NO:34, and a LCDR3 comprising the amino acid sequence of SEQ ID NO:35.

[0019] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof comprises: a HCDR1 comprising the amino acid sequence shown in SEQ ID NO:11, a HCDR2 comprising the amino acid sequence shown in SEQ ID NO:12, a HCDR3 comprising the amino acid sequence shown in SEQ ID NO:13, a LCDR1 comprising the amino acid sequence shown in SEQ ID NO:14, a LCDR2 comprising the amino acid sequence shown in SEQ ID NO:15, and a LCDR3 comprising the amino acid sequence shown in SEQ ID NO:16.

[0020] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof comprises: a HCDR1 comprising the amino acid sequence of SEQ ID NO:48, a HCDR2 comprising the amino acid sequence of SEQ ID NO:49, a HCDR3 comprising the amino acid sequence of SEQ ID NO:13, a LCDR1 comprising the amino acid sequence of SEQ ID NO:14, a LCDR2 comprising the amino acid sequence of SEQ ID NO:15, and a LCDR3 comprising the amino acid sequence of SEQ ID NO:16.

[0021] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof comprises: a HCDR1 comprising the amino acid sequence shown in SEQ ID NO:48, a HCDR2 comprising the amino acid sequence shown in SEQ ID NO:12, a HCDR3 comprising the amino acid sequence shown in SEQ ID NO:13, a LCDR1 comprising the amino acid sequence shown in SEQ ID NO:14, a LCDR2 comprising the amino acid sequence shown in SEQ ID NO:15, and a LCDR3 comprising the amino acid sequence shown in SEQ ID NO:16.

[0022] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof comprises: a HCDR1 comprising the amino acid sequence shown in SEQ ID NO:17, a HCDR2 comprising the amino acid sequence shown in SEQ ID NO:18, a HCDR3 comprising the amino acid sequence shown in SEQ ID NO:19, a LCDR1 comprising the amino acid sequence shown in SEQ ID NO:20, a LCDR2 comprising the amino acid sequence shown in SEQ ID NO:21, and a LCDR3 comprising the amino acid sequence shown in SEQ ID NO:22.

[0023] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof comprises: a HCDR1 comprising the amino acid sequence of SEQ ID NO:17, a HCDR2 comprising the amino acid sequence of SEQ ID NO:62, a HCDR3 comprising the amino acid sequence of SEQ ID NO:19, a LCDR1 comprising the amino acid sequence of SEQ ID NO:20, a LCDR2 comprising the amino acid sequence of SEQ ID NO:21, and a LCDR3 comprising the amino acid sequence of SEQ ID NO:22.

[0024] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof comprises: HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with an amino acid sequence as shown in SEQ ID NO: 27, 63, 64, 65, 23, 25, 36, 37, 38, 39, 50, 51, 52 or 53, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with an amino acid sequence as shown in SEQ ID NO: 28, 66, 67, 24, 26, 40, 41, 54 or 55.

[0025] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof comprises: HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with an amino acid sequence as shown in SEQ ID NO:23, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with an amino acid sequence as shown in SEQ ID NO:24.

[0026] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof comprises: HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with an amino acid sequence as shown in SEQ ID NO:25, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with an amino acid sequence as shown in SEQ ID NO:26.

[0027] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof comprises: HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with an amino acid sequence as shown in SEQ ID NO:27, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with an amino acid sequence as shown in SEQ ID NO:28.

[0028] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof comprises: HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with an amino acid sequence as shown in SEQ ID NO:36, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with an amino acid sequence as shown in SEQ ID NO:40.

[0029] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof comprises: HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with an amino acid sequence as shown in SEQ ID NO:37, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with an amino acid sequence as shown in SEQ ID NO:40.

[0030] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof comprises: HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with an amino acid sequence as shown in SEQ ID NO:38, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with an amino acid sequence as shown in SEQ ID NO:40.

[0031] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof comprises: HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with an amino acid sequence as shown in SEQ ID NO:39, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with an amino acid sequence as shown in SEQ ID NO:40.

[0032] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof comprises: HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with an amino acid sequence as shown in SEQ ID NO:36, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with an amino acid sequence as shown in SEQ ID NO:41.

[0033] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof comprises: HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with an amino acid sequence as shown in SEQ ID NO:37, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with an amino acid sequence as shown in SEQ ID NO:41.

[0034] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof comprises: HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with an amino acid sequence as shown in SEQ ID NO:38, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with an amino acid sequence as shown in SEQ ID NO:41.

[0035] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof comprises: HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with an amino acid sequence as shown in SEQ ID NO:39, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with an amino acid sequence as shown in SEQ ID NO:41.

[0036] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof comprises: HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with an amino acid sequence as shown in SEQ ID NO:50, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with an amino acid sequence as shown in SEQ ID NO:54.

[0037] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof comprises: HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with an amino acid sequence as shown in SEQ ID NO:51, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with an amino acid sequence as shown in SEQ ID NO:54.

[0038] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof comprises: HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with an amino acid sequence as shown in SEQ ID NO:52, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with an amino acid sequence as shown in SEQ ID NO:54.

[0039] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof comprises: HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with an amino acid sequence as shown in SEQ ID NO:53, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with an amino acid sequence as shown in SEQ ID NO:54.

[0040] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof comprises: HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with an amino acid sequence as shown in SEQ ID NO:50, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with an amino acid sequence as shown in SEQ ID NO:55.

[0041] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof comprises: HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with an amino acid sequence as shown in SEQ ID NO:51, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with an amino acid sequence as shown in SEQ ID NO:55.

[0042] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof comprises: HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with an amino acid sequence as shown in SEQ ID NO:52, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with an amino acid sequence as shown in SEQ ID NO:55.

[0043] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof comprises: HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with an amino acid sequence as shown in SEQ ID NO:53, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with an amino acid sequence as shown in SEQ ID NO:55.

[0044] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof comprises: HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with an amino acid sequence as shown in SEQ ID NO:63, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with an amino acid sequence as shown in SEQ ID NO:66.

[0045] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof comprises: HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with an amino acid sequence as shown in SEQ ID NO:64, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with an amino acid sequence as shown in SEQ ID NO:66.

[0046] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof comprises: HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with an amino acid sequence as shown in SEQ ID NO:65, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with an amino acid sequence as shown in SEQ ID NO:66.

[0047] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof comprises: HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with an amino acid sequence as shown in SEQ ID NO:63, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with an amino acid sequence as shown in SEQ ID NO:67.

[0048] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof comprises: HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with an amino acid sequence as shown in SEQ ID NO:64, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with an amino acid sequence as shown in SEQ ID NO:67.

[0049] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof comprises: HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with an amino acid sequence as shown in SEQ ID NO:65, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with an amino acid sequence as shown in SEQ ID NO:67.

[0050] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 23, 25, 27, 36, 37, 38, 39, 50, 51, 52, 53, 63, 64 or 65, and an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: The amino acid sequences shown in NO:24, 26, 28, 40, 41, 54, 55, 66 or 67 have a light chain variable region that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical.

[0051] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:23, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:24. Further, in some such embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof further comprises: a HCDR1 comprising the amino acid sequence shown in SEQ ID NO:5, a HCDR2 comprising the amino acid sequence shown in SEQ ID NO:6, a HCDR3 comprising the amino acid sequence shown in SEQ ID NO:7, a LCDR1 comprising the amino acid sequence shown in SEQ ID NO:8, a LCDR2 comprising the amino acid sequence shown in SEQ ID NO:9, and a LCDR3 comprising the amino acid sequence shown in SEQ ID NO:10.

[0052] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:25, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:26. Further, in some such embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof further comprises: a HCDR1 comprising the amino acid sequence shown in SEQ ID NO:11, a HCDR2 comprising the amino acid sequence shown in SEQ ID NO:12, a HCDR3 comprising the amino acid sequence shown in SEQ ID NO:13, a LCDR1 comprising the amino acid sequence shown in SEQ ID NO:14, a LCDR2 comprising the amino acid sequence shown in SEQ ID NO:15, and a LCDR3 comprising the amino acid sequence shown in SEQ ID NO:16.

[0053] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:27, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:28. Further, in some such embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof further comprises: a HCDR1 comprising the amino acid sequence shown in SEQ ID NO:17, a HCDR2 comprising the amino acid sequence shown in SEQ ID NO:18, a HCDR3 comprising the amino acid sequence shown in SEQ ID NO:19, a LCDR1 comprising the amino acid sequence shown in SEQ ID NO:20, a LCDR2 comprising the amino acid sequence shown in SEQ ID NO:21, and a LCDR3 comprising the amino acid sequence shown in SEQ ID NO:22.

[0054] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:36, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:40. Further, in some such embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof further comprises: a HCDR1 comprising the amino acid sequence shown in SEQ ID NO:5, a HCDR2 comprising the amino acid sequence shown in SEQ ID NO:31, a HCDR3 comprising the amino acid sequence shown in SEQ ID NO:7, a LCDR1 comprising the amino acid sequence shown in SEQ ID NO:8, a LCDR2 comprising the amino acid sequence shown in SEQ ID NO:34, and a LCDR3 comprising the amino acid sequence shown in SEQ ID NO:10.

[0055] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:37, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:40. Further, in some such embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof further comprises: a HCDR1 comprising the amino acid sequence shown in SEQ ID NO:5, a HCDR2 comprising the amino acid sequence shown in SEQ ID NO:32, a HCDR3 comprising the amino acid sequence shown in SEQ ID NO:7, a LCDR1 comprising the amino acid sequence shown in SEQ ID NO:8, a LCDR2 comprising the amino acid sequence shown in SEQ ID NO:34, and a LCDR3 comprising the amino acid sequence shown in SEQ ID NO:10.

[0056] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:38, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:40. Further, in some such embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof further comprises: a HCDR1 comprising the amino acid sequence shown in SEQ ID NO:5, a HCDR2 comprising the amino acid sequence shown in SEQ ID NO:31, a HCDR3 comprising the amino acid sequence shown in SEQ ID NO:7, a LCDR1 comprising the amino acid sequence shown in SEQ ID NO:8, a LCDR2 comprising the amino acid sequence shown in SEQ ID NO:34, and a LCDR3 comprising the amino acid sequence shown in SEQ ID NO:10.

[0057] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:39, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:40. Further, in some such embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof further comprises: a HCDR1 comprising the amino acid sequence shown in SEQ ID NO:5, a HCDR2 comprising the amino acid sequence shown in SEQ ID NO:31, a HCDR3 comprising the amino acid sequence shown in SEQ ID NO:7, a LCDR1 comprising the amino acid sequence shown in SEQ ID NO:8, a LCDR2 comprising the amino acid sequence shown in SEQ ID NO:34, and a LCDR3 comprising the amino acid sequence shown in SEQ ID NO:10.

[0058] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:36, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:41. Further, in some such embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof further comprises: a HCDR1 comprising the amino acid sequence shown in SEQ ID NO:5, a HCDR2 comprising the amino acid sequence shown in SEQ ID NO:31, a HCDR3 comprising the amino acid sequence shown in SEQ ID NO:7, a LCDR1 comprising the amino acid sequence shown in SEQ ID NO:33, a LCDR2 comprising the amino acid sequence shown in SEQ ID NO:34, and a LCDR3 comprising the amino acid sequence shown in SEQ ID NO:35.

[0059] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:37, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:41. Further, in some such embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof further comprises: a HCDR1 comprising the amino acid sequence shown in SEQ ID NO:5, a HCDR2 comprising the amino acid sequence shown in SEQ ID NO:32, a HCDR3 comprising the amino acid sequence shown in SEQ ID NO:7, a LCDR1 comprising the amino acid sequence shown in SEQ ID NO:33, a LCDR2 comprising the amino acid sequence shown in SEQ ID NO:34, and a LCDR3 comprising the amino acid sequence shown in SEQ ID NO:35.

[0060] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:38, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:41. Further, in some such embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof further comprises: a HCDR1 comprising the amino acid sequence shown in SEQ ID NO:5, a HCDR2 comprising the amino acid sequence shown in SEQ ID NO:31, a HCDR3 comprising the amino acid sequence shown in SEQ ID NO:7, a LCDR1 comprising the amino acid sequence shown in SEQ ID NO:33, a LCDR2 comprising the amino acid sequence shown in SEQ ID NO:34, and a LCDR3 comprising the amino acid sequence shown in SEQ ID NO:35.

[0061] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:39, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:41. Further, in some such embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof further comprises: a HCDR1 comprising the amino acid sequence shown in SEQ ID NO:5, a HCDR2 comprising the amino acid sequence shown in SEQ ID NO:31, a HCDR3 comprising the amino acid sequence shown in SEQ ID NO:7, a LCDR1 comprising the amino acid sequence shown in SEQ ID NO:33, a LCDR2 comprising the amino acid sequence shown in SEQ ID NO:34, and a LCDR3 comprising the amino acid sequence shown in SEQ ID NO:35.

[0062] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:50, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:54. Further, in some such embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof further comprises: a HCDR1 comprising the amino acid sequence shown in SEQ ID NO:48, a HCDR2 comprising the amino acid sequence shown in SEQ ID NO:49, a HCDR3 comprising the amino acid sequence shown in SEQ ID NO:13, a LCDR1 comprising the amino acid sequence shown in SEQ ID NO:14, a LCDR2 comprising the amino acid sequence shown in SEQ ID NO:15, and a LCDR3 comprising the amino acid sequence shown in SEQ ID NO:16.

[0063] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:51, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:54. Further, in some such embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof further comprises: a HCDR1 comprising the amino acid sequence shown in SEQ ID NO:48, a HCDR2 comprising the amino acid sequence shown in SEQ ID NO:12, a HCDR3 comprising the amino acid sequence shown in SEQ ID NO:13, a LCDR1 comprising the amino acid sequence shown in SEQ ID NO:14, a LCDR2 comprising the amino acid sequence shown in SEQ ID NO:15, and a LCDR3 comprising the amino acid sequence shown in SEQ ID NO:16.

[0064] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:52, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:54. Further, in some such embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof further comprises: a HCDR1 comprising the amino acid sequence shown in SEQ ID NO:48, a HCDR2 comprising the amino acid sequence shown in SEQ ID NO:49, a HCDR3 comprising the amino acid sequence shown in SEQ ID NO:13, a LCDR1 comprising the amino acid sequence shown in SEQ ID NO:14, a LCDR2 comprising the amino acid sequence shown in SEQ ID NO:15, and a LCDR3 comprising the amino acid sequence shown in SEQ ID NO:16.

[0065] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:53, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:54. Further, in some such embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof further comprises: a HCDR1 comprising the amino acid sequence shown in SEQ ID NO:48, a HCDR2 comprising the amino acid sequence shown in SEQ ID NO:12, a HCDR3 comprising the amino acid sequence shown in SEQ ID NO:13, a LCDR1 comprising the amino acid sequence shown in SEQ ID NO:14, a LCDR2 comprising the amino acid sequence shown in SEQ ID NO:15, and a LCDR3 comprising the amino acid sequence shown in SEQ ID NO:16.

[0066] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:50, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:55. Further, in some such embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof further comprises: a HCDR1 comprising the amino acid sequence shown in SEQ ID NO:48, a HCDR2 comprising the amino acid sequence shown in SEQ ID NO:49, a HCDR3 comprising the amino acid sequence shown in SEQ ID NO:13, a LCDR1 comprising the amino acid sequence shown in SEQ ID NO:14, a LCDR2 comprising the amino acid sequence shown in SEQ ID NO:15, and a LCDR3 comprising the amino acid sequence shown in SEQ ID NO:16.

[0067] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:51, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:55. Further, in some such embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof further comprises: a HCDR1 comprising the amino acid sequence shown in SEQ ID NO:48, a HCDR2 comprising the amino acid sequence shown in SEQ ID NO:12, a HCDR3 comprising the amino acid sequence shown in SEQ ID NO:13, a LCDR1 comprising the amino acid sequence shown in SEQ ID NO:14, a LCDR2 comprising the amino acid sequence shown in SEQ ID NO:15, and a LCDR3 comprising the amino acid sequence shown in SEQ ID NO:16.

[0068] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:52, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:55. Further, in some such embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof further comprises: a HCDR1 comprising the amino acid sequence shown in SEQ ID NO:48, a HCDR2 comprising the amino acid sequence shown in SEQ ID NO:49, a HCDR3 comprising the amino acid sequence shown in SEQ ID NO:13, a LCDR1 comprising the amino acid sequence shown in SEQ ID NO:14, a LCDR2 comprising the amino acid sequence shown in SEQ ID NO:15, and a LCDR3 comprising the amino acid sequence shown in SEQ ID NO:16.

[0069] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:53, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:55. Further, in some such embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof further comprises: a HCDR1 comprising the amino acid sequence shown in SEQ ID NO:48, a HCDR2 comprising the amino acid sequence shown in SEQ ID NO:12, a HCDR3 comprising the amino acid sequence shown in SEQ ID NO:13, a LCDR1 comprising the amino acid sequence shown in SEQ ID NO:14, a LCDR2 comprising the amino acid sequence shown in SEQ ID NO:15, and a LCDR3 comprising the amino acid sequence shown in SEQ ID NO:16.

[0070] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:63, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:66. Further, in some such embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof further comprises: a HCDR1 comprising the amino acid sequence shown in SEQ ID NO:17, a HCDR2 comprising the amino acid sequence shown in SEQ ID NO:62, a HCDR3 comprising the amino acid sequence shown in SEQ ID NO:19, a LCDR1 comprising the amino acid sequence shown in SEQ ID NO:20, a LCDR2 comprising the amino acid sequence shown in SEQ ID NO:21, and a LCDR3 comprising the amino acid sequence shown in SEQ ID NO:22.

[0071] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:64, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:66. Further, in some such embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof further comprises: a HCDR1 comprising the amino acid sequence shown in SEQ ID NO:17, a HCDR2 comprising the amino acid sequence shown in SEQ ID NO:18, a HCDR3 comprising the amino acid sequence shown in SEQ ID NO:19, a LCDR1 comprising the amino acid sequence shown in SEQ ID NO:20, a LCDR2 comprising the amino acid sequence shown in SEQ ID NO:21, and a LCDR3 comprising the amino acid sequence shown in SEQ ID NO:22.

[0072] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:65, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:66. Further, in some such embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof further comprises: a HCDR1 comprising the amino acid sequence shown in SEQ ID NO:17, a HCDR2 comprising the amino acid sequence shown in SEQ ID NO:18, a HCDR3 comprising the amino acid sequence shown in SEQ ID NO:19, a LCDR1 comprising the amino acid sequence shown in SEQ ID NO:20, a LCDR2 comprising the amino acid sequence shown in SEQ ID NO:21, and a LCDR3 comprising the amino acid sequence shown in SEQ ID NO:22.

[0073] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:63, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:67. Further, in some such embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof further comprises: a HCDR1 comprising the amino acid sequence shown in SEQ ID NO:17, a HCDR2 comprising the amino acid sequence shown in SEQ ID NO:62, a HCDR3 comprising the amino acid sequence shown in SEQ ID NO:19, a LCDR1 comprising the amino acid sequence shown in SEQ ID NO:20, a LCDR2 comprising the amino acid sequence shown in SEQ ID NO:21, and a LCDR3 comprising the amino acid sequence shown in SEQ ID NO:22.

[0074] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:64, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:67. Further, in some such embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof further comprises: a HCDR1 comprising the amino acid sequence shown in SEQ ID NO:17, a HCDR2 comprising the amino acid sequence shown in SEQ ID NO:18, a HCDR3 comprising the amino acid sequence shown in SEQ ID NO:19, a LCDR1 comprising the amino acid sequence shown in SEQ ID NO:20, a LCDR2 comprising the amino acid sequence shown in SEQ ID NO:21, and a LCDR3 comprising the amino acid sequence shown in SEQ ID NO:22.

[0075] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:65, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:67. Further, in some such embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof further comprises: a HCDR1 comprising the amino acid sequence shown in SEQ ID NO:17, a HCDR2 comprising the amino acid sequence shown in SEQ ID NO:18, a HCDR3 comprising the amino acid sequence shown in SEQ ID NO:19, a LCDR1 comprising the amino acid sequence shown in SEQ ID NO:20, a LCDR2 comprising the amino acid sequence shown in SEQ ID NO:21, and a LCDR3 comprising the amino acid sequence shown in SEQ ID NO:22.

[0076] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof comprises a heavy chain variable region of the amino acid sequence shown in SEQ ID NO:23, and a light chain variable region of the amino acid sequence shown in SEQ ID NO:24.

[0077] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof comprises a heavy chain variable region of the amino acid sequence shown in SEQ ID NO:25, and a light chain variable region of the amino acid sequence shown in SEQ ID NO:26.

[0078] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof comprises a heavy chain variable region of the amino acid sequence shown in SEQ ID NO:27, and a light chain variable region of the amino acid sequence shown in SEQ ID NO:28.

[0079] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof comprises a heavy chain variable region having an amino acid sequence as shown in SEQ ID NO:36, and a light chain variable region having an amino acid sequence as shown in SEQ ID NO:40.

[0080] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof comprises a heavy chain variable region having an amino acid sequence as shown in SEQ ID NO:37, and a light chain variable region having an amino acid sequence as shown in SEQ ID NO:40.

[0081] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof comprises a heavy chain variable region of the amino acid sequence shown in SEQ ID NO:38, and a light chain variable region of the amino acid sequence shown in SEQ ID NO:40.

[0082] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof comprises a heavy chain variable region of the amino acid sequence shown in SEQ ID NO:39, and a light chain variable region of the amino acid sequence shown in SEQ ID NO:40.

[0083] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof comprises a heavy chain variable region having an amino acid sequence as shown in SEQ ID NO:36, and a light chain variable region having an amino acid sequence as shown in SEQ ID NO:41.

[0084] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof comprises a heavy chain variable region having an amino acid sequence as shown in SEQ ID NO:37, and a light chain variable region having an amino acid sequence as shown in SEQ ID NO:41.

[0085] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof comprises a heavy chain variable region of the amino acid sequence shown in SEQ ID NO:38, and a light chain variable region of the amino acid sequence shown in SEQ ID NO:41.

[0086] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof comprises a heavy chain variable region of the amino acid sequence shown in SEQ ID NO:39, and a light chain variable region of the amino acid sequence shown in SEQ ID NO:41.

[0087] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof comprises a heavy chain variable region having an amino acid sequence as shown in SEQ ID NO:50, and a light chain variable region having an amino acid sequence as shown in SEQ ID NO:54.

[0088] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof comprises a heavy chain variable region having an amino acid sequence as shown in SEQ ID NO:51, and a light chain variable region having an amino acid sequence as shown in SEQ ID NO:54.

[0089] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof comprises a heavy chain variable region of the amino acid sequence shown in SEQ ID NO:52, and a light chain variable region of the amino acid sequence shown in SEQ ID NO:54.

[0090] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof comprises a heavy chain variable region of the amino acid sequence shown in SEQ ID NO:53, and a light chain variable region of the amino acid sequence shown in SEQ ID NO:54.

[0091] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof comprises a heavy chain variable region having an amino acid sequence as shown in SEQ ID NO:50, and a light chain variable region having an amino acid sequence as shown in SEQ ID NO:55.

[0092] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof comprises a heavy chain variable region having an amino acid sequence as shown in SEQ ID NO:51, and a light chain variable region having an amino acid sequence as shown in SEQ ID NO:55.

[0093] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof comprises a heavy chain variable region having an amino acid sequence as shown in SEQ ID NO:52, and a light chain variable region having an amino acid sequence as shown in SEQ ID NO:55.

[0094] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof comprises a heavy chain variable region having an amino acid sequence as shown in SEQ ID NO:53, and a light chain variable region having an amino acid sequence as shown in SEQ ID NO:55.

[0095] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof comprises a heavy chain variable region of the amino acid sequence shown in SEQ ID NO:63, and a light chain variable region of the amino acid sequence shown in SEQ ID NO:66.

[0096] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof comprises a heavy chain variable region of the amino acid sequence shown in SEQ ID NO:64, and a light chain variable region of the amino acid sequence shown in SEQ ID NO:66.

[0097] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof comprises a heavy chain variable region of the amino acid sequence shown in SEQ ID NO:65, and a light chain variable region of the amino acid sequence shown in SEQ ID NO:66.

[0098] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof comprises a heavy chain variable region of the amino acid sequence shown in SEQ ID NO:63, and a light chain variable region of the amino acid sequence shown in SEQ ID NO:67.

[0099] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof comprises a heavy chain variable region of the amino acid sequence shown in SEQ ID NO:64, and a light chain variable region of the amino acid sequence shown in SEQ ID NO:67.

[0100] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof comprises a heavy chain variable region of the amino acid sequence shown in SEQ ID NO:65, and a light chain variable region of the amino acid sequence shown in SEQ ID NO:67.

[0101] Table S1 provides the amino acid sequence information of CDR and variable region of some exemplary anti-Trop-2 antibodies or antigen-binding fragments thereof. Among them, some anti-Trop-2 antibodies or antigen-binding fragments thereof have the same CDR, and some anti-Trop-2 antibodies or antigen-binding fragments thereof have the same VH or VL. These exemplary anti-Trop-2 antibodies or antigen-binding fragments thereof can be used to construct the antibody drug conjugates of the present disclosure.

[0102] Table S1. Amino acid sequence IDs of variable regions and CDRs (SEQ ID NO.)

[0103]

[0104] For the variable region amino acid sequence of an antibody or its antigen-binding fragment, a person skilled in the art can determine which residues constitute a specific CDR by conventional methods. As known to those skilled in the art, the CDR of an antibody can be defined by a variety of methods, such as by using a numbering system / method such as Kabat, Chothia, IMGT, AbM, CCG or Contact; or by using a combination of two or more of the numbering systems / methods such as Kabat, Chothia, IMGT, AbM, CCG and Contact; or by using a Combined numbering system that includes Kabat and Chothia, wherein the Combined numbering system combines the ranges defined by Kabat and Chothia, and based on this, a larger range is taken (for example, HCDR1 defined by Kabat is H31-H35, HCDR1 defined by Chothia is H26-H32, and HCDR1 defined by Combined is H26-H35). In different numbering systems, the precise numbering and position of CDRs are different. It will be understood by those skilled in the art that, unless otherwise specified, the terms "CDR" and "complementarity determining region" of a given antibody or region thereof (e.g., variable region) should be understood to encompass complementarity determining regions defined by any known scheme. Although the CDRs claimed for protection in the present disclosure are based on the sequences shown in Table S1 (one definition), amino acid sequences corresponding to other CDR definition rules should also fall within the scope of protection of the present disclosure.

[0105] The VH and / or VL sequences (or CDR sequences) of other antibodies that bind to Trop-2 can be "mixed and paired" with the VH and / or VL sequences (or CDR sequences) of the anti-Trop-2 antibodies or antigen-binding fragments thereof of the present disclosure. Preferably, when the VH and VL chains (or their CDRs) are mixed and paired, the VH sequence in a particular VH / VL pair can be replaced by a structurally similar VH sequence. Likewise, it is preferred that the VL sequence in a particular VH / VL pair be replaced by a structurally similar VL sequence.

[0106] Thus, in one embodiment, the antibodies or antigen-binding fragments thereof of the present disclosure include:

[0107] (a) a heavy chain variable region comprising the amino acid sequence listed in Table S1; and

[0108] (b) a light chain variable region comprising the amino acid sequence listed in Table S1, or the VL of another anti-Trop-2 antibody or antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment thereof specifically binds to Trop-2.

[0109] In another embodiment, the antibody or antigen-binding fragment thereof of the present disclosure comprises:

[0110] (a) HCDR1, HCDR2 and HCDR3 listed in Table S1; and

[0111] (b) LCDR1, LCDR2 and LCDR3 listed in Table S1, or LCDR(s) of another anti-Trop-2 antibody or antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment thereof specifically binds to Trop-2.

[0112] In another embodiment, the antibodies or antigen-binding fragments thereof of the present disclosure include the HCDR2 listed in Table S1 and the CDR(s) of other anti-Trop-2 antibodies or antigen-binding fragments thereof, such as the HCDR1 and / or HCDR3 of other anti-Trop-2 antibodies or antigen-binding fragments thereof, and / or the LCDR1, LCDR2 and / or LCDR3 of other anti-Trop-2 antibodies or antigen-binding fragments thereof.

[0113] In another embodiment, the antibody or antigen-binding fragment thereof of the present disclosure comprises a HCDR2 listed in Table S1, and a HCDR3 listed in Table S1 and / or a LCDR3 listed in Table S1, and CDR(s) of other anti-Trop-2 antibodies or antigen-binding fragments thereof, wherein the antibody or antigen-binding fragment thereof specifically binds to Trop-2. In another embodiment, the antibody or antigen-binding fragment thereof of the present disclosure further comprises a LCDR2 listed in Table S1, and CDR(s) of other anti-Trop-2 antibodies, wherein the antibody or antigen-binding fragment thereof specifically binds to Trop-2. In another embodiment, the antibody or antigen-binding fragment thereof of the present disclosure further comprises a HCDR1 listed in Table S1 or a LCDR1 listed in Table S1, and CDR(s) of other anti-Trop-2 antibodies, wherein the antibody or antigen-binding fragment thereof specifically binds to Trop-2. These antibodies preferably (a) compete with the anti-Trop-2 antibodies of the present disclosure for binding to Trop-2; (b) retain the same functional characteristics; (c) bind to the same epitope; and / or (d) have similar binding affinity.

[0114] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof further comprises a constant region or a variant of a constant region. In some embodiments, the constant region comprises a heavy chain constant region and a light chain constant region; wherein the heavy chain constant region includes but is not limited to a human IgG1 constant region, a human IgG2 constant region, a human IgG3 constant region or a human IgG4 constant region, preferably a human IgG1 constant region, and the light chain constant region includes but is not limited to a human κ constant region or a human λ constant region, preferably a human κ constant region. In some embodiments, the constant region comprises any modification disclosed herein or known in the art, such as insertion, deletion, substitution or chemical modification of amino acids. In some embodiments, the constant region comprises a mutation that changes effector function. In some embodiments, any amino acid residue in the constant region may be substituted with an amino acid residue of any allotype.

[0115] In some embodiments, the heavy chain constant region comprises the amino acid sequence shown in SEQ ID NO:29, or an amino acid sequence having 1, 2, 3, 4 or 5 amino acid substitutions, deletions or insertions compared to the amino acid sequence shown in SEQ ID NO:29, and the light chain constant region comprises the amino acid sequence shown in SEQ ID NO:30, or an amino acid sequence having 1, 2, 3, 4 or 5 amino acid substitutions, deletions or insertions compared to the amino acid sequence shown in SEQ ID NO:30.

[0116] In some embodiments, the anti-Trop-2 antibody comprises a heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:42, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:46.

[0117] In some embodiments, the anti-Trop-2 antibody comprises a heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:43, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:46.

[0118] In some embodiments, the anti-Trop-2 antibody comprises a heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:44, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:46.

[0119] In some embodiments, the anti-Trop-2 antibody comprises a heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:45, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:46.

[0120] In some embodiments, the anti-Trop-2 antibody comprises a heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:42, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:47.

[0121] In some embodiments, the anti-Trop-2 antibody comprises a heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:43, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:47.

[0122] In some embodiments, the anti-Trop-2 antibody comprises a heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:44, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:47.

[0123] In some embodiments, the anti-Trop-2 antibody comprises a heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:45, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:47.

[0124] In some embodiments, the anti-Trop-2 antibody comprises a heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:56, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:60.

[0125] In some embodiments, the anti-Trop-2 antibody comprises a heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:57, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:60.

[0126] In some embodiments, the anti-Trop-2 antibody comprises a heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:58, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:60.

[0127] In some embodiments, the anti-Trop-2 antibody comprises a heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:59, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:60.

[0128] In some embodiments, the anti-Trop-2 antibody comprises a heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:56, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:61.

[0129] In some embodiments, the anti-Trop-2 antibody comprises a heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:57, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:61.

[0130] In some embodiments, the anti-Trop-2 antibody comprises a heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:58, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:61.

[0131] In some embodiments, the anti-Trop-2 antibody comprises a heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:59, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:61.

[0132] In some embodiments, the anti-Trop-2 antibody comprises a heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:68, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:71.

[0133] In some embodiments, the anti-Trop-2 antibody comprises a heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:69, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:71.

[0134] In some embodiments, the anti-Trop-2 antibody comprises a heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:70, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:71.

[0135] In some embodiments, the anti-Trop-2 antibody comprises a heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:68, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:72.

[0136] In some embodiments, the anti-Trop-2 antibody comprises a heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:69, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:72.

[0137] In some embodiments, the anti-Trop-2 antibody comprises a heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:70, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:72.

[0138] In some embodiments, the anti-Trop-2 antibody comprises a heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:73, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:74.

[0139] In some embodiments, the anti-Trop-2 antibody comprises a heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:75, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:76.

[0140] In some embodiments, the anti-Trop-2 antibody comprises a heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:77, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:78.

[0141] In some embodiments, the anti-Trop-2 antibody comprises a heavy chain having an amino acid sequence as shown in SEQ ID NO:42, and a light chain having an amino acid sequence as shown in SEQ ID NO:46.

[0142] In some embodiments, the anti-Trop-2 antibody comprises a heavy chain having an amino acid sequence as shown in SEQ ID NO:43, and a light chain having an amino acid sequence as shown in SEQ ID NO:46.

[0143] In some embodiments, the anti-Trop-2 antibody comprises a heavy chain having an amino acid sequence as shown in SEQ ID NO:44, and a light chain having an amino acid sequence as shown in SEQ ID NO:46.

[0144] In some embodiments, the anti-Trop-2 antibody comprises a heavy chain having an amino acid sequence as shown in SEQ ID NO:45, and a light chain having an amino acid sequence as shown in SEQ ID NO:46.

[0145] In some embodiments, the anti-Trop-2 antibody comprises a heavy chain having an amino acid sequence as shown in SEQ ID NO:42, and a light chain having an amino acid sequence as shown in SEQ ID NO:47.

[0146] In some embodiments, the anti-Trop-2 antibody comprises a heavy chain having an amino acid sequence as shown in SEQ ID NO:43, and a light chain having an amino acid sequence as shown in SEQ ID NO:47.

[0147] In some embodiments, the anti-Trop-2 antibody comprises a heavy chain having an amino acid sequence as shown in SEQ ID NO:44, and a light chain having an amino acid sequence as shown in SEQ ID NO:47.

[0148] In some embodiments, the anti-Trop-2 antibody comprises a heavy chain having an amino acid sequence as shown in SEQ ID NO:45, and a light chain having an amino acid sequence as shown in SEQ ID NO:47.

[0149] In some embodiments, the anti-Trop-2 antibody comprises a heavy chain having an amino acid sequence as shown in SEQ ID NO:56, and a light chain having an amino acid sequence as shown in SEQ ID NO:60.

[0150] In some embodiments, the anti-Trop-2 antibody comprises a heavy chain having an amino acid sequence as shown in SEQ ID NO:57, and a light chain having an amino acid sequence as shown in SEQ ID NO:60.

[0151] In some embodiments, the anti-Trop-2 antibody comprises a heavy chain having an amino acid sequence as shown in SEQ ID NO:58, and a light chain having an amino acid sequence as shown in SEQ ID NO:60.

[0152] In some embodiments, the anti-Trop-2 antibody comprises a heavy chain having an amino acid sequence as shown in SEQ ID NO:59, and a light chain having an amino acid sequence as shown in SEQ ID NO:60.

[0153] In some embodiments, the anti-Trop-2 antibody comprises a heavy chain having an amino acid sequence as shown in SEQ ID NO:56, and a light chain having an amino acid sequence as shown in SEQ ID NO:61.

[0154] In some embodiments, the anti-Trop-2 antibody comprises a heavy chain having an amino acid sequence as shown in SEQ ID NO:57, and a light chain having an amino acid sequence as shown in SEQ ID NO:61.

[0155] In some embodiments, the anti-Trop-2 antibody comprises a heavy chain having an amino acid sequence as shown in SEQ ID NO:58, and a light chain having an amino acid sequence as shown in SEQ ID NO:61.

[0156] In some embodiments, the anti-Trop-2 antibody comprises a heavy chain having an amino acid sequence as shown in SEQ ID NO:59, and a light chain having an amino acid sequence as shown in SEQ ID NO:61.

[0157] In some embodiments, the anti-Trop-2 antibody comprises a heavy chain having an amino acid sequence as shown in SEQ ID NO:68, and a light chain having an amino acid sequence as shown in SEQ ID NO:71.

[0158] In some embodiments, the anti-Trop-2 antibody comprises a heavy chain having an amino acid sequence as shown in SEQ ID NO:69, and a light chain having an amino acid sequence as shown in SEQ ID NO:71.

[0159] In some embodiments, the anti-Trop-2 antibody comprises a heavy chain having an amino acid sequence as shown in SEQ ID NO:70, and a light chain having an amino acid sequence as shown in SEQ ID NO:71.

[0160] In some embodiments, the anti-Trop-2 antibody comprises a heavy chain having an amino acid sequence as shown in SEQ ID NO:68, and a light chain having an amino acid sequence as shown in SEQ ID NO:72.

[0161] In some embodiments, the anti-Trop-2 antibody comprises a heavy chain having an amino acid sequence as shown in SEQ ID NO:69, and a light chain having an amino acid sequence as shown in SEQ ID NO:72.

[0162] In some embodiments, the anti-Trop-2 antibody comprises a heavy chain having an amino acid sequence as shown in SEQ ID NO:70, and a light chain having an amino acid sequence as shown in SEQ ID NO:72.

[0163] In some embodiments, the anti-Trop-2 antibody comprises a heavy chain having an amino acid sequence as shown in SEQ ID NO:73, and a light chain having an amino acid sequence as shown in SEQ ID NO:74.

[0164] In some embodiments, the anti-Trop-2 antibody comprises a heavy chain having an amino acid sequence as shown in SEQ ID NO:75, and a light chain having an amino acid sequence as shown in SEQ ID NO:76.

[0165] In some embodiments, the anti-Trop-2 antibody comprises a heavy chain having an amino acid sequence as shown in SEQ ID NO:77, and a light chain having an amino acid sequence as shown in SEQ ID NO:78.

[0166] In some specific embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof in the antibody-drug conjugate, its stereoisomer, its pharmaceutically acceptable salt, or the solvate of the antibody-drug conjugate, its stereoisomer, or its pharmaceutically acceptable salt provided by the present disclosure comprises: HCDR1 of the amino acid sequence shown in SEQ ID NO: 17, HCDR2 of the amino acid sequence shown in SEQ ID NO: 18, HCDR3 of the amino acid sequence shown in SEQ ID NO: 19, LCDR1 of the amino acid sequence shown in SEQ ID NO: 20, LCDR2 of the amino acid sequence shown in SEQ ID NO: 21, and LCDR3 of the amino acid sequence shown in SEQ ID NO: 22.

[0167] In some specific embodiments, in the antibody-drug conjugate, its stereoisomer, its pharmaceutically acceptable salt, or the solvate of the antibody-drug conjugate, its stereoisomer, or its pharmaceutically acceptable salt provided by the present disclosure, the anti-Trop-2 antibody or its antigen-binding fragment comprises: HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence as shown in SEQ ID NO:65, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence as shown in SEQ ID NO:66.

[0168] In some specific embodiments, the present disclosure provides an antibody drug conjugate, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a solvate of the antibody drug conjugate, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein the anti-Trop-2 antibody or antigen-binding fragment thereof comprises: a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:65, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:66.

[0169] In some specific embodiments, in the antibody-drug conjugate, its stereoisomer, its pharmaceutically acceptable salt, or the solvate of the antibody-drug conjugate, its stereoisomer, or its pharmaceutically acceptable salt provided by the present disclosure, the anti-Trop-2 antibody or its antigen-binding fragment comprises: a heavy chain variable region of the amino acid sequence shown in SEQ ID NO:65, and a light chain variable region of the amino acid sequence shown in SEQ ID NO:66.

[0170] In some specific embodiments, the present disclosure provides an antibody drug conjugate, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a solvate of the antibody drug conjugate, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein the anti-Trop-2 antibody comprises: a heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:70, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:71.

[0171] In some specific embodiments, the anti-Trop-2 antibody in the antibody-drug conjugate, its stereoisomer, its pharmaceutically acceptable salt, or the solvate of the antibody-drug conjugate, its stereoisomer, or its pharmaceutically acceptable salt provided by the present disclosure comprises: a heavy chain with the amino acid sequence shown in SEQ ID NO:70, and a light chain with the amino acid sequence shown in SEQ ID NO:71.

[0172] In some embodiments, the anti-Trop-2 antibody comprises two heavy chains (H) and two light chains (L), or consists of two heavy chains and two light chains, the heavy chains and the light chains are interconnected by disulfide bonds, wherein each heavy chain comprises the above-mentioned heavy chain variable region (VH) and a heavy chain constant region, wherein the heavy chain variable region (VH) comprises a framework region (FR) and the above-mentioned heavy chain complementarity determining region (HCDR), and each light chain comprises the above-mentioned light chain variable region (VL) and a light chain constant region, wherein the light chain variable region (VL) comprises FR and the above-mentioned light chain complementarity determining region (LCDR), wherein the C-terminus of the heavy chain variable region is connected to the N-terminus of the heavy chain constant region, and the C-terminus of the light chain variable region is connected to the N-terminus of the light chain constant region.

[0173] In some embodiments, the anti-Trop-2 antibody or antigen-binding fragment thereof can be modified, for example, including the insertion, deletion or substitution of one or more amino acids. In this context, the modified anti-Trop-2 antibody or antigen-binding fragment thereof still retains the activity of specifically binding to Trop-2 (e.g., human Trop-2 and / or monkey Trop-2). In some embodiments, the C-terminal lysine of the heavy chain constant region can be present or absent.

[0174] In the antibody-drug conjugates, stereoisomers, pharmaceutically acceptable salts thereof, or solvates of the antibody-drug conjugates, stereoisomers, or pharmaceutically acceptable salts provided by the present disclosure, the cytotoxic drug is coupled to the anti-Trop-2 antibody or its antigen-binding fragment through a linker. In some specific embodiments, in the antibody-drug conjugates, stereoisomers, pharmaceutically acceptable salts thereof, or solvates of the antibody-drug conjugates, stereoisomers, or pharmaceutically acceptable salts provided by the present disclosure, each cytotoxic drug is coupled to the anti-Trop-2 antibody or its antigen-binding fragment through a linker. The linker disclosed herein can be connected to the anti-Trop-2 antibody or its antigen-binding fragment by any method known in the art. In some preferred embodiments, the linker is connected to the anti-Trop-2 antibody or its antigen-binding fragment through a sulfhydryl group and / or an amino group. In some more preferred embodiments, the linker is connected to the anti-Trop-2 antibody or its antigen-binding fragment through a sulfhydryl group.

[0175] In some embodiments, the linker is a cleavable linker or a non-cleavable linker. In some embodiments, the linker is a cleavable linker, for example, it can be a low pH-dependent degradation type (including hydrazone bonds, carbonate bonds, etc.), a proteolytic type (including peptidyl bonds), or a high glutathione concentration-dependent degradation type (including disulfide bonds), etc. The cleavable linker can be broken in the target cell, thereby releasing the cytotoxic drug. In other embodiments, the linker is a non-cleavable linker, for example, it can be a maleimidohexanoyl group, etc.

[0176] In some embodiments, the antibody drug conjugate, its stereoisomer, its pharmaceutically acceptable salt, or the solvate of the antibody drug conjugate, its stereoisomer, or its pharmaceutically acceptable salt provided by the present invention, the anti-Trop-2 antibody or its antigen-binding fragment is coupled with one or more cytotoxic drugs, and the cytotoxic drugs can be, for example, alkaloids, antimetabolites, antitumor antibiotics, alkylating agents, and platinums. In some embodiments, the cytotoxic drug is a tubulin inhibitor cytotoxic drug or a cytotoxic drug that acts on DNA. In some embodiments, the tubulin inhibitor cytotoxic drugs include but are not limited to maytansines, auristatins, dolastatins, tubulysins, cryptomycins, and eribulin or its derivatives. In some embodiments, the cytotoxic drugs acting on DNA include but are not limited to calicheamicins, duocarmycins, anthramycin derivatives PBD (Pyrrolobenzodiazepine), topoisomerase I inhibitors and topoisomerase II inhibitors.

[0177] In some embodiments, the cytotoxic drug is a tubulin inhibitor.

[0178] In some specific embodiments, the cytotoxic drug is eribulin or a derivative thereof.

[0179] In some embodiments, the cytotoxic drug is connected to the linker via a functional group, and the antibody-drug conjugate is hydrolyzed in tumor cells to form free cytotoxic drugs, thereby exerting an anti-tumor effect.

[0180] In some embodiments, the present disclosure provides an antibody drug conjugate, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a solvate of the antibody drug conjugate, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein the general formula of the antibody drug conjugate is Ab-(LU) n , Ab is the anti-Trop-2 antibody or its antigen-binding fragment, L is a linker, U is a cytotoxic drug, and n is 1-10; preferably, U is a tubulin inhibitor; more preferably, U is eribulin or its derivatives.

[0181] In some embodiments, the general formula Ab-(LU) n -U in is a structure shown in the following formula Ia:

[0182]

[0183] Among them, R a is selected from a hydrogen atom, a deuterium atom, an optionally substituted C 1-6 Alkyl, optionally substituted C 3-7 Cycloalkyl, optionally substituted C 3-7 Heterocyclic group, optionally substituted C 6-10 Aryl, optionally substituted C 5-12 Heteroaryl, R b is selected from a hydrogen atom, a deuterium atom, an optionally substituted C 1-6 Alkyl, optionally substituted C 3-7 Cycloalkyl, optionally substituted C 3-7 Heterocyclic group, optionally substituted C 6-10 Aryl, optionally substituted C 5-12 heteroaryl; or, R a With R b Together with the atoms to which it is attached, it forms an optionally substituted 5- to 8-membered heterocyclic group; and the wavy line () indicates the connection position between the structure shown in Formula Ia and L. In some embodiments, the R a With R b are independently selected from a hydrogen atom or C 1-5 Alkyl (preferably C 1-4 Alkyl groups, such as C 1-3 In some embodiments, the R a With R b Each is independently selected from a hydrogen atom, a methyl group, an ethyl group, a propyl group or an isopropyl group. a and R b A hydrogen atom.

[0184] In some embodiments, the general formula Ab-(LU) n -U in the formula is the structure described in the following formula Ia-1:

[0185]

[0186] The wavy line indicates the connection position between the structure shown in Formula Ia-1 and L.

[0187] In some embodiments, the general formula Ab-(LU) n The -LU in is a structure shown in the following formula IIa:

[0188]

[0189] Among them, R a is selected from a hydrogen atom, a deuterium atom, an optionally substituted C 1-6 Alkyl, optionally substituted C 3-7 Cycloalkyl, optionally substituted C 3-7Heterocyclic group, optionally substituted C 6-10 Aryl, optionally substituted C 5-12 Heteroaryl, R b is selected from a hydrogen atom, a deuterium atom, an optionally substituted C 1-6 Alkyl, optionally substituted C 3-7 Cycloalkyl, optionally substituted C 3-7 Heterocyclic group, optionally substituted C 6-10 Aryl, optionally substituted C 5-12 heteroaryl; or, R a With R b Together with the atoms to which it is attached, it forms an optionally substituted 5- to 8-membered heterocyclic group; and the wavy line indicates the connection position between the structure shown in Formula IIa and Ab. a With R b are independently selected from a hydrogen atom or C 1-5 Alkyl (preferably C 1-4 Alkyl groups, such as C 1-3 In some embodiments, the R a With R b Each is independently selected from a hydrogen atom, a methyl group, an ethyl group, a propyl group or an isopropyl group. a and R b In some embodiments, the 3-position of -(succinimide-3-yl-N)- in the structure shown in Formula IIa is connected to the disulfide bond site of Ab, and Ab is connected to the structure shown in Formula IIa via a thioether bond.

[0190] In some embodiments, the general formula Ab-(LU) n The -LU in the formula is the structure shown in the following formula IIa-1:

[0191]

[0192] The wavy line indicates the connection position between the structure shown in Formula IIa-1 and Ab. In some embodiments, the 3-position of -(succinimide-3-yl-N)- in the structure shown in Formula IIa-1 is connected to the disulfide bond site of Ab, and Ab is connected to the structure shown in Formula IIa-1 via a thioether bond.

[0193] In some embodiments, the structure of the antibody-drug conjugate, its stereoisomer, its pharmaceutically acceptable salt, or the solvate of the antibody-drug conjugate, its stereoisomer, or its pharmaceutically acceptable salt is as shown in Formula III:

[0194]

[0195] Wherein, Ab is an anti-Trop-2 antibody or an antigen-binding fragment thereof, n is 1-10, R a is selected from a hydrogen atom, a deuterium atom, an optionally substituted C 1-6 Alkyl, optionally substituted C 3-7 Cycloalkyl, optionally substituted C 3-7 Heterocyclic group, optionally substituted C 6-10 Aryl, optionally substituted C 5-12 Heteroaryl, R b is selected from a hydrogen atom, a deuterium atom, an optionally substituted C 1-6 Alkyl, optionally substituted C 3-7 Cycloalkyl, optionally substituted C 3-7 Heterocyclic group, optionally substituted C 6-10 Aryl, optionally substituted C 5-12 heteroaryl; or, R a With R b The atoms to which they are attached form an optionally substituted 5- to 8-membered heterocyclic group; and the 3-position of -(succinimidyl-3-yl-N)- in Formula III is connected to Ab. In some embodiments, the R a With R b are independently selected from a hydrogen atom or C 1-5 Alkyl (preferably C 1-4 Alkyl groups, such as C 1-3 In some embodiments, the R a With R b Each is independently selected from a hydrogen atom, a methyl group, an ethyl group, a propyl group or an isopropyl group. a and R b In some embodiments, the 3-position of -(succinimide-3-yl-N)- in the structure shown in Formula III is connected to the disulfide bond site of Ab, and Ab is connected to the structure shown in Formula IIa via a thioether bond.

[0196] In some embodiments, the antibody-drug conjugate, its stereoisomer, its pharmaceutically acceptable salt, or the solvate of the antibody-drug conjugate, its stereoisomer, or its pharmaceutically acceptable salt has a structure as shown in Formula III-1:

[0197]

[0198] Wherein, Ab is an anti-Trop-2 antibody or an antigen-binding fragment thereof, n is 1-10, and the 3-position of -(succinimide-3-yl-N)- in formula III-1 is connected to Ab. In some embodiments, the 3-position of -(succinimide-3-yl-N)- in the structure shown in formula III-1 is connected to the disulfide bond site of Ab, and Ab is connected to the structure shown in formula IIa-1 through a thioether bond.

[0199] In some embodiments, in the antibody drug conjugate, its stereoisomer, its pharmaceutically acceptable salt, or the solvate of the antibody drug conjugate, its stereoisomer, or its pharmaceutically acceptable salt, n is 2-8, 3.5-8, 4-8, 3.5-4.8, 3.5-4.5, 3.5-4.3, 4-4.8, 4-4.5, 4-4.3, 7-8, 7-7.8, 7-7.5, or 7.5-8. In some embodiments, n is 3.5, 3.8, 4, 4.1, 4.3, 4.5, 4.6, 4.8, 7.5, 7.8, or 8.

[0200] In the antibody-drug conjugate, stereoisomer thereof, pharmaceutically acceptable salt thereof, or solvate of the antibody-drug conjugate, stereoisomer thereof, or pharmaceutically acceptable salt thereof provided by the present disclosure, the number of cytotoxic drugs linked to the anti-Trop-2 antibody or its antigen-binding fragment may vary, so that the antibody-drug conjugate (ADC) may be heterogeneous, that is, the antibody-drug conjugate includes anti-Trop-2 antibodies or their antigen-binding fragments linked to different numbers of cytotoxic drugs, for example, one molecule of anti-Trop-2 antibody or its antigen-binding fragment is linked to 0 (i.e., no cytotoxic drug), 1, 2, 3, 4, 5, 6, 7, 8 or more molecules of cytotoxic drugs.

[0201] By controlling the ratio of the above antibodies or antigen-binding fragments to which different numbers of cytotoxic drugs are linked, antibody-drug conjugates, stereoisomers thereof, pharmaceutically acceptable salts thereof, or solvates of the antibody-drug conjugates, stereoisomers thereof, or pharmaceutically acceptable salts thereof having different drug-antibody ratios (DAR) can be produced. In this article, "DAR" and "n" are used interchangeably. It should be understood that the DAR or n is the average number of cytotoxic drugs linked per molecule of antibody or antigen-binding fragment in the antibody-drug conjugate, its stereoisomer, its pharmaceutically acceptable salt, or the antibody-drug conjugate, its stereoisomer, its pharmaceutically acceptable salt The solvate of the salt is acceptable. For example, "DAR is 4" means that such an antibody-drug conjugate, its stereoisomer, its pharmaceutically acceptable salt, or a solvate of the antibody-drug conjugate, its stereoisomer, or its pharmaceutically acceptable salt comprises a heterogeneous mixture in which each antibody or antigen-binding fragment molecule thereof is linked to the same or different number of cytotoxic drugs (e.g., each antibody or antigen-binding fragment thereof is linked to 0, 1, 2, 3, 4, 5, 6, 7 and / or 8 cytotoxic drugs), but the average number of cytotoxic drugs linked to each molecule of the antibody or antigen-binding fragment thereof is 4. Similarly, "DAR is 8" means that the average number of cytotoxic drugs linked to each molecule of the antibody-drug conjugate, its stereoisomer, its pharmaceutically acceptable salt, or a solvate of the antibody-drug conjugate, its stereoisomer, or its pharmaceutically acceptable salt is 8.

[0202] In some embodiments, the antibody drug conjugate provided by the present disclosure, its stereoisomer, its pharmaceutically acceptable salt, or the solvate of the antibody drug conjugate, its stereoisomer, or its pharmaceutically acceptable salt, the antibody drug conjugate is represented by the following formula IIa

[0203]

[0204] The structure shown is connected with an anti-Trop-2 antibody or an antigen-binding fragment thereof, wherein R a is selected from a hydrogen atom, a deuterium atom, an optionally substituted C 1-6 Alkyl, optionally substituted C 3-7 Cycloalkyl, optionally substituted C 3-7 Heterocyclic group, optionally substituted C 6-10 Aryl, optionally substituted C 5-12 Heteroaryl, R b is selected from a hydrogen atom, a deuterium atom, an optionally substituted C 1-6 Alkyl, optionally substituted C 3-7 Cycloalkyl, optionally substituted C 3-7 Heterocyclic group, optionally substituted C 6-10 Aryl, optionally substituted C5-12 heteroaryl; or, R a With R b The atoms to which it is attached form an optionally substituted 5- to 8-membered heterocyclic group; the 3-position of -(succinimidyl-3-yl-N)- in the structure shown in Formula IIa is connected to an anti-Trop-2 antibody or an antigen-binding fragment thereof. In some embodiments, the R a With R b are independently selected from a hydrogen atom or C 1-5 Alkyl (preferably C 1-4 Alkyl groups, such as C 1-3 In some embodiments, the R a With R b Each is independently selected from a hydrogen atom, a methyl group, an ethyl group, a propyl group or an isopropyl group. a and R b A hydrogen atom.

[0205] In some embodiments, the average number of cytotoxic drugs attached per anti-Trop-2 antibody or antigen-binding fragment thereof in the antibody drug conjugate, its stereoisomer, its pharmaceutically acceptable salt, or the solvate of the antibody drug conjugate, its stereoisomer, or its pharmaceutically acceptable salt is 2-8, 3.5-8, 4-8, 3.5-4.8, 3.5-4.5, 3.5-4.3, 4-4.8, 4-4.5, 4-4.3, 7-8, 7-7.8, or 7-7.5. In some embodiments, the average number of cytotoxic drugs attached per anti-Trop-2 antibody or antigen-binding fragment thereof is 3.5, 3.8, 4, 4.1, 4.3, 4.5, 4.6, 4.8, 7.5, 7.8, or 8.

[0206] In some embodiments, the antibody-drug conjugate, its stereoisomer, its pharmaceutically acceptable salt, or the solvate of the antibody-drug conjugate, its stereoisomer, or its pharmaceutically acceptable salt provided by the present disclosure has a structure as shown in Formula III-1, wherein Ab is an anti-Trop-2 antibody or an antigen-binding fragment thereof, which comprises: HCDR1 of the amino acid sequence shown in SEQ ID NO: 17, HCDR2 of the amino acid sequence shown in SEQ ID NO: 18, HCDR3 of the amino acid sequence shown in SEQ ID NO: 19, LCDR1 of the amino acid sequence shown in SEQ ID NO: 20, LCDR2 of the amino acid sequence shown in SEQ ID NO: 21, and LCDR3 of the amino acid sequence shown in SEQ ID NO: 22. In some such embodiments, n is 2-8, 3.5-8, 4-8, 3.5-4.8, 3.5-4.5, 3.5-4.3, 4-4.8, 4-4.5, 4-4.3, 7-8, 7-7.8, 7-7.5 or 7.5-8; preferably, n is 3.5, 3.8, 4, 4.1, 4.3, 4.5, 4.6, 4.8, 7.5, 7.8 or 8.

[0207] In some embodiments, the antibody drug conjugate, its stereoisomer, its pharmaceutically acceptable salt, or the solvate of the antibody drug conjugate, its stereoisomer, or its pharmaceutically acceptable salt provided by the present disclosure has a structure as shown in Formula III-1, wherein Ab is an anti-Trop-2 antibody or an antigen-binding fragment thereof, which comprises: HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with an amino acid sequence as shown in SEQ ID NO: 65, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with an amino acid sequence as shown in SEQ ID NO: 66. In some such embodiments, n is 2-8, 3.5-8, 4-8, 3.5-4.8, 3.5-4.5, 3.5-4.3, 4-4.8, 4-4.5, 4-4.3, 7-8, 7-7.8, 7-7.5 or 7.5-8; preferably, n is 3.5, 3.8, 4, 4.1, 4.3, 4.5, 4.6, 4.8, 7.5, 7.8 or 8.

[0208] In some embodiments, the antibody drug conjugate, its stereoisomer, its pharmaceutically acceptable salt, or the solvate of the antibody drug conjugate, its stereoisomer, or its pharmaceutically acceptable salt provided by the present disclosure has a structure as shown in Formula III-1, wherein Ab is an anti-Trop-2 antibody or an antigen-binding fragment thereof, which comprises: a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 65, and an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO: 65. The amino acid sequence shown in NO:66 has a light chain variable region with at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity. In some such embodiments, n is 2-8, 3.5-8, 4-8, 3.5-4.8, 3.5-4.5, 3.5-4.3, 4-4.8, 4-4.5, 4-4.3, 7-8, 7-7.8, 7-7.5 or 7.5-8; preferably, n is 3.5, 3.8, 4, 4.1, 4.3, 4.5, 4.6, 4.8, 7.5, 7.8 or 8.

[0209] In some embodiments, the antibody drug conjugate, its stereoisomer, its pharmaceutically acceptable salt, or the solvate of the antibody drug conjugate, its stereoisomer, or its pharmaceutically acceptable salt provided by the present disclosure, the structure of the antibody drug conjugate is as shown in Formula III-1, wherein Ab is an anti-Trop-2 antibody or an antigen-binding fragment thereof, which comprises: a heavy chain variable region of the amino acid sequence shown in SEQ ID NO: 65, and a light chain variable region of the amino acid sequence shown in SEQ ID NO: 66. In some such embodiments, n is 2-8, 3.5-8, 4-8, 3.5-4.8, 3.5-4.5, 3.5-4.3, 4-4.8, 4-4.5, 4-4.3, 7-8, 7-7.8, 7-7.5 or 7.5-8; preferably, n is 3.5, 3.8, 4, 4.1, 4.3, 4.5, 4.6, 4.8, 7.5, 7.8 or 8.

[0210] In some embodiments, the antibody drug conjugate, its stereoisomer, its pharmaceutically acceptable salt, or the solvate of the antibody drug conjugate, its stereoisomer, or its pharmaceutically acceptable salt provided by the present disclosure has a structure as shown in Formula III-1, wherein Ab is an anti-Trop-2 antibody, which comprises: a heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO:70, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO:71. In some such embodiments, n is 2-8, 3.5-8, 4-8, 3.5-4.8, 3.5-4.5, 3.5-4.3, 4-4.8, 4-4.5, 4-4.3, 7-8, 7-7.8, 7-7.5 or 7.5-8; preferably, n is 3.5, 3.8, 4, 4.1, 4.3, 4.5, 4.6, 4.8, 7.5, 7.8 or 8.

[0211] In some embodiments, the antibody drug conjugate, its stereoisomer, its pharmaceutically acceptable salt, or the solvate of the antibody drug conjugate, its stereoisomer, or its pharmaceutically acceptable salt provided by the present disclosure has a structure as shown in Formula III-1, wherein Ab is an anti-Trop-2 antibody, which comprises: a heavy chain of the amino acid sequence shown in SEQ ID NO: 70, and a light chain of the amino acid sequence shown in SEQ ID NO: 71. In some such embodiments, n is 2-8, 3.5-8, 4-8, 3.5-4.8, 3.5-4.5, 3.5-4.3, 4-4.8, 4-4.5, 4-4.3, 7-8, 7-7.8, 7-7.5, or 7.5-8; preferably, n is 3.5, 3.8, 4, 4.1, 4.3, 4.5, 4.6, 4.8, 7.5, 7.8, or 8.

[0212] In some embodiments, the present disclosure provides a general formula of Ab-(LU) nAn antibody-drug conjugate, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a solvate of the antibody-drug conjugate, its stereoisomer, or a pharmaceutically acceptable salt thereof, wherein n is 3.5-4.5 or 4, wherein the mass fraction of the antibody-drug conjugate in which each antibody or antigen-binding fragment thereof is connected to four cytotoxic drugs is not less than 40%, not less than 45%, not less than 50%, not less than 65%, not less than 70%, not less than 75%, not less than 80%, not less than 85%, not less than 90%, not less than 95%, or not less than 99%.

[0213] In some embodiments, the present disclosure provides a general formula of Ab-(LU) n An antibody-drug conjugate, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a solvate of the antibody-drug conjugate, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein n is 7-8, 7.5-8, or 8, wherein the mass fraction of the antibody-drug conjugate in which each antibody or antigen-binding fragment thereof is connected to 8 cytotoxic drugs is not less than 40%, not less than 45%, not less than 50%, not less than 65%, not less than 70%, not less than 75%, not less than 80%, not less than 85%, not less than 90%, not less than 95%, or not less than 99%.

[0214] In some embodiments, the antibody drug conjugates, stereoisomers thereof, pharmaceutically acceptable salts thereof, or solvates of the antibody drug conjugates, stereoisomers thereof, pharmaceutically acceptable salts thereof provided by the present disclosure exhibit a combination of one or more of the following properties:

[0215] (1) Binds to human Trop-2, preferably with a K of 2E-09 M or less D Value binds human Trop-2;

[0216] (2) binding to monkey Trop-2;

[0217] (3) showed endocytosis in cells expressing Trop-2;

[0218] (4) has killing activity against tumor cells expressing Trop-2;

[0219] (5) There is a bystander effect;

[0220] (6) having ADCC activity; and

[0221] (7) Does not bind to cells that do not express Trop-2.

[0222] In some embodiments, the antibody drug conjugate, its stereoisomer, its pharmaceutically acceptable salt, or a solvate of the antibody drug conjugate, its stereoisomer, or its pharmaceutically acceptable salt has properties (1) to (7).

[0223] The antibody drug conjugates, stereoisomers thereof, pharmaceutically acceptable salts thereof, or solvates of the antibody drug conjugates, stereoisomers thereof, and pharmaceutically acceptable salts provided by the present disclosure show strong endocytosis in cells with different Trop-2 expression levels, and can continuously accumulate the amount of the internalized antibody drug conjugate as the endocytosis time increases.

[0224] The antibody drug conjugate, its stereoisomer, its pharmaceutically acceptable salt, or the antibody drug conjugate, its stereoisomer, its pharmaceutically acceptable salt solvate provided by the present disclosure achieves excellent anti-tumor effect and / or safety. In some embodiments, the antibody drug conjugate, its stereoisomer, its pharmaceutically acceptable salt, or the antibody drug conjugate, its stereoisomer, its pharmaceutically acceptable salt solvate shows good killing activity against a variety of tumor cells expressing Trop-2. In some embodiments, the antibody drug conjugate, its stereoisomer, its pharmaceutically acceptable salt, or the antibody drug conjugate, its stereoisomer, its pharmaceutically acceptable salt solvate has good in vivo anti-tumor activity. In some embodiments, the antibody drug conjugate, its stereoisomer, its pharmaceutically acceptable salt, or the antibody drug conjugate, its stereoisomer, its pharmaceutically acceptable salt solvate has excellent safety. In some embodiments, the antibody drug conjugate, its stereoisomer, its pharmaceutically acceptable salt, or a solvate of the antibody drug conjugate, its stereoisomer, its pharmaceutically acceptable salt is not prone to aggregation.

[0225] Pharmaceutical composition

[0226] In one aspect, the present disclosure provides a pharmaceutical composition comprising the antibody drug conjugate of the present disclosure, its stereoisomer, its pharmaceutically acceptable salt, or the antibody drug conjugate, its stereoisomer, its pharmaceutically acceptable salt solvate. In some embodiments, the present disclosure provides a pharmaceutical composition comprising the antibody drug conjugate of the present disclosure, its stereoisomer, its pharmaceutically acceptable salt, or the antibody drug conjugate, its stereoisomer, its pharmaceutically acceptable salt solvate, and pharmaceutically acceptable excipients. Pharmaceutically acceptable excipients include, for example, excipients, diluents, encapsulating materials, fillers, buffers or other agents.

[0227] use

[0228] The present disclosure provides uses of the antibody-drug conjugate, its stereoisomer, its pharmaceutically acceptable salt, or a solvate of the antibody-drug conjugate, its stereoisomer, or its pharmaceutically acceptable salt. The present disclosure also provides uses of the pharmaceutical composition of the present disclosure.

[0229] In one aspect, the present disclosure provides use of the antibody drug conjugate, its stereoisomer, its pharmaceutically acceptable salt, or a solvate of the antibody drug conjugate, its stereoisomer, or its pharmaceutically acceptable salt in the preparation of a medicament for treating a disease expressing Trop-2.

[0230] In one aspect, the present disclosure provides use of the pharmaceutical composition of the present disclosure in the preparation of a medicament for treating a disease expressing Trop-2.

[0231] In one aspect, the present disclosure provides use of the antibody drug conjugate of the present disclosure, its stereoisomers, its pharmaceutically acceptable salts, or solvates of the antibody drug conjugate, its stereoisomers, its pharmaceutically acceptable salts, and one or more additional therapeutic agents in the preparation of a medicament for treating a disease expressing Trop-2.

[0232] In one aspect, the present disclosure provides use of a pharmaceutical composition of the present disclosure and one or more additional therapeutic agents in the preparation of a medicament for treating a Trop-2 expressing disease.

[0233] In one aspect, the present disclosure provides a method for treating a disease expressing Trop-2, the method comprising administering to a subject in need thereof a therapeutically effective amount of an antibody drug conjugate of the present disclosure, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a solvate of the antibody drug conjugate, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof. In one aspect, the present disclosure provides a method for treating a disease expressing Trop-2, the method comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition of the present disclosure.

[0234] In one aspect, the present disclosure provides a method for treating a disease expressing Trop-2, the method comprising administering to a subject in need thereof a therapeutically effective amount of an antibody drug conjugate of the present disclosure, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a solvate of the antibody drug conjugate, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, and one or more additional therapeutic agents. In one aspect, the present disclosure provides a method for treating a disease expressing Trop-2, the method comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition of the present disclosure and one or more additional therapeutic agents.

[0235] In some embodiments, the Trop-2 expressing disease is a tumor. In some embodiments, the additional therapeutic agent may be a tumor therapeutic agent known in the art.

[0236] In some embodiments, the method comprises contacting tumor cells with the antibody-drug conjugate, its stereoisomer, its pharmaceutically acceptable salt, or the solvate of the antibody-drug conjugate, its stereoisomer, its pharmaceutically acceptable salt, or the pharmaceutical composition, thereby killing the tumor cells or inhibiting the growth of the tumor cells.

[0237] In some embodiments, the method comprises contacting the tumor cells with the antibody drug conjugate, its stereoisomer, its pharmaceutically acceptable salt, or the antibody drug conjugate, its stereoisomer, its pharmaceutically acceptable salt solvate, or the pharmaceutical composition, and simultaneously or sequentially contacting the tumor cells with one or more additional therapeutic agents, thereby killing the tumor cells or inhibiting the growth of the tumor cells.

[0238] In some embodiments, administering the antibody drug conjugate of the present disclosure, its stereoisomer, its pharmaceutically acceptable salt, or the antibody drug conjugate, its stereoisomer, its pharmaceutically acceptable salt solvate, or the pharmaceutical composition of the present disclosure to a subject can kill tumor cells or inhibit tumor cell growth. In some embodiments, administering a therapeutically effective amount of the antibody drug conjugate of the present disclosure, its stereoisomer, its pharmaceutically acceptable salt, or the antibody drug conjugate, its stereoisomer, its pharmaceutically acceptable salt solvate, or the pharmaceutical composition of the present disclosure to a subject can kill tumor cells or inhibit tumor cell growth.

[0239] In some embodiments, the antibody drug conjugate of the present disclosure, its stereoisomer, its pharmaceutically acceptable salt, or the antibody drug conjugate, its stereoisomer, its pharmaceutically acceptable salt solvate, and one or more additional therapeutic agents are administered to the subject, which can kill tumor cells or inhibit tumor cell growth. In some embodiments, the antibody drug conjugate of the present disclosure, its stereoisomer, its pharmaceutically acceptable salt, or the antibody drug conjugate, its stereoisomer, its pharmaceutically acceptable salt solvate, and one or more additional therapeutic agents are administered to the subject, which can kill tumor cells or inhibit tumor cell growth. In some embodiments, the pharmaceutical composition of the present disclosure and one or more additional therapeutic agents are administered to the subject, which can kill tumor cells or inhibit tumor cell growth. In some embodiments, the pharmaceutical composition of the present disclosure and one or more additional therapeutic agents are administered to the subject, which can kill tumor cells or inhibit tumor cell growth.

[0240] In some embodiments, the tumor is a Trop-2 positive tumor. In some embodiments, the tumor is lung cancer (including small cell lung cancer and non-small cell lung cancer), renal cancer, urothelial carcinoma, colorectal cancer, prostate cancer, glioblastoma (including glioblastoma multiforme), ovarian cancer, pancreatic cancer, breast cancer, melanoma, liver cancer, bladder cancer, gastric cancer, cervical cancer, endometrial cancer, head and neck cancer, biliary tract cancer or esophageal cancer.

[0241] Reagent test kit

[0242] The present disclosure provides a kit comprising the antibody-drug conjugate of the present disclosure, its stereoisomers, its pharmaceutically acceptable salts, or solvates of the antibody-drug conjugate, its stereoisomers, its pharmaceutically acceptable salts, or the pharmaceutical composition of the present disclosure.

[0243] The present disclosure describes a kit comprising the antibody drug conjugate, its stereoisomer, its pharmaceutically acceptable salt, or the antibody drug conjugate, its stereoisomer, its pharmaceutically acceptable salt solvate, or the pharmaceutical composition. The kit can be used to implement the antibody drug conjugate, its stereoisomer, its pharmaceutically acceptable salt, or the antibody drug conjugate, its stereoisomer, its pharmaceutically acceptable salt solvate, or the pharmaceutical composition provided by the present disclosure or other uses. In some embodiments, the kit may include the antibody drug conjugate, its stereoisomer, its pharmaceutically acceptable salt, or the antibody drug conjugate, its stereoisomer, its pharmaceutically acceptable salt solvate, or the pharmaceutical composition; optionally, the kit may also include instructions for use. The kit may also include other materials required from the perspective of business and users, such as other buffers, diluents, needles, syringes, etc.

[0244] Connector-Payload

[0245] In some aspects, the present disclosure provides a linker-payload having a structure shown in Formula II below:

[0246]

[0247] Among them, R a is selected from a hydrogen atom, a deuterium atom, an optionally substituted C 1-6 Alkyl, optionally substituted C 3-7 Cycloalkyl, optionally substituted C 3-7 Heterocyclic group, optionally substituted C 6-10 Aryl, optionally substituted C 5-12 Heteroaryl; R bis selected from a hydrogen atom, a deuterium atom, an optionally substituted C 1-6 Alkyl, optionally substituted C 3-7 Cycloalkyl, optionally substituted C 3-7 Heterocyclic group, optionally substituted C 6-10 Aryl, optionally substituted C 5-12 heteroaryl; or R a With R b Together with the atoms to which they are attached, they form an optionally substituted 5- to 8-membered heterocyclyl. a With R b are independently selected from a hydrogen atom or C 1-5 Alkyl (preferably C 1-4 Alkyl groups, such as C 1-3 In some embodiments, the R a With R b Each is independently selected from a hydrogen atom, a methyl group, an ethyl group, a propyl group or an isopropyl group. a and R b A hydrogen atom.

[0248] In a specific embodiment, the present invention provides a linker-payload having a structure shown in the following formula II-1:

[0249]

[0250] Preparation method

[0251] The present disclosure provides a method for preparing the antibody-drug conjugate, its stereoisomer, its pharmaceutically acceptable salt, or the solvate of the antibody-drug conjugate, its stereoisomer, or its pharmaceutically acceptable salt, which comprises treating an anti-Trop-2 antibody or an antigen-binding fragment thereof under reducing conditions, and then reacting the anti-Trop-2 antibody or the antigen-binding fragment thereof with a linker-payload selected from the structure shown in Formula II, wherein R a is selected from a hydrogen atom, a deuterium atom, an optionally substituted C 1-6 Alkyl, optionally substituted C 3-7 Cycloalkyl, optionally substituted C 3-7 Heterocyclic group, optionally substituted C 6-10 Aryl, optionally substituted C 5-12 Heteroaryl; R b is selected from a hydrogen atom, a deuterium atom, an optionally substituted C 1-6 Alkyl, optionally substituted C 3-7 Cycloalkyl, optionally substituted C 3-7 Heterocyclic group, optionally substituted C 6-10 Aryl, optionally substituted C 5-12heteroaryl; or R a With R b Together with the atoms to which they are attached, they form an optionally substituted 5- to 8-membered heterocyclyl. a With R b are independently selected from a hydrogen atom or C 1-5 Alkyl (preferably C 1-4 Alkyl groups, such as C 1-3 In some embodiments, the R a With R b Each is independently selected from a hydrogen atom, a methyl group, an ethyl group, a propyl group or an isopropyl group. a and R b A hydrogen atom.

[0252] In some embodiments, the method comprises treating an anti-Trop-2 antibody or an antigen-binding fragment thereof under reducing conditions, followed by reacting the anti-Trop-2 antibody or an antigen-binding fragment thereof with a linker-payload selected from the structure shown in Formula II-1.

[0253] Explanation and Definitions

[0254] Unless otherwise specified, the following terms used in the present invention have the following meanings. A particular term should not be considered as uncertain or unclear in the absence of a special definition, but should be understood according to the common meaning in the art. When a trade name appears in this article, it is intended to refer to the corresponding commodity or its active ingredient.

[0255] The term "substituted" means that any one or more hydrogen atoms on a particular atom are replaced by a substituent, as long as the valence state of the particular atom is normal and the substituted compound is stable. When the substituent is oxo (i.e., =O), it means that two hydrogen atoms are replaced, and oxo will not occur on an aromatic group.

[0256] When any variable (e.g., R) occurs more than once in a compound's composition or structure, its definition at each occurrence is independent. Thus, for example, if a group is substituted with 2 R's, each R has an independent choice.

[0257] As used herein, the structure of "-(succinimidyl-3-yl-N)-" is as follows:

[0258]

[0259] Unless otherwise specified, the key is a solid wedge. and dotted wedge key Indicates the absolute configuration of a stereocenter.

[0260] Unless otherwise specified, when a group has a bondable site, the bond from that site to another group is represented by a wavy line. express.

[0261] As used herein, compounds formed by substitution of atoms or atomic groups in a molecule of a parent compound with other atoms or atomic groups are referred to as "derivatives" of the parent compound.

[0262] The compounds and intermediates of the present disclosure may also exist in different tautomeric forms, and all such forms are included within the scope of the present disclosure. The term "tautomer" or "tautomeric form" refers to structural isomers of different energies that can interconvert via a low energy barrier. For example, proton tautomers (also known as prototropic tautomers) include interconversions via proton migration, such as keto-enol and imine-enamine isomerizations. A specific example of a proton tautomer is an imidazole moiety, in which a proton can migrate between two ring nitrogens. Valence tautomers include interconversions by reorganization of some bonding electrons.

[0263] The compounds of the present disclosure may be asymmetric, for example, having one or more stereoisomers. Unless otherwise indicated, all stereoisomers are included in the present disclosure, such as enantiomers and diastereomers. The compounds of the present disclosure containing asymmetric carbon atoms can be isolated in optically pure form or racemic form. Optically pure forms can be resolved from racemic mixtures or synthesized by using chiral starting materials or chiral reagents.

[0264] The term "bystander effect", as used herein, refers to an effect in which a cytotoxic drug coupled to an antibody or antigen-binding fragment thereof by a cleavable or non-cleavable linker has the ability to diffuse across the cell membrane after release from the antibody or antigen-binding fragment thereof, and thereby causes killing of adjacent cells. The ability to diffuse across the cell membrane is related to the hydrophobicity of the cytotoxic drug or the combination of the cytotoxic drug and the linker. Such cytotoxic drugs may be, for example, eribulin or a derivative thereof, an exatecan derivative, or MMAE. In particular, in tumors with heterogeneous target expression and solid tumors in which antibody penetration may be limited, a bystander effect may be desirable.

[0265] The term "treatment" means administering the compounds or pharmaceutical compositions of the present disclosure to prevent, improve or eliminate a disease or one or more symptoms associated with the disease, and includes but is not limited to:

[0266] (i) preventing a disease or disease state from occurring in a mammal, particularly where such mammal is susceptible to such disease state but has not yet been diagnosed as having such disease state;

[0267] (ii) inhibiting a disease or disease state, i.e., arresting its development;

[0268] (iii) ameliorating a disease or condition, even if such disease or condition regresses;

[0269] (iv) reduce any direct or indirect pathological consequence of the disease or disease state.

[0270] The term "therapeutically effective amount" means an amount of the disclosed compound that (i) treats or prevents a particular disease, condition, or disorder, (ii) alleviates, ameliorates, or eliminates one or more symptoms of a particular disease, condition, or disorder, or (iii) prevents or delays the onset of one or more symptoms of a particular disease, condition, or disorder described herein. The amount of the disclosed compound or pharmaceutical composition that constitutes a "therapeutically effective amount" may vary according to a number of factors, such as the compound or pharmaceutical composition and its ability to elicit a desired response in an individual, the disease state and its severity, the mode of administration, and the age, sex, and weight of the mammal to be treated. The therapeutically effective amount may also be routinely determined by those skilled in the art based on their own knowledge and the present disclosure.

[0271] The term "pharmaceutically acceptable" refers to those compounds, materials, compositions and / or dosage forms which, within the scope of sound medical judgment, are suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response or other problems or complications, commensurate with a reasonable benefit / risk ratio.

[0272] The term "pharmaceutically acceptable salt" refers to a salt of a compound (e.g., the antibody drug conjugate of the present disclosure), which is safe and effective when used in mammals and has the desired biological activity, for example, a metal salt, an ammonium salt, a salt formed with an organic base, a salt formed with an inorganic acid, a salt formed with an organic acid, a salt formed with a basic or acidic amino acid, etc.

[0273] The term "excipient" refers to any ingredient other than an active ingredient (e.g., an antibody drug conjugate of the present disclosure). The choice of excipient will largely depend on factors such as the specific mode of administration, the effect of the excipient on solubility and stability, and the nature of the dosage form.

[0274] The term "solvate" refers to an association of a compound with solvent molecules.

[0275] The term "antibody" is used in the broadest sense and includes, but is not limited to, various antibody structures including monoclonal antibodies, polyclonal antibodies, and multispecific antibodies (eg, bispecific antibodies, trispecific antibodies), so long as they exhibit the desired antigen-binding activity.

[0276] An "antigen-binding fragment" of an antibody refers to one or more fragments of an antibody that retain the function of specifically binding to an antigen (e.g., CLDN18.2 protein). It has been demonstrated that the antigen-binding function of an antibody can be implemented by a fragment of a full-length antibody. Examples encompassed by the term "antigen-binding fragment" of an antibody include: (i) Fab fragment: a monovalent fragment consisting of VL, VH, CL, and CH1 domains; (ii) F(ab')2 fragment, a bivalent fragment comprising two Fab fragments connected by a disulfide bridge at the hinge region; (iii) Fd fragment consisting of VH and CH1 domains; (iv) Fv fragment consisting of the VL and VH domains of a single antibody arm; (v) dAb fragment consisting of a VH domain (see Ward et al., Nature. 341: 544-546 (1989)); and (vi) nanobodies, an antibody comprising a single variable domain and two constant domains. In addition, although the two domains VL and VH of the Fv fragment are encoded by different genes, VH and VL can be connected into a single protein chain by a recombinant method through a linker, wherein VL and VH are paired to form a monovalent molecule called single-chain Fv (scFv) (see Bird et al., Science. 242: 423-426 (1988); Huston et al., Proc. Natl. Acad. Sci. 85: 5879-5883 (1988)), and these single-chain antibodies are also included in the term antigen-binding fragment. These antibody fragments can be obtained by conventional techniques known to those skilled in the art, and the fragments can be functionally screened by the same method as full-length antibodies.

[0277] The anti-Trop-2 antibodies or antigen-binding fragments thereof of the present disclosure may be of IgG1, IgG2, IgG3 or IgG4 isotypes. The term "isotype" refers to the class of antibodies encoded by the heavy chain constant region gene. In some embodiments, the anti-Trop-2 antibodies or antigen-binding fragments thereof of the present disclosure are of IgG1 isotype. The anti-Trop-2 antibodies or antigen-binding fragments thereof of the present disclosure may be derived from any species, including but not limited to mice, rats, rabbits, non-human primates (such as chimpanzees, cynomolgus monkeys, spider monkeys, macaques), llamas and humans. The anti-Trop-2 antibodies or antigen-binding fragments thereof of the present disclosure may be murine antibodies, chimeric antibodies, humanized antibodies or human antibodies.

[0278] The term "mouse antibody" or "murine antibody" refers to an antibody in which the framework region and CDR region in the variable region are both derived from mouse germline immunoglobulin sequences. In addition, if the antibody comprises a constant region, the constant region is also derived from a mouse germline immunoglobulin sequence. The murine antibody of the present disclosure may include amino acid residues not encoded by mouse germline immunoglobulin sequences (e.g., mutations introduced by random mutations or point mutations in vitro or by somatic mutations in vivo), but "mouse antibody" or "murine antibody" does not include antibodies in which CDR sequences derived from other mammalian germlines are inserted into mouse framework sequences.

[0279] "Chimeric antibodies" are antibodies formed by fusing the variable region of a mouse antibody with the constant region of a human antibody, which can reduce the immune response induced by mouse antibodies. To create chimeric antibodies, you must first create a hybridoma that secretes mouse-specific monoclonal antibodies, then clone the variable region genes from the hybridoma cells, and then clone the constant region genes of human antibodies as needed. The mouse variable region genes and human constant region genes are connected into chimeric genes and inserted into an expression vector, and finally the chimeric antibodies are expressed in a eukaryotic or prokaryotic system.

[0280] A "humanized antibody" is an antibody that contains a complementary determining region (CDR) derived from a non-human antibody and a framework region and a constant region derived from a human antibody. For example, a humanized antibody that binds to Trop-2 in an antibody drug conjugate provided herein may contain CDRs derived from one or more murine antibodies and a human framework region and a human constant region. Thus, in some embodiments, the humanized antibody in the antibody drug conjugate provided herein binds to the same epitope on Trop-2 as the murine antibody from which the CDRs of the antibody are derived. Exemplary humanized antibodies are provided herein. Additional humanized antibodies that bind to Trop-2 or variants thereof that contain the heavy chain CDRs and light chain CDRs provided herein can be produced using any human framework sequence and are also included in the present disclosure. In some embodiments, framework sequences suitable for use in the present disclosure include those that are structurally similar to the framework sequences provided herein. Additional modifications may be made in the framework region to alter the properties of the antibodies provided herein. Such additional framework modifications may include chemical modifications, point mutations to reduce immunogenicity or remove T cell epitopes, or back mutations to residues in the original germline sequence. In some embodiments, such additional modifications include those corresponding to the mutations exemplified herein, including back mutations to germline sequences. For example, in some embodiments, one or more amino acids in the human framework regions of the VH and / or VL of the humanized antibodies provided herein are back mutated to the corresponding amino acids in the parental murine antibody. In the present disclosure, humanized antibodies are also represented as "hz".

[0281] The term “CDR” (complementarity determining region), also known as “hypervariable region.” A natural four-chain antibody usually contains six CDRs, three in the heavy chain variable region and three in the light chain variable region.

[0282] The term "variable region" refers to a domain of about 100 to 110 or more amino acids defined by the N-terminal domain of the light or heavy chain of an antibody that is primarily responsible for antigen recognition. The terms light chain variable region (VL) and heavy chain variable region (VH) refer to these light chain domains and heavy chain domains, respectively.

[0283] As used herein, the term “EC 50 ", or half maximal effective concentration, refers to the concentration of the antibody when the induced response is 50% of the maximum response, that is, halfway between the maximum response and the baseline. EC 50 Measurement may be performed by ELISA or FACS analysis or any other method known in the art.

[0284] “K D ” refers to the equilibrium dissociation constant, which is obtained from the dissociation rate constant (k d ) than the binding rate constant (k a )(i.e., k d / k a ) and expressed as molar concentration (M). D The K value can be determined using methods well established in the art. D A preferred method is by using surface plasmon resonance (SPR) technology, preferably using a biosensor system such as a Biacore surface plasmon resonance system analysis.

[0285] The term "identity" is also known as consistency. The "percentage (%) identity" of an amino acid sequence refers to the percentage of amino acid residues in the sequence to be compared that are identical to the amino acid residues in the specific amino acid sequence shown in this article, after comparing the sequence to be compared with the specific amino acid sequence shown in this article and introducing spaces if necessary to achieve the maximum sequence identity percentage, and not considering any conservative substitutions as part of the sequence identity. The amino acid sequence alignment of identity can be carried out in a variety of ways within the scope of the art, such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. Those skilled in the art can determine the appropriate parameters for comparing sequences, including any algorithm required to obtain the maximum alignment in the full length of the comparison sequence.

[0286] The term "subject" includes any human or non-human animal. The term "non-human animal" includes all vertebrates, e.g., mammals and non-mammals, such as non-human primates, sheep, dogs, cats, horses, cattle, chickens, amphibians, reptiles, etc. Preferably, the subject according to the present disclosure is a human. Unless otherwise indicated, the terms "patient" or "subject" can be used interchangeably. "Subjects in need" include those subjects who already have a disease or condition, subjects who are at risk of developing a disease or condition, and subjects who may have a disease or condition and whose purpose is to prevent, delay or attenuate the disease or condition.

[0287] As used herein, "about" means within the acceptable error range for a particular value as determined by one of ordinary skill in the art, which depends in part on how the value is measured or determined, i.e., the limitations of the measurement system. For example, "about" may mean within 1 or more than 1 standard deviation as practiced in the art. Alternatively, "about" may mean a range of up to ±5%, such as fluctuations within ±2%, within ±1%, or within ±0.5% of a given specific numerical range. When a specific value is given in the scope of the present disclosure, unless otherwise indicated, the meaning of "about" should be considered to be within the acceptable error range for that specific value. In this document, unless otherwise indicated, the values ​​of step parameters or conditions are modified by "about" by default.

[0288] The terms "comprise," "comprises," or "comprising" and their equivalents (for example, contain, contains, containing, include, includes, and including) should be understood as "including but not limited to," meaning that in addition to the listed elements, components, and steps, other unspecified elements, components, and steps may also be included.

[0289] Herein, singular terms include plural referents and vice versa unless the context clearly dictates otherwise. BRIEF DESCRIPTION OF THE DRAWINGS

[0290] Figure 1 The binding curves of chimeric or humanized antibodies of Ab2, Ab21 and Ab35 to human Trop-2-His were detected by ELISA (enzyme-linked immunosorbent assay);

[0291] Figure 2 The binding curves of humanized antibodies Ab2, Ab21 and Ab35 to A549 lung tumor cells were detected by flow cytometry;

[0292] Figure 3 Flow cytometry was used to detect the internalization of humanized antibodies Ab2 and Ab21 in HCC38 cells (cultured for 2 hours);

[0293] Figure 4 Flow cytometry was used to detect the internalization of humanized Ab35 antibody in OVCAR3 cells (cultured for 2 hours);

[0294] Figure 5 Flow cytometry was used to detect the internalization of hz-Ab2-2.4, hz-Ab21-2.1, and hz-Ab35-2.3 humanized antibodies in HCC38 cells (cultured for 2 hours, 4 hours, or 6 hours);

[0295] Figure 6 Flow cytometry was used to detect the internalization of the positive control datopotamab in HCC38 cells (cultured for 2 hours, 4 hours, or 6 hours);

[0296] Figure 7A-Figure 7I The binding curve of anti-Trop-2 antibody drug conjugates to different Trop-2 expressing cells was detected by flow cytometry. Fig. 7A For NCI-H292 cells, Figure 7B For HCC38 cells, Figure 7C For NCI-H322 cells, Fig.7D For HCC1806 cells, Fig. 7E For Capan-1 cells, Figure 7F For OVCAR-3 cells, Figure 7G For BT474 cells, Figure 7H For PC-3 cells, Fig.7I AC16 cells;

[0297] Figure 8A-8G Flow cytometry was used to detect the internalization of anti-Trop-2 antibody drug conjugates in different Trop-2 expressing cells. Fig. 8A For NCI-H292 cells, Figure 8B For NCI-H322 cells, Figure 8C For Capan-1 cells, Fig.8D For BT474 cells, Fig. 8E For OVCAR-3 cells, Fig.8F For PC-3 cells, Figure 8G HCC38 cells;

[0298] Figure 9A-9D is the killing rate of anti-Trop-2 antibody drug conjugates on tumor cells with different Trop-2 expressions, Fig.9A For NCI-H292 cells, Fig. 9B For NCI-H322 cells, Fig. 9C For HCC1806 cells, Fig.9D HCC38 cells;

[0299] Fig.10 This is the bystander effect of the anti-Trop-2 antibody-drug conjugate, where the Trop-2 positive cells are NCI-H322 cells and the Trop-2 negative cells are Jurkat cells. DETAILED DESCRIPTION

[0300] The present disclosure also provides the following specific implementation schemes, but the protection scope of the present disclosure is not limited thereto:

[0301] Embodiment 1. An antibody-drug conjugate, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a solvate of the antibody-drug conjugate, its stereoisomer, or a pharmaceutically acceptable salt thereof, comprising an anti-Trop-2 antibody or an antigen-binding fragment thereof, wherein the anti-Trop-2 antibody or the antigen-binding fragment thereof comprises: a HCDR1 comprising the amino acid sequence of SEQ ID NO: 17, 5, 11 or 48, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 18, 6, 12, 31, 32, 49 or 62, a HCDR3 comprising the amino acid sequence of SEQ ID NO: 19, 7 or 13, a LCDR1 comprising the amino acid sequence of SEQ ID NO: 20, 8, 14 or 33, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 21, 9, 15 or 34, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 22, 10, 16 or 35.

[0302] Embodiment 2. The antibody-drug conjugate, its stereoisomer, its pharmaceutically acceptable salt, or the solvate of the antibody-drug conjugate, its stereoisomer, or its pharmaceutically acceptable salt according to Embodiment 1, wherein the anti-Trop-2 antibody or antigen-binding fragment thereof comprises:

[0303] (1) a HCDR1 comprising the amino acid sequence of SEQ ID NO:5, a HCDR2 comprising the amino acid sequence of SEQ ID NO:6, a HCDR3 comprising the amino acid sequence of SEQ ID NO:7, a LCDR1 comprising the amino acid sequence of SEQ ID NO:8, a LCDR2 comprising the amino acid sequence of SEQ ID NO:9, and a LCDR3 comprising the amino acid sequence of SEQ ID NO:10;

[0304] (2) a HCDR1 comprising the amino acid sequence of SEQ ID NO:5, a HCDR2 comprising the amino acid sequence of SEQ ID NO:31, a HCDR3 comprising the amino acid sequence of SEQ ID NO:7, a LCDR1 comprising the amino acid sequence of SEQ ID NO:8, a LCDR2 comprising the amino acid sequence of SEQ ID NO:34, and a LCDR3 comprising the amino acid sequence of SEQ ID NO:10;

[0305] (3) a HCDR1 comprising the amino acid sequence of SEQ ID NO:5, a HCDR2 comprising the amino acid sequence of SEQ ID NO:32, a HCDR3 comprising the amino acid sequence of SEQ ID NO:7, a LCDR1 comprising the amino acid sequence of SEQ ID NO:8, a LCDR2 comprising the amino acid sequence of SEQ ID NO:34, and a LCDR3 comprising the amino acid sequence of SEQ ID NO:10;

[0306] (4) a HCDR1 comprising the amino acid sequence of SEQ ID NO:5, a HCDR2 comprising the amino acid sequence of SEQ ID NO:31, a HCDR3 comprising the amino acid sequence of SEQ ID NO:7, a LCDR1 comprising the amino acid sequence of SEQ ID NO:33, a LCDR2 comprising the amino acid sequence of SEQ ID NO:34, and a LCDR3 comprising the amino acid sequence of SEQ ID NO:35;

[0307] (5) a HCDR1 comprising the amino acid sequence of SEQ ID NO:5, a HCDR2 comprising the amino acid sequence of SEQ ID NO:32, a HCDR3 comprising the amino acid sequence of SEQ ID NO:7, a LCDR1 comprising the amino acid sequence of SEQ ID NO:33, a LCDR2 comprising the amino acid sequence of SEQ ID NO:34, and a LCDR3 comprising the amino acid sequence of SEQ ID NO:35;

[0308] (6) a HCDR1 comprising the amino acid sequence of SEQ ID NO:11, a HCDR2 comprising the amino acid sequence of SEQ ID NO:12, a HCDR3 comprising the amino acid sequence of SEQ ID NO:13, a LCDR1 comprising the amino acid sequence of SEQ ID NO:14, a LCDR2 comprising the amino acid sequence of SEQ ID NO:15, and a LCDR3 comprising the amino acid sequence of SEQ ID NO:16;

[0309] (7) a HCDR1 comprising the amino acid sequence of SEQ ID NO:48, a HCDR2 comprising the amino acid sequence of SEQ ID NO:49, a HCDR3 comprising the amino acid sequence of SEQ ID NO:13, a LCDR1 comprising the amino acid sequence of SEQ ID NO:14, a LCDR2 comprising the amino acid sequence of SEQ ID NO:15, and a LCDR3 comprising the amino acid sequence of SEQ ID NO:16;

[0310] (8) a HCDR1 comprising the amino acid sequence of SEQ ID NO:48, a HCDR2 comprising the amino acid sequence of SEQ ID NO:12, a HCDR3 comprising the amino acid sequence of SEQ ID NO:13, a LCDR1 comprising the amino acid sequence of SEQ ID NO:14, a LCDR2 comprising the amino acid sequence of SEQ ID NO:15, and a LCDR3 comprising the amino acid sequence of SEQ ID NO:16;

[0311] (9) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 17, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 18, a HCDR3 comprising the amino acid sequence of SEQ ID NO: 19, a LCDR1 comprising the amino acid sequence of SEQ ID NO: 20, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 21, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 22; or

[0312] (10) A HCDR1 comprising the amino acid sequence of SEQ ID NO: 17, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 62, a HCDR3 comprising the amino acid sequence of SEQ ID NO: 19, a LCDR1 comprising the amino acid sequence of SEQ ID NO: 20, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 21, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 22.

[0313] Embodiment 3. An antibody drug conjugate, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a solvate of the antibody drug conjugate, its stereoisomer, or a pharmaceutically acceptable salt thereof, comprising an anti-Trop-2 antibody or an antigen-binding fragment thereof, wherein the anti-Trop-2 antibody or the antigen-binding fragment thereof comprises: HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in the amino acid sequence of SEQ ID NO: 27, 63, 64, 65, 23, 25, 36, 37, 38, 39, 50, 51, 52 or 53, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in the amino acid sequence of SEQ ID NO: 28, 66, 67, 24, 26, 40, 41, 54 or 55.

[0314] Embodiment 4. The antibody-drug conjugate, its stereoisomer, its pharmaceutically acceptable salt, or the solvate of the antibody-drug conjugate, its stereoisomer, or its pharmaceutically acceptable salt according to Embodiment 3, wherein the anti-Trop-2 antibody or antigen-binding fragment thereof comprises:

[0315] (1) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence shown in SEQ ID NO: 23, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence shown in SEQ ID NO: 24;

[0316] (2) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence set forth in SEQ ID NO:25, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence set forth in SEQ ID NO:26;

[0317] (3) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence set forth in SEQ ID NO:27, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence set forth in SEQ ID NO:28;

[0318] (4) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence set forth in SEQ ID NO:36, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence set forth in SEQ ID NO:40;

[0319] (5) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence set forth in SEQ ID NO:37, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence set forth in SEQ ID NO:40;

[0320] (6) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence set forth in SEQ ID NO:38, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence set forth in SEQ ID NO:40;

[0321] (7) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence shown in SEQ ID NO:39, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence shown in SEQ ID NO:40;

[0322] (8) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence shown in SEQ ID NO:36, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence shown in SEQ ID NO:41;

[0323] (9) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence shown in SEQ ID NO:37, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence shown in SEQ ID NO:41;

[0324] (10) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence shown in SEQ ID NO:38, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence shown in SEQ ID NO:41;

[0325] (11) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence shown in SEQ ID NO:39, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence shown in SEQ ID NO:41;

[0326] (12) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence shown in SEQ ID NO:50, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence shown in SEQ ID NO:54;

[0327] (13) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence shown in SEQ ID NO:51, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence shown in SEQ ID NO:54;

[0328] (14) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence shown in SEQ ID NO:52, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence shown in SEQ ID NO:54;

[0329] (15) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence shown in SEQ ID NO:53, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence shown in SEQ ID NO:54;

[0330] (16) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence shown in SEQ ID NO:50, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence shown in SEQ ID NO:55;

[0331] (17) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence shown in SEQ ID NO:51, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence shown in SEQ ID NO:55;

[0332] (18) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence shown in SEQ ID NO:52, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence shown in SEQ ID NO:55;

[0333] (19) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence shown in SEQ ID NO:53, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence shown in SEQ ID NO:55;

[0334] (20) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence shown in SEQ ID NO:63, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence shown in SEQ ID NO:66;

[0335] (21) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence shown in SEQ ID NO:64, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence shown in SEQ ID NO:66;

[0336] (22) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence shown in SEQ ID NO:65, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence shown in SEQ ID NO:66;

[0337] (23) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence shown in SEQ ID NO:63, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence shown in SEQ ID NO:67;

[0338] (24) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence of SEQ ID NO:64, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence of SEQ ID NO:67; or

[0339] (25) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region whose amino acid sequence is shown in SEQ ID NO:65, and LCDR1, LCDR2 and LCDR3 in the light chain variable region whose amino acid sequence is shown in SEQ ID NO:67.

[0340] Embodiment 5. The antibody drug conjugate, stereoisomer thereof, pharmaceutically acceptable salt thereof, or solvate of the antibody drug conjugate, stereoisomer thereof, pharmaceutically acceptable salt thereof, according to any one of Embodiments 1 to 4, wherein the anti-Trop-2 antibody or antigen-binding fragment thereof comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 23, 25, 27, 36, 37, 38, 39, 50, 51, 52, 53, 63, 64 or 65, and an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: The amino acid sequences shown in NO:24, 26, 28, 40, 41, 54, 55, 66 or 67 have a light chain variable region that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical.

[0341] Embodiment 6. The antibody drug conjugate, its stereoisomer, its pharmaceutically acceptable salt, or the solvate of the antibody drug conjugate, its stereoisomer, or its pharmaceutically acceptable salt according to any one of Embodiments 1 to 5, wherein the anti-Trop-2 antibody or antigen-binding fragment thereof comprises:

[0342] (1) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:23, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:24;

[0343] (2) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:25, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:26;

[0344] (3) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:27, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:28;

[0345] (4) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:36, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:40;

[0346] (5) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:37, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:40;

[0347] (6) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:38, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:40;

[0348] (7) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:39, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:40;

[0349] (8) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:36, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:41;

[0350] (9) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:37, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:41;

[0351] (10) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:38, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:41;

[0352] (11) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:39, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:41;

[0353] (12) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:50, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:54;

[0354] (13) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:51, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:54;

[0355] (14) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:52, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:54;

[0356] (15) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:53, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:54;

[0357] (16) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:50, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:55;

[0358] (17) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:51, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:55;

[0359] (18) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:52, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:55;

[0360] (19) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:53, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:55;

[0361] (20) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:63, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:66;

[0362] (21) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:64, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:66;

[0363] (22) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:65, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:66;

[0364] (23) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:63, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:67;

[0365] (24) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:64, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:67; or

[0366] (25) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:65, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:67.

[0367] Embodiment 7. The antibody drug conjugate, its stereoisomer, its pharmaceutically acceptable salt, or the solvate of the antibody drug conjugate, its stereoisomer, or its pharmaceutically acceptable salt according to any one of Embodiments 1 to 6, wherein the anti-Trop-2 antibody or antigen-binding fragment thereof comprises:

[0368] (1) a heavy chain variable region having an amino acid sequence as shown in SEQ ID NO: 23, and a light chain variable region having an amino acid sequence as shown in SEQ ID NO: 24;

[0369] (2) a heavy chain variable region having an amino acid sequence as shown in SEQ ID NO: 25, and a light chain variable region having an amino acid sequence as shown in SEQ ID NO: 26;

[0370] (3) a heavy chain variable region having an amino acid sequence as shown in SEQ ID NO: 27, and a light chain variable region having an amino acid sequence as shown in SEQ ID NO: 28;

[0371] (4) a heavy chain variable region having an amino acid sequence as shown in SEQ ID NO:36, and a light chain variable region having an amino acid sequence as shown in SEQ ID NO:40;

[0372] (5) a heavy chain variable region having an amino acid sequence as shown in SEQ ID NO:37, and a light chain variable region having an amino acid sequence as shown in SEQ ID NO:40;

[0373] (6) a heavy chain variable region having an amino acid sequence as shown in SEQ ID NO:38, and a light chain variable region having an amino acid sequence as shown in SEQ ID NO:40;

[0374] (7) a heavy chain variable region having an amino acid sequence as shown in SEQ ID NO:39, and a light chain variable region having an amino acid sequence as shown in SEQ ID NO:40;

[0375] (8) a heavy chain variable region having an amino acid sequence as shown in SEQ ID NO:36, and a light chain variable region having an amino acid sequence as shown in SEQ ID NO:41;

[0376] (9) a heavy chain variable region having an amino acid sequence as shown in SEQ ID NO:37, and a light chain variable region having an amino acid sequence as shown in SEQ ID NO:41;

[0377] (10) a heavy chain variable region having an amino acid sequence as shown in SEQ ID NO:38, and a light chain variable region having an amino acid sequence as shown in SEQ ID NO:41;

[0378] (11) a heavy chain variable region having an amino acid sequence as shown in SEQ ID NO:39, and a light chain variable region having an amino acid sequence as shown in SEQ ID NO:41;

[0379] (12) a heavy chain variable region having an amino acid sequence as shown in SEQ ID NO:50, and a light chain variable region having an amino acid sequence as shown in SEQ ID NO:54;

[0380] (13) a heavy chain variable region having an amino acid sequence as shown in SEQ ID NO:51, and a light chain variable region having an amino acid sequence as shown in SEQ ID NO:54;

[0381] (14) a heavy chain variable region having an amino acid sequence as shown in SEQ ID NO:52, and a light chain variable region having an amino acid sequence as shown in SEQ ID NO:54;

[0382] (15) a heavy chain variable region having an amino acid sequence as shown in SEQ ID NO:53, and a light chain variable region having an amino acid sequence as shown in SEQ ID NO:54;

[0383] (16) a heavy chain variable region having an amino acid sequence as shown in SEQ ID NO:50, and a light chain variable region having an amino acid sequence as shown in SEQ ID NO:55;

[0384] (17) a heavy chain variable region having an amino acid sequence as shown in SEQ ID NO:51, and a light chain variable region having an amino acid sequence as shown in SEQ ID NO:55;

[0385] (18) a heavy chain variable region having an amino acid sequence as shown in SEQ ID NO:52, and a light chain variable region having an amino acid sequence as shown in SEQ ID NO:55;

[0386] (19) a heavy chain variable region having an amino acid sequence as shown in SEQ ID NO:53, and a light chain variable region having an amino acid sequence as shown in SEQ ID NO:55;

[0387] (20) a heavy chain variable region having an amino acid sequence as shown in SEQ ID NO:63, and a light chain variable region having an amino acid sequence as shown in SEQ ID NO:66;

[0388] (21) a heavy chain variable region having an amino acid sequence as shown in SEQ ID NO:64, and a light chain variable region having an amino acid sequence as shown in SEQ ID NO:66;

[0389] (22) a heavy chain variable region having an amino acid sequence as shown in SEQ ID NO:65, and a light chain variable region having an amino acid sequence as shown in SEQ ID NO:66;

[0390] (23) a heavy chain variable region having an amino acid sequence as shown in SEQ ID NO:63, and a light chain variable region having an amino acid sequence as shown in SEQ ID NO:67;

[0391] (24) the heavy chain variable region of the amino acid sequence shown in SEQ ID NO:64, and the light chain variable region of the amino acid sequence shown in SEQ ID NO:67; or (25) the heavy chain variable region of the amino acid sequence shown in SEQ ID NO:65, and the light chain variable region of the amino acid sequence shown in SEQ ID NO:67.

[0392] Embodiment 8. The antibody drug conjugate, its stereoisomer, its pharmaceutically acceptable salt, or a solvate of the antibody drug conjugate, its stereoisomer, or its pharmaceutically acceptable salt according to any one of Embodiments 1-7, wherein the anti-Trop-2 antibody is of IgG1, IgG2, IgG3 or IgG4 isotype.

[0393] Embodiment 9. The antibody drug conjugate, stereoisomer thereof, pharmaceutically acceptable salt thereof, or solvate of the antibody drug conjugate, stereoisomer thereof, pharmaceutically acceptable salt thereof, or solvate of the antibody drug conjugate, stereoisomer thereof, pharmaceutically acceptable salt thereof according to any one of Embodiments 1 to 8, wherein the anti-Trop-2 antibody further comprises a heavy chain constant region and a light chain constant region, the heavy chain constant region comprising the amino acid sequence shown in SEQ ID NO: 29 or an amino acid sequence having 1, 2, 3, 4 or 5 amino acid substitutions, deletions or insertions compared to the amino acid sequence shown in SEQ ID NO: 29, and the light chain constant region comprising the amino acid sequence shown in SEQ ID NO: 30 or an amino acid sequence having 1, 2, 3, 4 or 5 amino acid substitutions, deletions or insertions compared to the amino acid sequence shown in SEQ ID NO: 30.

[0394] Embodiment 10. An antibody drug conjugate, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a solvate of the antibody drug conjugate, its stereoisomer, or a pharmaceutically acceptable salt thereof, comprising an anti-Trop-2 antibody, wherein the anti-Trop-2 antibody comprises a heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 70, and an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 70. NO:71 has a light chain that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence shown in SEQ ID NO:71; and the anti-Trop-2 antibody comprises a HCDR1 comprising the amino acid sequence shown in SEQ ID NO:17, a HCDR2 comprising the amino acid sequence shown in SEQ ID NO:18, a HCDR3 comprising the amino acid sequence shown in SEQ ID NO:19, a LCDR1 comprising the amino acid sequence shown in SEQ ID NO:20, a LCDR2 comprising the amino acid sequence shown in SEQ ID NO:21, and a LCDR3 comprising the amino acid sequence shown in SEQ ID NO:22.

[0395] Embodiment 11. The antibody-drug conjugate, its stereoisomer, its pharmaceutically acceptable salt, or a solvate of the antibody-drug conjugate, its stereoisomer, or its pharmaceutically acceptable salt according to Embodiment 10, wherein the anti-Trop-2 antibody comprises a heavy chain having the amino acid sequence shown in SEQ ID NO: 70, and a light chain having the amino acid sequence shown in SEQ ID NO: 71.

[0396] Embodiment 12. The antibody-drug conjugate, its stereoisomer, its pharmaceutically acceptable salt, or the solvate of the antibody-drug conjugate, its stereoisomer, or its pharmaceutically acceptable salt according to any one of Embodiments 1-11, wherein the general formula of the antibody-drug conjugate is Ab-(LU) n , Ab is the anti-Trop-2 antibody or its antigen-binding fragment, L is a linker, U is a cytotoxic drug, and n is 1-10; preferably, U is a tubulin inhibitor; more preferably, U is eribulin or its derivatives.

[0397] Embodiment 13. The antibody-drug conjugate, its stereoisomer, its pharmaceutically acceptable salt, or the solvate of the antibody-drug conjugate, its stereoisomer, or its pharmaceutically acceptable salt according to Embodiment 12, wherein the general formula Ab-(LU) n-U in is a structure shown in the following formula Ⅰa:

[0398]

[0399] in,

[0400] R a is selected from a hydrogen atom, a deuterium atom, an optionally substituted C 1-6 Alkyl, optionally substituted C 3-7 Cycloalkyl, optionally substituted C 3-7 Heterocyclic group, optionally substituted C 6-10 Aryl, optionally substituted C 5-12 Heteroaryl, R b is selected from a hydrogen atom, a deuterium atom, an optionally substituted C 1-6 Alkyl, optionally substituted C 3-7 Cycloalkyl, optionally substituted C 3-7 Heterocyclic group, optionally substituted C 6-10 Aryl, optionally substituted C 5-12 heteroaryl; or, R a With R b together with the atoms to which they are attached, form an optionally substituted 5- to 8-membered heterocyclyl;

[0401] Furthermore, the wavy line indicates the connection position between the structure represented by Formula Ia and L.

[0402] Embodiment 14. The antibody-drug conjugate, its stereoisomer, its pharmaceutically acceptable salt, or the solvate of the antibody-drug conjugate, its stereoisomer, or its pharmaceutically acceptable salt according to Embodiment 13, wherein the general formula Ab-(LU) n The -LU in is a structure shown in the following formula IIa:

[0403]

[0404] in,

[0405] R a is selected from a hydrogen atom, a deuterium atom, an optionally substituted C 1-6 Alkyl, optionally substituted C 3-7 Cycloalkyl, optionally substituted C 3-7 Heterocyclic group, optionally substituted C 6-10 Aryl, optionally substituted C 5-12 Heteroaryl, R b is selected from a hydrogen atom, a deuterium atom, an optionally substituted C 1-6 Alkyl, optionally substituted C 3-7 Cycloalkyl, optionally substituted C 3-7 Heterocyclic group, optionally substituted C 6-10Aryl, optionally substituted C 5-12 heteroaryl; or, R a With R b together with the atoms to which they are attached, form an optionally substituted 5- to 8-membered heterocyclyl;

[0406] Also, the wavy line indicates the connection position between the structure represented by Formula IIa and Ab.

[0407] Embodiment 15. The antibody drug conjugate, its stereoisomer, its pharmaceutically acceptable salt, or the solvate of the antibody drug conjugate, its stereoisomer, or its pharmaceutically acceptable salt according to any one of Embodiments 1 to 11, wherein the structure of the antibody drug conjugate is as shown in Formula III:

[0408]

[0409] in,

[0410] R a is selected from a hydrogen atom, a deuterium atom, an optionally substituted C 1-6 Alkyl, optionally substituted C 3-7 Cycloalkyl, optionally substituted C 3-7 Heterocyclic group, optionally substituted C 6-10 Aryl, optionally substituted C 5-12 Heteroaryl, R b is selected from a hydrogen atom, a deuterium atom, an optionally substituted C 1-6 Alkyl, optionally substituted C 3-7 Cycloalkyl, optionally substituted C 3-7 Heterocyclic group, optionally substituted C 6-10 Aryl, optionally substituted C 5-12 heteroaryl; or, R a With R b together with the atoms to which they are attached, form an optionally substituted 5- to 8-membered heterocyclyl;

[0411] n is 1-10;

[0412] Furthermore, the 3-position of -(succinimidyl-3-yl-N)- in Formula III is connected to Ab.

[0413] Embodiment 16. The antibody drug conjugate, its stereoisomer, its pharmaceutically acceptable salt, or the solvate of the antibody drug conjugate, its stereoisomer, or its pharmaceutically acceptable salt according to any one of Embodiments 13-15, wherein the R a With R b are independently selected from a hydrogen atom or C 1-5 Alkyl, preferably C 1-4 Alkyl, preferably C1-3 alkyl.

[0414] Embodiment 17. The antibody drug conjugate, its stereoisomer, its pharmaceutically acceptable salt, or the solvate of the antibody drug conjugate, its stereoisomer, or its pharmaceutically acceptable salt according to any one of Embodiments 13-16, wherein the R a With R b Each is independently selected from a hydrogen atom, a methyl group, an ethyl group, a propyl group or an isopropyl group.

[0415] Embodiment 18. The antibody drug conjugate, its stereoisomer, its pharmaceutically acceptable salt, or the solvate of the antibody drug conjugate, its stereoisomer, or its pharmaceutically acceptable salt according to any one of Embodiments 13-17, wherein the R a and R b A hydrogen atom.

[0416] Embodiment 19. The antibody drug conjugate, its stereoisomer, its pharmaceutically acceptable salt, or the solvate of the antibody drug conjugate, its stereoisomer, or its pharmaceutically acceptable salt according to any one of Embodiments 12-18, wherein n is 2-8, 3.5-8, 4-8, 3.5-4.8, 3.5-4.5, 3.5-4.3, 4-4.8, 4-4.5, 4-4.3, 7-8, 7-7.8, or 7-7.5.

[0417] Embodiment 20. The antibody drug conjugate, its stereoisomer, its pharmaceutically acceptable salt, or the solvate of the antibody drug conjugate, its stereoisomer, or its pharmaceutically acceptable salt according to any one of Embodiments 12-19, wherein n is 3.5, 3.8, 4, 4.1, 4.3, 4.5, 4.6, 4.8, 7.5, 7.8 or 8.

[0418] Embodiment 21. The antibody drug conjugate, its stereoisomer, its pharmaceutically acceptable salt, or the solvate of the antibody drug conjugate, its stereoisomer, or its pharmaceutically acceptable salt according to any one of Embodiments 1-11, wherein the antibody drug conjugate is represented by the following formula IIa

[0419]

[0420] The structure shown is connected with an anti-Trop-2 antibody or an antigen-binding fragment thereof, wherein

[0421] R a is selected from a hydrogen atom, a deuterium atom, an optionally substituted C 1-6 Alkyl, optionally substituted C 3-7 Cycloalkyl, optionally substituted C3-7 Heterocyclic group, optionally substituted C 6-10 Aryl, optionally substituted C 5-12 Heteroaryl, R b is selected from a hydrogen atom, a deuterium atom, an optionally substituted C 1-6 Alkyl, optionally substituted C 3-7 Cycloalkyl, optionally substituted C 3-7 Heterocyclic group, optionally substituted C 6-10 Aryl, optionally substituted C 5-12 heteroaryl; or, R a With R b together with the atoms to which they are attached, form an optionally substituted 5- to 8-membered heterocyclyl;

[0422] The 3-position of -(succinimide-3-yl-N)- in the structure represented by Formula IIa is linked to the anti-Trop-2 antibody or its antigen-binding fragment.

[0423] Embodiment 22. The antibody drug conjugate, its stereoisomer, its pharmaceutically acceptable salt, or the solvate of the antibody drug conjugate, its stereoisomer, or its pharmaceutically acceptable salt according to Embodiment 21, wherein the R a With R b are independently selected from a hydrogen atom or C 1-5 Alkyl, preferably C 1-4 Alkyl, preferably C 1-3 alkyl.

[0424] Embodiment 23. The antibody drug conjugate, its stereoisomer, its pharmaceutically acceptable salt, or the solvate of the antibody drug conjugate, its stereoisomer, or its pharmaceutically acceptable salt according to Embodiment 21 or 22, wherein the R a With R b Each is independently selected from a hydrogen atom, a methyl group, an ethyl group, a propyl group or an isopropyl group.

[0425] Embodiment 24. The antibody drug conjugate, its stereoisomer, its pharmaceutically acceptable salt, or the solvate of the antibody drug conjugate, its stereoisomer, or its pharmaceutically acceptable salt according to any one of Embodiments 21-23, wherein the R a and R b A hydrogen atom.

[0426] Embodiment 25. The antibody drug conjugate, stereoisomer thereof, pharmaceutically acceptable salt thereof, or solvate of the antibody drug conjugate, stereoisomer thereof, or pharmaceutically acceptable salt thereof according to any one of Embodiments 21-24, wherein the average number of linkages of the cytotoxic drug per anti-Trop-2 antibody or antigen-binding fragment thereof is 2-8, 3.5-8, 4-8, 3.5-4.8, 3.5-4.5, 3.5-4.3, 4-4.8, 4-4.5, 4-4.3, 7-8, 7-7.8, or 7-7.5.

[0427] Embodiment 26. The antibody drug conjugate, stereoisomer thereof, pharmaceutically acceptable salt thereof, or solvate of the antibody drug conjugate, stereoisomer thereof, or pharmaceutically acceptable salt thereof according to any one of Embodiments 21-25, wherein the average number of linkages of the cytotoxic drug per anti-Trop-2 antibody or antigen-binding fragment thereof is 3.5, 3.8, 4, 4.1, 4.3, 4.5, 4.6, 4.8, 7.5, 7.8 or 8.

[0428] Embodiment 27. The antibody drug conjugate, its stereoisomer, its pharmaceutically acceptable salt, or the solvate of the antibody drug conjugate, its stereoisomer, or its pharmaceutically acceptable salt according to any one of Embodiments 1-26, wherein the antibody drug conjugate, its stereoisomer, its pharmaceutically acceptable salt, or the solvate of the antibody drug conjugate, its stereoisomer, or its pharmaceutically acceptable salt exhibits one or a combination of the following properties:

[0429] (1) bind to human Trop-2, preferably with a KD value of 2E-09M or less;

[0430] (2) binding to monkey Trop-2;

[0431] (3) showed endocytosis in cells expressing Trop-2;

[0432] (4) has killing activity against tumor cells expressing Trop-2;

[0433] (5) There is a bystander effect;

[0434] (6) having ADCC activity; and

[0435] (7) Does not bind to cells that do not express Trop-2.

[0436] Embodiment 28. A pharmaceutical composition comprising the antibody drug conjugate, its stereoisomer, its pharmaceutically acceptable salt, or a solvate of the antibody drug conjugate, its stereoisomer, or its pharmaceutically acceptable salt according to any one of Embodiments 1-27; optionally, the pharmaceutical composition further comprises a pharmaceutically acceptable excipient.

[0437] Embodiment 29. A method for preparing an antibody drug conjugate, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a solvate of the antibody drug conjugate, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof according to any one of Embodiments 14 to 27, comprising treating an anti-Trop-2 antibody or an antigen-binding fragment thereof under reducing conditions, and then reacting the anti-Trop-2 antibody or the antigen-binding fragment thereof with a linker-payload selected from the structure shown in Formula II, wherein the structure shown in Formula II is as follows:

[0438] in,

[0439] R a is selected from a hydrogen atom, a deuterium atom, an optionally substituted C 1-6 Alkyl, optionally substituted C 3-7 Cycloalkyl, optionally substituted C 3-7 Heterocyclic group, optionally substituted C 6-10 Aryl, optionally substituted C 5-12 heteroaryl;

[0440] R b is selected from a hydrogen atom, a deuterium atom, an optionally substituted C 1-6 Alkyl, optionally substituted C 3-7 Cycloalkyl, optionally substituted C 3-7 Heterocyclic group, optionally substituted C 6-10 Aryl, optionally substituted C 5-12 heteroaryl;

[0441] or R a With R b Together with the atoms to which it is attached, it forms an optionally substituted 5- to 8-membered heterocyclyl.

[0442] Embodiment 30. The method according to embodiment 29, wherein the R a With R b are independently selected from a hydrogen atom or C 1-5 alkyl.

[0443] Embodiment 31. The method according to embodiment 29 or 30, wherein the R a With R b Each is independently selected from a hydrogen atom, a methyl group, an ethyl group, a propyl group or an isopropyl group.

[0444] Embodiment 32. The method according to any one of embodiments 29-31, wherein the R a and R b A hydrogen atom.

[0445] Embodiment 33. Use of the antibody-drug conjugate, its stereoisomer, its pharmaceutically acceptable salt, or the solvate of the antibody-drug conjugate, its stereoisomer, or its pharmaceutically acceptable salt according to any one of Embodiments 1-27, or the pharmaceutical composition according to Embodiment 28 in the preparation of a medicament for treating a disease expressing Trop-2.

[0446] Embodiment 34. Use of the antibody drug conjugate, its stereoisomer, its pharmaceutically acceptable salt, or the solvate of the antibody drug conjugate, its stereoisomer, or its pharmaceutically acceptable salt according to any one of Embodiments 1-27, or the pharmaceutical composition according to Embodiment 28, and one or more additional therapeutic agents in the preparation of a medicament for treating a disease expressing Trop-2.

[0447] Embodiment 35. The use according to Embodiment 34, wherein the additional therapeutic agent is a tumor therapeutic agent.

[0448] Embodiment 36. The use according to any one of Embodiments 33 to 35, wherein the disease expressing Trop-2 is a tumor.

[0449] Embodiment 37. The use according to Embodiment 35 or 36, wherein the tumor is a Trop-2 positive tumor; preferably, the tumor is lung cancer, kidney cancer, urothelial carcinoma, colorectal cancer, prostate cancer, glioblastoma, ovarian cancer, pancreatic cancer, breast cancer, melanoma, liver cancer, bladder cancer, gastric cancer, cervical cancer, endometrial cancer, head and neck cancer, biliary tract cancer or esophageal cancer.

[0450] Embodiment 38. A method for treating a tumor, comprising administering to a subject in need thereof a therapeutically effective amount of the antibody-drug conjugate, its stereoisomer, its pharmaceutically acceptable salt, or the solvate of the antibody-drug conjugate, its stereoisomer, its pharmaceutically acceptable salt, or the pharmaceutical composition of Embodiment 28 according to any one of Embodiments 1-27.

[0451] Embodiment 39. A method according to Embodiment 38, comprising contacting tumor cells with the antibody drug conjugate, its stereoisomer, its pharmaceutically acceptable salt, or the solvate of the antibody drug conjugate, its stereoisomer, or its pharmaceutically acceptable salt described in any one of Embodiments 1-27, or the pharmaceutical composition described in Embodiment 28, thereby killing tumor cells or inhibiting tumor cell growth.

[0452] Embodiment 40. The method of Embodiment 38 or 39, wherein the method further comprises administering one or more additional therapeutic agents; preferably, the additional therapeutic agent is a tumor therapeutic agent.

[0453] Embodiment 41. A method according to any one of Embodiments 38-40, wherein the tumor is a Trop-2 positive tumor; preferably, the tumor is lung cancer, kidney cancer, urothelial carcinoma, colorectal cancer, prostate cancer, glioblastoma, ovarian cancer, pancreatic cancer, breast cancer, melanoma, liver cancer, bladder cancer, gastric cancer, cervical cancer, endometrial cancer, head and neck cancer, biliary tract cancer or esophageal cancer.

[0454] Embodiment 42. A kit comprising the antibody drug conjugate, its stereoisomer, its pharmaceutically acceptable salt, or the solvate of the antibody drug conjugate, its stereoisomer, or its pharmaceutically acceptable salt according to any one of Embodiments 1-27, or the pharmaceutical composition according to Embodiment 28; optionally, the kit further comprises instructions for use.

[0455] For the sake of clarity, the present disclosure is further illustrated by examples, but the examples do not limit the scope of the present disclosure. Those skilled in the art will readily recognize a variety of non-critical parameters that can be changed or modified to produce substantially similar results.

[0456] In the disclosed embodiments, Datopotamab (also known as TINA) is prepared according to conventional methods for antibodies, first constructing a vector, then transfecting eukaryotic cells and purifying and expressing. The heavy chain amino acid sequence of Datopotamab corresponds to sequence number 12 in CN105849126A, and the light chain amino acid sequence corresponds to sequence number 18 in CN105849126A. Datopotamab is an anti-Trop-2 antibody developed by Daiichi Sankyo Co., Ltd.

[0457] The cell information involved in Examples 18-22 of the present disclosure is shown in the following table, wherein FBS is from Gibco, catalog number 10099141C:

[0458] Table 1. Cell information

[0459]

[0460] Example 1: Construction of Trop-2 High-Expression Cell Line

[0461] The DNA sequence of the full-length open reading frame of human Trop-2 was synthesized by Universal Biosystems (Anhui) Co., Ltd. and subcloned into the expression vector pcDNA3.1 (Invitrogen, catalog number: V-79020), and transfected into blank CHO-K1 cells using Lipofectamine3000 (Gibco) transfection reagent, and after 2-3 weeks of selection by geneticin, the limiting dilution method was used to separate the monoclonal clones, and the Trop-2 expression level on the surface of the monoclonal cell line CHO-K1 obtained by the limiting dilution method was detected by FACS, and the CHO-K1 / hTrop-2 monoclonal cell line with high Trop-2 expression level was selected. The full-length amino acid sequence of human Trop-2 is shown in SEQ ID NO: 1.

[0462] Example 2: Generation of murine Trop-2 monoclonal antibodies

[0463] Obtaining mouse anti-human Trop-2 antibodies: Human Trop-2-hFc was used to immunize mice, specifically, the extracellular domain of human Trop-2 was recombinantly linked to human IgG Fc to form Trop-2-hFc (SEQ ID NO: 2). The DNA sequence was synthesized by General Biosystems (Anhui) Co., Ltd. and subcloned into the expression vector pcDNA3.1 (Invitrogen catalog number: V-79020). After transient expression in FreeStyle293 cells, human Trop-2-hFc was purified using a protein A column (GE healthcare). Recombinant human Trop-2-hFc protein (100 μg / mouse) emulsified with an equal volume of complete / incomplete Freund's adjuvant was used to subcutaneously immunize BALB / c and A / J mice (Shanghai Xipu-Bikai Experimental Animal Co., Ltd.) every 2 weeks for 6 weeks. Three days before fusion, mice were boosted by intravenous injection of adjuvant-free antigen. Splenocytes (1×10 8 ) and SP2 / 0 myeloma cells (1×10 7 After fusion, cells were dispensed into a 96-well plate at 0.1 mL / well and incubated at 37°C, 5% CO 2Incubate in an incubator at 4 °C. On day 1, feed the cells by adding an additional 0.1 mL of HAT medium containing serum and 2× methotrexate to each well. On days 3 and 7, replace 0.1 mL of medium from each well with 0.1 mL of fresh HT medium. Screening is usually performed between days 9-14, and hybridoma culture supernatants are screened by ELISA for reactions with human Trop-2-His (SEQ ID NO: 3).

[0464] Example 3: Cloning of anti-Trop-2 antibody cDNA sequence

[0465] Total RNA isolated from a hybridoma cell line producing human Trop-2 antibody using the RNeasy mini kit (Qiagen, catalog number: 74104) was used as a template. Then, cDNA was synthesized using the PrimeScript 1 cDNA synthesis kit according to the manufacturer's protocol. st The first strand cDNA was synthesized according to the instructions of strand cDNA Synthesis kit (TAKARA, catalog number: D6110A). The cDNA product was then subjected to PCR using degenerate mouse IgG primers in a 50 μL volume of reaction mixture (Kettleborough CA et al., European Journal of Immunology 23: 206-211 (1993), Strebe N et al., Antibody Engineering 1: 3-14 (2010)). The reaction was carried out in a S1000TM thermal cycler (Bio-Rad, catalog number: 184-2000) and the following cycles were performed 25 times: 94°C, denaturation for 1.5 minutes; 50°C, annealing for 1 minute; and 72°C extension for 1 minute. At the end of the 25th cycle, the reaction mixture was incubated at 72°C for another 5 minutes for filling. The PCR mixture was subjected to electrophoresis in a 1% agarose / Tris-borate gel containing 0.5 μg / mL ethidium bromide. DNA fragments with expected size were cut from the gel and purified. 3 μL of purified PCR products were cloned into pMD-18T vector (Takara, catalog number: D101A) and transformed into OneTOP10 chemical competent Escherichia coli (Invitrogen, catalog number: C4040-03). Universal M13 forward primer and reverse primer were used to screen clones by colony PCR, and 6 positive clones were selected from each reaction for DNA sequencing in both directions using M13 forward primer and M13 reverse primer.

[0466] The heavy chain variable region sequences and light chain variable region sequences of antibodies were amplified from the corresponding hybridoma clones, and these antibodies included Ab2, Ab21 and Ab35. These antibodies showed desirable properties, such as binding to tumor cells expressing human Trop-2, species cross-binding ability, and high internalization rate.

[0467] Ab2 heavy chain variable region (SEQ ID NO: 23):

[0468] EVQLVESGPGLVAPSQSLSITCTVS GFSLTYYGID WVRQPPGKGLEWLG VIWGSGNTKYNSALMS RLSISKDNSKSQVFLRMNSLQSDDTAIYYCAR FYEGFAY WGQGTLVTVSA;

[0469] Ab2 light chain variable region (SEQ ID NO: 24):

[0470] AIVLTQSPSSMYASLGERVTITC KASQDINSYLS WFQQKPGKSPKTLIY RANRLVD GVPSRFSGSGSGQDYSLTISSLEYEDMGIYYC LQYDEFPLT FGVGTKLELK.

[0471] Table 2. CDR sequences of Ab2

[0472] name sequence serial number name sequence serial number HCDR1 GFSLTYYGID SEQ ID NO:5 LCDR1 KASQDINSYLS SEQ ID NO:8 HCDR2 VIWGSGNTKYNSALMS SEQ ID NO:6 LCDR2 RANRLVD SEQ ID NO:9 HCDR3 FYEGFAY SEQ ID NO:7 LCDR3 LQYDEFPLT SEQ ID NO:10

[0473] Ab21 heavy chain variable region (SEQ ID NO:25):

[0474] EVQLKQSGPGLVQPSQSLSITCTVS GFSLRNYGVH WVRQSPGKGLEWLG VIWSSGTTDYNAAFISR LSITKDNSKSQVFFKMNSLQVDDTAIYNCAR DGDYDYYTMDY WGQGTSVTVSS

[0475] Ab21 light chain variable region (SEQ ID NO:26):

[0476] AIVLTQSPASLAVSLGQRATISC RASKSVSTSAYSYIH WYQQKPGQPPKLLIY LTSNLES GVPARFSGSGSGTDFTLNIHPVEEEDAATYYC QHSRELPYT FGGGTKLEIK

[0477] Table 3. CDR sequences of Ab21

[0478]

[0479]

[0480] Ab35 heavy chain variable region (SEQ ID NO: 27):

[0481] EVQLQQSGPDLVRPGASVKLSCKAS GYTFTSSDIN WVKQRPGQGLEWIG WIYPRDGSKKYNEKFKG KATLTVDTSSSTAYMEVHSLTSEDSAVYFCAT RFATVVSNYGLDP WGQGTSVTVSS

[0482] Ab35 light chain variable region (SEQ ID NO: 28):

[0483] AIVLTQSPAIMSASPGEKVTMTC SASSSVNYIY WYQRKPGSSPRLLIY DTSNLAS GVPVRFSGSGSGTSYSLTISRMEAEDAATYYC QQWNSYPLT FGAGTKLELK

[0484] Table 4. CDR sequences of Ab35

[0485] name sequence serial number name sequence serial number HCDR1 GYTFTSSDIN SEQ ID NO:17 LCDR1 SASSSVNYIY SEQ ID NO:20 HCDR2 WIYPRDGSKKYNEKFKG SEQ ID NO:18 LCDR2 DTSNLAS SEQ ID NO:21 HCDR3 RFATVVSNYGLDP SEQ ID NO:19 LCDR3 QQWNSYPLT SEQ ID NO:22

[0486] Example 4: Construction and expression of chimeric antibodies

[0487] The chimeric light chains of ch-Ab2, ch-Ab21 and ch-Ab35 were constructed by connecting the cDNA of the mouse VL region cloned by PCR to the human κ chain constant region (amino acid sequence as shown in SEQ ID NO: 30, respectively) (amino acid sequences are shown in SEQ ID NO: 74, SEQ ID NO: 76, SEQ ID NO: 78, respectively). The chimeric heavy chains of ch-Ab2, ch-Ab21 and ch-Ab35 were constructed by connecting the cDNA of the mouse VH region cloned by PCR to the human IgG1 constant region (amino acid sequence as shown in SEQ ID NO: 29, respectively) (amino acid sequences are shown in SEQ ID NO: 73, SEQ ID NO: 75, SEQ ID NO: 77, respectively). The 5' end of the mouse cDNA sequence was modified using PCR primers designed to add leader sequences to both the light chain and the heavy chain.

[0488] ExpiCHO cells (100 mL, 6.3 × 10 6The chimeric heavy chain expression plasmid and light chain expression plasmid were transfected with 40 μg of each plasmid and cultured for 10-12 days. The chimeric antibody in the supernatant was then purified using a protein A column (GE healthcare). The binding of the chimeric antibody to Trop-2 was measured by ELISA and Biacore, and the results showed that the chimeric antibody bound to Trop-2 with an affinity comparable to that of the murine antibody.

[0489] Example 5: Humanized antibody design

[0490] Ab2, Ab21 and Ab35 antibodies are humanized using CDR transplantation methods (see, for example, U.S. Patent No. 5,225,539). Homology modeling is performed on mouse antibodies Ab2, Ab21 and Ab35 by MOE (Molecular Operating Environment) to generate a protein structure model of the Fv domain. The VH and VL amino acid sequences of mouse Ab2, Ab21 and Ab35 antibodies are respectively input to the website of the International Immunogenetic Information System Related Tools (http: / / www.imgt.org / 3Dstructure-DB / cgi / DomainGapAlign.cgi), from which the human germline antibody sequences with a high degree of identity to mouse Ab2, Ab21 and Ab35 antibodies are screened out. The complementary determining regions (CDRs) in the VH and VL of mouse Ab2, Ab21 and Ab35 antibodies are grafted to template human antibodies. The CDR boundaries of antibodies can be named or identified by Kabat, Chothia, IMGT or Al-Lazikani nomenclature. (Al-Lazikani, B., Chothia, C., Lesk, AM, J. Mol. Biol., 273(4), 927 (1997); Chothia, C. et al., J Mol Biol. Dec 5; 186(3): 651-63 (1985); Chothia, C. and Lesk, AM, J. Mol. Biol., 196, 901 (1987); Chothia, C. et al., Nature. Dec 21-28; 342(6252): 877-83 (1989); Kabat EA et al.) For Ab2, the selected template human VH was a combination of IGHV3-53*01, IGHV4-4*08 and IGHJ4*01, and the selected template human VL was a combination of IGKV1-39*01 and IGKJ1*01. For Ab21, the selected template human VH was a combination of IGHV3-15*01 and IGHJ4*01, and the selected template human VL was a combination of IGKV3-11*01 and IGKJ1*01. For Ab35, the selected template human VH was a combination of IGHV1-46*01 and IGHJ4*01, and the selected template human VL was a combination of IGKV3-11*01 and IGKJ1*01.

[0491] The CDR amino acid sequence of the above template human antibody is replaced by the CDR of the mouse antibody. The essential amino acid sequences of VH and VL from mouse Ab2, Ab21 and Ab35 antibodies are grafted onto the VH and VL frameworks of the above template human germline antibodies to obtain functional humanized antibodies. For VH and VL of Ab2, Ab21 and Ab35 antibodies, several positions of the framework amino acids of the above template human antibody are backmutated to the corresponding amino acid sequences in mouse Ab2, Ab21 and Ab35 antibodies.

[0492] Table 5. Sequence numbers of humanized antibodies

[0493]

[0494]

[0495] Example 6: Antibody protein level binding experiment

[0496] The human Trop-2-His (SEQ ID NO: 3) protein was diluted to 2 μg / mL with PBS (SmartBuffer, PBS-2050) buffer at pH 7.4, added to a 96-well ELISA plate at a volume of 100 μL / well, and incubated overnight at 4°C. After discarding the liquid, 300 μL of 2% BSA (SIGMA, B2064-100G) diluted with PBS was added to each well for blocking and incubated at 37°C for 2 hours. After the blocking was completed, the blocking solution was discarded, and the plate was washed 3 times with PBST buffer (pH 7.4 PBS containing 0.1% tween-20), and 100 μL of gradient diluted antibody solution was added to each well, and incubated at 37°C for 1 hour. After incubation, wash the plate three times with PBST, add 100 μL goat anti-human IgG (H+L) (Jackson ImmunoResearch, 109-035-098, 1:5000 dilution) to each well, and incubate at 37°C for 1 hour. After washing the plate three times with PBST, add 100 μL TMB colorimetric substrate (TIANGEN, PA107-01) to each well, incubate at room temperature for 10-15 minutes, and add 50 μL 1M H 2 SO 4 Stop the reaction, read the absorbance at 450nm with an enzyme reader, fit the binding curve of antibody and antigen with software, and calculate EC 50 The binding activity of antibodies and proteins is shown in Table 6-1, Table 6-2, Table 6-3 and Figure 1 The results showed that the binding activity of the humanized antibody to human Trop-2-His protein was comparable to that of the parent chimeric antibody.

[0497] Table 6-1. Affinity EC of Ab2 chimeric and humanized antibodies to Trop-2-His protein 50 (nM)

[0498] Antibody <![CDATA[Affinity, EC 50 (nM)]]> ch-Ab2 0.085 hz-Ab2-1.1 0.082 hz-Ab2-1.2 0.076 hz-Ab2-1.3 0.081 hz-Ab2-1.4 0.068 hz-Ab2-2.1 1.078 hz-Ab2-2.2 0.218 hz-Ab2-2.3 0.359 hz-Ab2-2.4 0.100 Datopotamab 0.083

[0499] Table 6-2. Affinity EC of Ab21 humanized antibody and Trop-2-His protein 50 (nM)

[0500] Antibody <![CDATA[Affinity, EC 50 (nM)]]> ch-Ab21 0.165 hz-Ab21-1.1 0.162 hz-Ab21-1.2 0.248 hz-Ab21-2.1 0.214 hz-Ab21-2.2 0.223 Datopotamab 0.166

[0501] Table 6-3. Affinity EC of Ab35 humanized antibody and Trop-2-His protein 50 (nM)

[0502] Antibody <![CDATA[Affinity, EC 50 (nM)]]> ch-Ab35 0.043 hz-Ab35-1.1 0.052 hz-Ab35-1.2 0.035 hz-Ab35-1.3 0.042 hz-Ab35-2.1 0.055 hz-Ab35-2.2 0.054 hz-Ab35-2.3 0.065 Datopotamab 0.083

[0503] Example 7: Trop-2 expression levels in different cells

[0504] The cells were prepared with FACS buffer (Miltenyi Biotec, 130-091-221) at 0.5 × 10 6 -1×10 6 Cell suspension of 100 μL / well was added to a 96-well V-bottom plate. After centrifugation to remove the supernatant, 50 μL / well of TINA and human IgG1 control antibody diluted with FACS buffer at 3 μg / mL were added, and incubated in a 4°C refrigerator in the dark for 1 hour. After centrifugation and washing 3 times with FACS buffer at 300g, AlexaFluor488 goat anti-human IgG (H+L) (Bio-legend, 409304, 1:500 dilution) at a working concentration was added and incubated in a 4°C refrigerator in the dark for 40 minutes. After centrifugation and washing 3 times with FACS buffer at 300g, the geometric mean fluorescence intensity (MFI) was detected on a Sartorius iQue3 flow cytometer. According to the MFI value detected by TINA and the ratio of the IgG1 control antibody detection, it is believed that the expression level of Trop-2 on the surface of NCI-H322, HCC38 and HCC1806 cells is high, the expression of Trop-2 on the surface of Capan-1, PC-3, HUVEC and OVCAR-3 cells is moderate, and there is no Trop-2 expression on the surface of A549 cells.

[0505] Table 7. Expression of Trop-2 in different cells

[0506] Cell Name Organization Source MFI(TINA) MFI(hIgG1) Positive rate (%) ratio NCI-H322 Non-small cell lung cancer cells 2826998 21265 99.97 132.9 Capan-1 Human pancreatic cancer cells 1205346 65600 98.36 18.4 PC-3 Human prostate cancer cells 68507 8925 69.09 7.7 A549 Human lung adenocarcinoma cells 10105 9921 0.27 1.0 HUVEC Human umbilical vein endothelial cells 125092 20475 22.86 6.1 OVCAR-3 Human ovarian cancer cells 182074 11792 99.00 15.4 HCC38 Human breast ductal carcinoma cells 3853305 32418 99.30 118.9 HCC1806 Human breast cancer cells 1655211 16247 99.87 101.9

[0507] Example 8: Antibody cell level binding experiment

[0508] Tumor cells expressing Trop-2 were prepared with FACS buffer (Miltenyi Biotec, 130-091-221) at a concentration of 0.5 × 106 -1×10 6 100 μL / well of a cell suspension of 100 cells / mL was added to a 96-well V-bottom plate. After centrifugation to remove the supernatant, 50 μL / well of different concentrations of the test antibody (0.006nM-100nM) diluted with FACS buffer was added and incubated in a 4°C refrigerator in the dark for 1 hour. After centrifugation and washing three times at 300g with FACS buffer, the working concentration of AlexaFluor488 goat anti-human IgG (H+L) (Bio-legend, 409304, 1:500 dilution) was added and incubated in a 4°C refrigerator in the dark for 40 minutes. After centrifugation and washing three times at 300g with FACS buffer, the geometric mean fluorescence intensity (MFI) was detected on a Sartorius iQue3 flow cytometer to calculate the binding EC of the antibody to tumor cells with different Trop-2 expression levels. 50 value.

[0509] Table 8-1. Affinity of humanized antibody Ab2 for different tumor cells (EC 50 )

[0510] Antibody <![CDATA[HCC38(EC 50 ,nM)]]> <![CDATA[HCC1806(EC 50 ,nM)]]> ch-Ab2 0.59 0.78 hz-Ab2-1.1 0.99 3.06 hz-Ab2-1.2 0.76 0.90 hz-Ab2-1.3 0.65 1.22 hz-Ab2-1.4 1.20 1.07 hz-Ab2-2.4 0.45 1.23 TINA 1.21 1.44

[0511] Table 8-2. Affinity of humanized antibody Ab21 for different tumor cells (EC 50 )

[0512] Antibody <![CDATA[HCC38(EC 50 ,nM)]]> <![CDATA[HCC1806(EC 50 ,nM)]]> <![CDATA[OVCAR-3(EC 50 ,nM)]]> ch-Ab21 0.64 0.65 1.02 hz-Ab21-1.1 0.55 0.64 0.62 hz-Ab21-1.2 0.66 1.23 0.67 hz-Ab21-2.1 0.64 0.63 0.68 hz-Ab21-2.2 0.66 1.18 0.80 TINA 0.79 0.84 1.29

[0513] Table 8-3. Affinity of humanized antibody Ab35 for different tumor cells (EC 50 )

[0514] Antibody <![CDATA[HCC38(EC 50 ,nM)]]> <![CDATA[HCC1806(EC 50 ,nM)]]> <![CDATA[OVCAR-3(EC 50 ,nM) <!-- 53 -->]]> ch-Ab35 0.45 0.38 0.37 hz-Ab35-1.1 0.77 0.80 0.83 hz-Ab35-1.2 0.71 0.62 0.57 hz-Ab35-1.3 0.70 0.54 0.64 hz-Ab35-2.1 0.89 0.76 0.90 hz-Ab35-2.2 0.91 0.58 0.88 hz-Ab35-2.3 0.91 0.61 0.74 TINA 1.04 0.73 1.28

[0515] Example 9: Antibody and human Trop-2-His affinity test data

[0516] The antibody affinity for human Trop-2-His protein was detected in the form of capture antibody. The antibody was captured by affinity using a CM5 (Catalog No. 29149603, GE) biosensor chip coupled with anti-human IgG antibody (from Human antibody capture kit, Catalog No. 29234600, GE), and then the antigen human Trop-2-His protein was passed through the chip surface. The Biacore8K instrument was used to detect the reaction signal in real time to obtain the binding and dissociation curves. After each experimental cycle, the dissociation was completed with a regeneration buffer of 3M MgCl 2(From Human antibody capture kit, catalog number 29234600, GE) The chip was washed and regenerated. Biacore 8K Control Software 3.0 collected the binding and dissociation curves in real time, and Biacore InsightEvaluation Software 3.0 analyzed the data. The data were double-subtracted (i.e., the experimental channel signal was subtracted from the control channel signal in each cycle, and the sample signal was subtracted from the blank signal) and the Langmuir 1:1 model was fitted to calculate the binding rate constant k a , dissociation rate constant k d , equilibrium constant K D The results show that all humanized antibodies in the present disclosure have a high affinity (K D <10 -8 M). See Table 9 for details.

[0517] Table 9. Humanized antibody affinity

[0518]

[0519]

[0520] Example 10: Detection of cross-reactivity between antibodies and monkey-derived proteins

[0521] The macaque Trop-2-His (specifically, the extracellular domain of monkey Trop-2 was recombinantly linked to His, SEQ ID NO: 4) was diluted to 2 μg / mL with PBS (SmartBuffer, PBS-2050) buffer at pH 7.4, added to a 96-well ELISA plate at a volume of 100 μL / well, and incubated overnight at 4°C. After discarding the liquid, 300 μL of 2% BSA (SIGMA, B2064-100G) diluted with PBS was added to each well for blocking and incubated at 37°C for 2 hours. After the blocking was completed, the blocking solution was discarded, and the plate was washed 3 times with PBST buffer (pH7.4 PBS containing 0.1% tween-20), and 100 μL of gradient diluted antibody solution was added to each well, and incubated at 37°C for 1 hour. After the incubation, the plate was washed three times with PBST, 100 μL goat anti-human IgG (H+L) (Jackson ImmunoResearch, 109-035-098, 1:5000 dilution) was added to each well, and incubated at 37°C for 1 hour. After washing the plate three times with PBST, 100 μL TMB colorimetric substrate (TIANGEN, PA107-01) was added to each well, and incubated at room temperature for 10-15 minutes. 50 μL 1M H 2 SO 4Stop the reaction, read the absorbance at 450nm with an enzyme reader, fit the binding curve of antibody and antigen with software, and calculate EC 50 The test data show that all humanized antibodies disclosed in the present invention have good binding activity with monkey Trop-2.

[0522] Table 10-1. Binding activity of chimeric and humanized antibodies of Ab2 to monkey Trop-2-His protein

[0523] Humanized Antibodies <![CDATA[Affinity, EC 50 (nM)]]> ch-Ab2 0.048 hz-Ab2-1.1 0.133 hz-Ab2-1.2 0.064 hz-Ab2-1.3 0.068 hz-Ab2-1.4 0.053 hz-Ab2-2.1 1.188 hz-Ab2-2.2 0.341 hz-Ab2-2.3 0.830 hz-Ab2-2.4 0.070 TINA 0.106

[0524] Table 10-2. Binding activity of chimeric and humanized antibodies of Ab21 to monkey Trop-2-His protein

[0525] Humanized Antibodies <![CDATA[Affinity, EC 50 (nM)]]> ch-Ab21 0.093 hz-Ab21-1.1 0.098 hz-Ab21-1.2 0.086 hz-Ab21-2.1 0.064 hz-Ab21-2.2 0.081 TINA 0.063

[0526] Table 10-3. Binding activity of chimeric and humanized antibodies of Ab35 to monkey Trop-2-His protein

[0527] Humanized Antibodies <![CDATA[Affinity, EC 50 (nM)]]> ch-Ab35 0.048 hz-Ab35-1.1 0.047 hz-Ab35-1.2 0.038 hz-Ab35-1.3 0.033 hz-Ab35-2.1 0.056 hz-Ab35-2.2 0.050 hz-Ab35-2.3 0.031 TINA 0.046

[0528] Example 11: Non-specific binding of antibodies in tumor cells that do not express Trop-2

[0529] A549 tumor cells (lung cancer tumor cells) that do not express Trop-2 were prepared with FACS buffer (Miltenyi Biotec, 130-091-221) to a concentration of 0.5 × 10 6 -1×10 6 / mL cell suspension, 100μL / well was added to a 96-well V-bottom plate. After centrifugation to remove the supernatant, 50μL / well of different concentrations of the test antibody (0.0006nM-50nM) diluted with FACS buffer was added, and incubated in a 4°C refrigerator in the dark for 1 hour. After centrifugation and washing 3 times with FACS buffer at 300g, AlexaFluor488 goat anti-human IgG (H+L) (Bio-legend, 409304, 1:500 dilution) at the working concentration was added and incubated in a 4°C refrigerator in the dark for 40 minutes. After centrifugation and washing 3 times with FACS buffer at 300g, the geometric mean fluorescence intensity (MFI) was detected on a Sartorius iQue3 flow cytometer. Figure 2 The results showed that the humanized antibody of the present invention had no non-specific binding to the lung cancer tumor cell A549 which does not express Trop-2.

[0530] Example 12: Antibody tumor cell endocytosis experiment

[0531] The antibody internalization kit (Sartoius, 90564) was used to detect the internalization of antibodies in tumor cells. The labeled antibodies in the kit and the humanized or chimeric antibodies to be tested were first diluted to 40 nM with the complete culture medium used for the test cells. The first gradient was mixed in a 96-well V-bottom cell culture plate (Corning, catalog number 3894) at a ratio of 1:1. After 2-fold dilution, the cells were placed at 37°C and cultured for different time periods (2 hours, 4 hours, or 6 hours). The geometric mean fluorescence intensity (MFI) was detected on a Sartorius iQue3 flow cytometer. The stronger the geometric mean fluorescence intensity (MFI), the stronger the internalization of the antibody in the cell. The test results are as follows: Figure 3-Figure 6 As shown, the humanized antibody of the present invention exhibited strong endocytosis activity in cell lines with different Trop-2 expression levels, and could continuously accumulate the amount of internalized antibody with increasing endocytosis time, and did not show obvious saturation at a higher antibody concentration (20 nM).

[0532] Example 13: Preparation of linker-payload

[0533] Example 13-1: Preparation of MC-GGFG-Eribulin

[0534]

[0535] Weigh compound I (100 mg, 0.12 mmol) and compound J (75 mg, 0.145 mmol) and add them to a 20 mL reaction tube (the CAS number of compound I is 441045-17-6, and the CAS number of compound J is 2413428-36-9). Add 2 mL of N,N-dimethylformamide. Cool to 0°C. Add 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (70 mg, 0.18 mmol) and N,N-diisopropylethylamine (49 mg, 0.36 mmol) and react at 0°C for 1 hour. Prepare about 70 mg of compound MC-GGFG-Eribulin in liquid phase.

[0536] ESI-MS analysis showed that m / z of MC-GGFG-Eribulin was 1241.72 [M+H] + , the hydrogen spectrum is as follows:

[0537] 1H NMR (500MHz, DMSO) δ8.22(t,J=5.3Hz,1H),8.12(d,J=8.0Hz,1H),8.06(t,J=5.4Hz,1H),7.9 9(t,J=5.3Hz,1H),7.65(d,J=5.2Hz,1H),7.30-7.21(m,4H),7.18(d,J=6.4Hz,1H),6.99(s, 2H),5.02(d,J=26.0Hz,2H),4.79(d,J=38.9Hz,2H),4.65-4.60(m,2H),4.56(d,J=3.7Hz,1H ),4.50-4.42(m,1H),4.26(d,J=10.1Hz,1H),4.21-4.14(m,1H),4.10(s,3H),4.05-3.98(m,1 H),3.86-3.64(m,8H),3.60-3.45(m,4H),3.37-3.30(m,2H),3.26(s,4H),3.17-3.09(m,1H) ,3.08-2.99(m,2H),2.84(d,J=10.4Hz,1H),2.86-2.66(m,3H),2.56-2.50(m,1H),2.37-2.1 8(m,5H),2.15-2.05(m,3H),2.05-1.96(m,2H),1.95-1.84(m,4H),1.75-1.57(m,6H),1.55- 1.38(m,6H),1.35-1.25(m,3H),1.23-1.12(m,3H),1.03(d,J=6.0Hz,3H),1.00-0.92(m,1H).

[0538] Example 13-2: Preparation of MC-GGFG-deuterated DXd (MC-GGFG-DDDXd)

[0539]

[0540] Step 1 Synthesis of Intermediate A

[0541] Under nitrogen protection, add 80g of ethyl diazoacetate into a 3L single-mouth bottle, and add 800mL of dichloromethane and 800mL of 1% deuterated acetic acid solution (8g of deuterated acetic acid dissolved in 800mL of deuterated water), and place the single-mouth bottle under light-shielding conditions and stir at room temperature for 75 hours. Separate and collect the organic phase, extract the aqueous phase with dichloromethane twice (200mL×2), and combine the organic phases. Wash the organic phase with 200mL of deuterated water, dry the obtained organic phase with anhydrous sodium sulfate, filter to remove sodium sulfate, and concentrate the filtrate to dryness under reduced pressure at 20°C to obtain 49.25g of intermediate A; the CAS of intermediate A is: 1356471-71-0.

[0542] Step 2 Synthesis of Intermediate B

[0543] Weigh 50g of N-fluorenylmethoxycarbonyl-glycyl-glycine into a 2L round-bottom flask, add 750mL of tetrahydrofuran and 150mL of glacial acetic acid, stir at 40°C for 20 minutes, add 100g of lead tetraacetate, heat to 80°C and continue to react for 3 hours. Cool to room temperature, filter with suction, and wash the filter cake with 250mL of ethyl acetate. Concentrate the filtrate to dryness, add 330mL of dichloromethane and 670mL of ethyl acetate to dissolve to obtain an organic phase. Wash the organic phase 3 times with 30% potassium bicarbonate aqueous solution (500mL×3), then dry with anhydrous sodium sulfate and filter. Concentrate the filtrate to dryness under reduced pressure, add 100mL of dichloromethane to dissolve, then add 100mL of n-hexane, stir at room temperature until solid precipitates, then add 300mL of a mixed solution of n-hexane and dichloromethane (n-hexane: dichloromethane = 1:1), and stir overnight. Filter, and dry the filter cake in a vacuum oven at 40°C for 4 hours to obtain 37.3 g of intermediate B, LC-MS (ESI) m / z: 391.09 [M+Na] + ; CAS number of intermediate B: 1599440-06-8.

[0544] Step 3 Synthesis of Intermediate C

[0545] Weigh 78g of intermediate B into a 3000mL single-necked flask, add 800mL of dichloromethane and 45g of intermediate A, and place the 3000mL single-necked flask in an ice-water bath to cool to 0°C. Dissolve 16g of lithium tert-butoxide in 400mL of dichloromethane to prepare a lithium tert-butoxide solution, add the lithium tert-butoxide solution to a 3000mL single-necked flask, and react at 0°C for 3 hours. Move to room temperature, add 800mL of water and stir. Separate the liquid, collect the organic phase, extract the aqueous phase with 400mL of dichloromethane, and combine the organic phases. Wash the organic phase once with 800mL of saturated brine, dry it with anhydrous sodium sulfate, filter it, concentrate the filtrate under reduced pressure, and chromatograph it on a silica gel column (petroleum ether: ethyl acetate = 3:1) to obtain 61g of intermediate C, LC-MS (ESI) m / z: 437.34 [M+Na] + ; CAS of intermediate C: 2760715-83-9.

[0546] Step 4 Synthesis of Compound D

[0547] 31.2 g of intermediate C was added to 270 mL of deuterated methanol and 70 mL of heavy water, stirred under ice bath, then 5.5 g of NaOH was added, and stirred at room temperature overnight. 300 mL of ethyl acetate and 300 mL of water were added to the reaction solution for extraction, and 20 mL of glacial acetic acid was added to the aqueous layer to adjust the pH to 2-3. Solids precipitated and were filtered to obtain 20.3 g of compound D.1 H-NMR (500 MHz, DMSO-d 6 )δ8.70(1H,t,J=6.6),7.89(2H,d,J=7.5),7.72(2H,d,J=7.5),7.57(1H,t,J=6.0),7.42(2H,t,J=7.5),7.34(2H,t ,J=7.5),4.61(2H,d,J=6.6),4.30(2H,d,J=7.1),4.23(1H,m),3.64(2H,d,J=6.0); LC-MS(ESI)m / z:409.08[M+Na] + .

[0548] Step 5 Synthesis of Compound E

[0549] Weigh 2.0g of exatecan mesylate dihydrate and 1.63g of compound D and add them to a 100mL round-bottom flask. Add 40mL of N,N-dimethylformamide and stir. Cool to 0°C. Add 2.0g of 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate and 1.82g of N,N-diisopropylethylamine in sequence and react at 0°C for 3h. Pour the reaction solution into 120mL of ice water and stir for 1h. Filter and dissolve the filter cake with dichloromethane. Chromatography was performed on a silica gel column (100g of 100-200 mesh silica gel, dichloromethane: methanol = 30:1, 2L) to obtain 2.6g of compound E. 1 H-NMR (500 MHz, DMSO-d 6 ), δ8.78(1H,t,J=6.6),8.47(1H,d,J=9.0),7.86(2H,d,J=7.5),7.73(1H,d,J=11.0),7.68(2H,d,J =7.5),7.53(1H,t,J=6.0),7.39(2H,t,J=7.5),7.30(2H,m),7.29(1H,s),6.50(1H,brs),5.56(1H, m),5.39(2H,m),5.14(2H,m),4.64(2H,m),4.25(2H,d,J=6.8),4.19(1H,m),3.62(2H,d,J=6.0),3. 15(2H,m),2.35(3H,s),2.17(2H,m),1.83(2H,m),0.85(3H,t,J=7.3); LC-MS(ESI)m / z:804.84[M+H] + .

[0550] Step 6 Preparation of Compound F

[0551] Weigh 0.38g of 1,8-diazabicyclo[5.4.0]undec-7-ene into a 100mL round-bottom flask, then add 20mL of tetrahydrofuran into the round-bottom flask and stir. Cool to 0°C. Weigh 2.0g of compound E and prepare a solution with 20mL of tetrahydrofuran. Slowly add the prepared solution of compound E into a 100mL round-bottom flask, naturally warm to room temperature, and react for 3h. Filter under nitrogen protection to obtain 1.45g of compound F. 1 H-NMR (500 MHz, DMSO-d 6 )δ8.76(1H,m),7.72(1H,m),7.28(1H,s),5.48(3H,m),5.16(2H,m),4.61(2H,m),3.40(2H,m),3.2 0(2H,m),2.35(3H,s),2.17(2H,m),1.83(2H,m),0.86(3H,t,J=7.1); LC-MS(ESI)m / z:582.39[M+H] + .

[0552] Step 7 Preparation of Compound H

[0553] Weigh 1.00g of compound F and 0.97g of compound G into a 100mL round-bottom flask, and add 10mL of N,N-dimethylformamide. Cool to -20°C, add 0.34g of 1-hydroxybenzotriazole and 0.49g of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, and react at -20°C for 3h. Add 20mL of dichloromethane and 20mL of water to the reaction solution, stir for 0.5h, let stand, separate the liquids, and collect the organic phase. Dry the organic phase with anhydrous sodium sulfate and filter. Concentrate the filtrate to dryness under reduced pressure. Use silica gel column chromatography (dichloromethane: methanol = 15:1) to obtain 400mg of compound H, MS m / z: 1037.08 [M+H] + . 1H-NMR (500MHz, DMSO-d6) δ8.62(1H,t,J=6.5),8.49(1H,d,J=8.5),8.29(1H,t,J=5.5),8.12(1H,d,J=8.0),8.06(1H,t,J=5.5),8.00(1H,t,J=5 .5),7.74(1H,d,J=10.5),7.30(1H,s),7.27~7.12(5H,m),6.98(2H,s), 6.51(1H,brs),5.61~5.58(1H,m),5.45~5.37(2H,m),5.22~5.13(2H,m), 4.64(2H,d,J=6.5),4.49~4.45(1H,m),3.76~3.57(6H,m),3.37~3.32(2 H,m),3.24~3.09(2H,m),3.02(1H,dd,J=4.5,14.0),2.77(1H,dd,J=9.5 ,13.5),2.36(3H,s),2.23~2.14(2H,m),2.09(2H,t,J=7.5),1.91~1.79 (2H,m),1.49~1.42(4H,m),1.20~1.14(2H,m),0.87(3H,t,J=7.5); HR-MS m / z:1036.4194[M+H] + .

[0554] Example 14: Preparation of anti-Trop-2 antibody drug conjugates

[0555] Example 14-1: Preparation of anti-Trop-2 antibody drug conjugate hz-Ab35-1.3-Eribulin (1)

[0556] Reagents:

[0557] The antibody was hz-Ab35-1.3 prepared in Example 5, and the Linker-payload was MC-GGFG-Eribulin synthesized in Example 13-1.

[0558] Experimental process:

[0559] 1. Antibody reduction : The antibody was replaced in a histidine buffer (L-histidine 1.43 mg / mL, L-histidine hydrochloride monohydrate 2.27 mg / mL) at pH 6.0, and the antibody concentration was adjusted to about 8 mg / mL with histidine buffer (pH 6.0). The antibody solution was added to a light-proof glass bottle and 0.3 M Na 2 HPO 4The pH was adjusted to about 7.0, and 10 mM TCEP (tris(2-carboxyethyl)phosphine hydrochloride) solution was added thereto so that the molar ratio of the antibody to TCEP was 1:3. The mixture was incubated at 30° C. in the dark for 1 hour with gentle stirring to reduce the interchain disulfide bonds of the antibody to obtain reaction solution 1.

[0560] 2. Conjugation of Antibodies to Linkers-Payloads : A linker-payload solution dissolved in DMSO at a concentration of 10 mg / mL was added to the reaction solution 1 so that the molar ratio of the antibody to the linker-payload was 1:6. The reaction solution was incubated at 25° C. in the dark for 1.5 hours with gentle stirring to connect the antibody to the linker-payload to obtain a reaction solution 2.

[0561] 3. Coupling termination and purification : The reaction solution 2 was ultrafiltered with pH 6.0 histidine buffer to obtain the anti-Trop-2 antibody drug conjugate hz-Ab35-1.3-Eribulin (1).

[0562] Referring to the method of Example 15-1, the DAR value of hz-Ab35-1.3-Eribulin (1) was measured to be 4.1.

[0563] The structure of hz-Ab35-1.3-Eribulin (1) is as follows:

[0564]

[0565] Example 14-2: Preparation of anti-Trop-2 antibody drug conjugate hz-Ab35-1.3-Eribulin (2)

[0566] Reagents:

[0567] The antibody was hz-Ab35-1.3 prepared in Example 5, and the Linker-payload was MC-GGFG-Eribulin synthesized in Example 13-1.

[0568] Experimental process:

[0569] 1. Antibody reduction : Replace the antibody with histidine buffer at pH 6.0 and adjust the antibody concentration to 10.63 mg / mL with histidine buffer (pH 6.0). Take 1 mL of the antibody solution and place it in a light-proof EP tube. 2 HPO 4 The pH was adjusted to about 7.0, and 18.54 μL of 10 mM TCEP solution was added thereto so that the molar ratio of the antibody to TCEP was 1:2.58. The mixture was incubated at 4° C. in the dark for 5 hours with gentle shaking to reduce the interchain disulfide bonds of the antibody, thereby obtaining reaction solution 1.

[0570] 2. Conjugation of Antibodies to Linkers-Payloads : 45.47 μL of a 10 mg / mL Linker-payload solution dissolved in a 50% acetone / water solution was added to the reaction solution 1, so that the molar ratio of the antibody to the Linker-payload was 1:5.1. The mixture was incubated at 4°C in the dark for 40 min with gentle stirring to connect the antibody to the linker-payload to obtain a reaction solution 2.

[0571] 3. Coupling termination and purification : The reaction solution 2 was ultrafiltered with pH 6.0 histidine buffer to obtain the anti-Trop-2 antibody drug conjugate hz-Ab35-1.3-Eribulin (2).

[0572] Referring to the method of Example 15-1, the DAR value of hz-Ab35-1.3-Eribulin (2) was measured to be 4.5.

[0573] The structure of hz-Ab35-1.3-Eribulin (2) is as follows:

[0574]

[0575] Example 14-3: Preparation of anti-Trop-2 antibody drug conjugate hz-Ab35-1.3-Eribulin (3)

[0576] Reagents:

[0577] The antibody was hz-Ab35-1.3 prepared in Example 5, and the Linker-payload was MC-GGFG-Eribulin synthesized in Example 13-1.

[0578] Experimental process:

[0579] 1. Antibody reduction : Replace the antibody with histidine buffer at pH 6.0 and adjust the antibody concentration to 10.36 mg / mL with histidine buffer (pH 6.0). Place 17 mL of the antibody solution in a light-proof glass bottle and add 0.3 M Na 2 HPO 4 The pH was adjusted to about 7.0, and 307.02 μL of 10 mM TCEP solution was added thereto so that the molar ratio of the antibody to TCEP was 1:2.58. The mixture was incubated at 4° C. in the dark for 5 hours with gentle stirring to reduce the interchain disulfide bonds of the antibody, thereby obtaining reaction solution 1.

[0580] 2. Conjugation of Antibodies to Linkers-Payloads: 738.395 μL of a 10 mg / mL Linker-payload solution dissolved in 50% acetone / water solution was added to reaction solution 1, so that the molar ratio of the antibody to the Linker-payload was 1:5.1. The mixture was incubated at 4°C in the dark for 40 min with gentle stirring to connect the antibody to the linker-payload to obtain reaction solution 2.

[0581] 3. Coupling termination and purification : The reaction solution 2 was ultrafiltered with pH 6.0 histidine buffer to obtain the anti-Trop-2 antibody drug conjugate hz-Ab35-1.3-Eribulin (3).

[0582] Referring to the method of Example 15-1, the DAR value of hz-Ab35-1.3-Eribulin (3) was measured to be 4.3.

[0583] The structure of hz-Ab35-1.3-Eribulin (3) is as follows:

[0584]

[0585] Example 14-4: Preparation of anti-Trop-2 antibody drug conjugate hz-Ab35-1.3-Eribulin (4)

[0586] Reagents:

[0587] The antibody was hz-Ab35-1.3 prepared in Example 5, and the Linker-payload was MC-GGFG-Eribulin synthesized in Example 13-1.

[0588] Experimental process:

[0589] 1. Antibody reduction: Replace the antibody with histidine buffer at pH 6.0 and adjust the antibody concentration to 10.19 mg / mL with histidine buffer (pH 6.0). Place 35 mL of the antibody solution in a light-proof glass bottle and add 0.3 M Na 2 HPO 4 The pH was adjusted to about 7.0, and 621.97 μL of 10 mM TCEP solution was added thereto so that the molar ratio of the antibody to TCEP was 1:2.58. The mixture was incubated at 4° C. in the dark for 5 hours with gentle stirring to reduce the interchain disulfide bonds of the antibody, thereby obtaining reaction solution 1.

[0590] 2. Conjugation of Antibodies to Linkers-Payloads:1495.87 μL of a 10 mg / mL Linker-payload solution dissolved in 50% acetone / water solution was added to the reaction solution 1, so that the molar ratio of the antibody to the Linker-payload was 1:5.1, and the mixture was incubated at 4°C in the dark for 40 min with gentle stirring to connect the antibody to the linker-payload, thereby obtaining a reaction solution 2.

[0591] 3. Coupling termination and purification: The reaction solution 2 was ultrafiltered with a pH 6.0 histidine buffer to obtain the anti-Trop-2 antibody drug conjugate hz-Ab35-1.3-Eribulin (4).

[0592] Referring to the method of Example 15-1, the DAR value of hz-Ab35-1.3-Eribulin (4) was measured to be 4.6.

[0593] The structure of hz-Ab35-1.3-Eribulin (4) is as follows:

[0594]

[0595] Example 14-5: Preparation of anti-Trop-2 antibody drug conjugate hz-Ab35-1.3-Eribulin (5)

[0596] Reagents:

[0597] The antibody was hz-Ab35-1.3 prepared in Example 5, and the Linker-payload was MC-GGFG-Eribulin synthesized in Example 13-1.

[0598] Experimental process:

[0599] 1. Antibody reduction: Replace the antibody with histidine buffer at pH 6.0 and adjust the antibody concentration to 10 mg / mL with histidine buffer (pH 6.0). Place 5 mL of the antibody solution in a light-proof glass bottle and add 0.3 M Na 2 HPO 4 The pH was adjusted to about 7.0, and 87.16 μL of 10 mM TCEP solution was added thereto so that the molar ratio of the antibody to TCEP was 1:2.58. The mixture was incubated at 4° C. in the dark for 5 hours with gentle stirring to reduce the interchain disulfide bonds of the antibody, thereby obtaining reaction solution 1.

[0600] 2. Conjugation of Antibodies to Linkers-Payloads:209.6 μL of a 10 mg / mL Linker-payload solution dissolved in 50% acetone / water solution was added to the reaction solution 1, so that the molar ratio of the antibody to the Linker-payload was 1:5, and the mixture was incubated at 4°C in the dark for 40 min with gentle stirring to connect the antibody to the linker-payload, thereby obtaining a reaction solution 2.

[0601] 3. Coupling termination and purification: The reaction solution 2 was ultrafiltered with a pH 6.0 histidine buffer to obtain the anti-Trop-2 antibody drug conjugate hz-Ab35-1.3-Eribulin (5).

[0602] Referring to the method of Example 15-1, the DAR value of hz-Ab35-1.3-Eribulin (5) was measured to be 4.8.

[0603] The structure of hz-Ab35-1.3-Eribulin (5) is as follows:

[0604]

[0605] Example 14-6: Preparation of anti-Trop-2 antibody drug conjugate hz-Ab35-1.3-Eribulin (6)

[0606] Reagents:

[0607] The antibody was hz-Ab35-1.3 prepared in Example 5, and the Linker-payload was MC-GGFG-Eribulin synthesized in Example 13-1.

[0608] Experimental process:

[0609] 1. Antibody reduction: Replace the antibody with histidine buffer at pH 6.0 and adjust the antibody concentration to 10 mg / mL with histidine buffer (pH 6.0). Place 5 mL of the antibody solution in a light-proof glass bottle and add 0.3 M Na 2 HPO 4 The pH was adjusted to about 7.0, and 270 μL of 10 mM TCEP solution was added thereto so that the molar ratio of the antibody to TCEP was 1:8. The mixture was incubated at 37° C. in the dark for 1 hour with gentle stirring to reduce the interchain disulfide bonds of the antibody, thereby obtaining reaction solution 1.

[0610] 2. Conjugation of Antibodies to Linkers-Payloads:419 μL of a 10 mg / mL Linker-payload solution dissolved in DMSO was added to the reaction solution 1, so that the molar ratio of the antibody to the Linker-payload was 1:10. The mixture was incubated at 37° C. in the dark for 1 hour with gentle stirring to connect the antibody to the linker-payload, thereby obtaining a reaction solution 2.

[0611] 3. Coupling termination and purification: The reaction solution 2 was ultrafiltered with a pH 6.0 histidine buffer to obtain the anti-Trop-2 antibody drug conjugate hz-Ab35-1.3-Eribulin (6).

[0612] Referring to the method of Example 15-1, the DAR value of hz-Ab35-1.3-Eribulin (6) was measured to be 7.8.

[0613] The structure of hz-Ab35-1.3-Eribulin (6) is as follows:

[0614]

[0615] Example 14-7: Preparation of anti-Trop-2 antibody drug conjugate hz-Ab35-1.3-Eribulin (7)

[0616] Reagents:

[0617] The antibody was hz-Ab35-1.3 prepared in Example 5, and the Linker-payload was MC-GGFG-Eribulin synthesized in Example 13-1.

[0618] Experimental process:

[0619] 1. Antibody reduction: Replace the antibody with histidine buffer at pH 6.0 and adjust the antibody concentration to 10.8 mg / mL with histidine buffer (pH 6.0). Place 40 mL of the antibody solution in a light-proof glass bottle and add 0.3 M Na 2 HPO 4 The pH was adjusted to about 7.0, and 2335 μL of 10 mM TCEP solution was added thereto so that the molar ratio of the antibody to TCEP was 1:8. The mixture was incubated at 37° C. in the dark for 1 hour with gentle stirring to reduce the interchain disulfide bonds of the antibody, thereby obtaining reaction solution 1.

[0620] 2. Conjugation of Antibodies to Linkers-Payloads:To the reaction solution 1, 3622 μL of a 10 mg / mL Linker-payload solution dissolved in DMSO was added so that the molar ratio of the antibody to the Linker-payload was 1:10. The mixture was incubated at 37° C. in the dark for 1 hour with gentle stirring to connect the antibody to the linker-payload, thereby obtaining a reaction solution 2.

[0621] 3. Coupling termination and purification: The reaction solution 2 was ultrafiltered with a pH 6.0 histidine buffer to obtain the anti-Trop-2 antibody drug conjugate hz-Ab35-1.3-Eribulin (7).

[0622] Referring to the method of Example 15-1, the DAR value of hz-Ab35-1.3-Eribulin (7) was measured to be 7.5.

[0623] The structure of hz-Ab35-1.3-Eribulin (7) is as follows:

[0624]

[0625] Example 14-8: Preparation of anti-Trop-2 antibody drug conjugate TINA-DDDXd (1)

[0626] Reagents:

[0627] The antibody was TINA prepared in-house, and the linker-payload was MC-GGFG-DDDXd synthesized in Example 13-2.

[0628] Experimental process:

[0629] 1. Antibody reduction: The antibody was replaced with histidine buffer at pH 6.0, and the antibody concentration was adjusted to about 8 mg / mL with histidine buffer (pH 6.0). The antibody solution was added to a light-proof glass bottle and diluted with 0.3 M Na 2 HPO 4 The pH was adjusted to about 7.0, and 10 mM TCEP solution was added thereto so that the molar ratio of the antibody to TCEP was 1:2.58; the mixture was incubated at 4° C. in the dark for 5 hours with gentle stirring to reduce the interchain disulfide bonds of the antibody, thereby obtaining a reaction solution 1.

[0630] 2. Conjugation of Antibodies to Linkers-Payloads: A linker-payload solution dissolved in DMSO at a concentration of 10 mg / mL was added to the reaction solution 1 so that the molar ratio of the antibody to the linker-payload was 1:5.1; the reaction solution was incubated at 4°C in the dark for 40 minutes with gentle stirring to connect the antibody to the linker-payload to obtain a reaction solution 2.

[0631] 3. Coupling termination and purification: The reaction solution 2 was ultrafiltered with a pH 6.0 histidine buffer to obtain the anti-Trop-2 antibody drug conjugate TINA-DDDXd (1).

[0632] Referring to the method of Example 15-2, the DAR value of TINA-DDDXd(1) was measured to be 3.9.

[0633] The structure of TINA-DDDXd(1) is as follows:

[0634]

[0635] Example 14-9: Preparation of anti-Trop-2 antibody drug conjugate TINA-DDDXd (2)

[0636] Reagents:

[0637] The antibody was TINA prepared in-house, and the linker-payload was MC-GGFG-DDDXd synthesized in Example 13-2.

[0638] Experimental process:

[0639] 1. Antibody reduction: Replace the antibody with histidine buffer at pH 6.0 and adjust the antibody concentration to 10.5 mg / mL with histidine buffer (pH 6.0). Place 1 mL of the antibody solution in a light-proof EP tube and add 0.3 M Na 2 HPO 4 The pH was adjusted to about 7.0, and 18.31 μL of 10 mM TCEP solution was added thereto so that the molar ratio of the antibody to TCEP was 1:2.58. The mixture was incubated at 4° C. in the dark for 5 hours with gentle shaking to reduce the interchain disulfide bonds of the antibody, thereby obtaining reaction solution 1.

[0640] 2. Conjugation of Antibodies to Linkers-Payloads: 37.5 μL of a 10 mg / mL Linker-payload solution dissolved in 50% acetone / water solution was added to the reaction solution 1, so that the molar ratio of the antibody to the Linker-payload was 1:5.1. The mixture was incubated at 4°C in the dark for 40 min with gentle stirring to connect the antibody to the linker-payload, thereby obtaining a reaction solution 2.

[0641] 3. Coupling termination and purification: The reaction solution 2 was ultrafiltered with a pH 6.0 histidine buffer to obtain the anti-Trop-2 antibody drug conjugate TINA-DDDXd (2).

[0642] Referring to the method of Example 15-2, the DAR value of TINA-DDDXd(2) was measured to be 4.5.

[0643] The structure of TINA-DDDXd(2) is as follows:

[0644]

[0645] Example 14-10: Preparation of anti-Trop-2 antibody drug conjugate TINA-DDDXd (3)

[0646] Reagents:

[0647] The antibody was TINA prepared in-house, and the linker-payload was MC-GGFG-DDDXd synthesized in Example 13-2.

[0648] Experimental process:

[0649] 1. Antibody reduction: Replace the antibody with histidine buffer at pH 6.0 and adjust the antibody concentration to 10.6 mg / mL with histidine buffer (pH 6.0). Place 70 mL of the antibody solution in a light-proof glass bottle and add 0.3 M Na 2 HPO 4 The pH was adjusted to about 7.0, and 1201 μL of 10 mM TCEP solution was added thereto so that the molar ratio of the antibody to TCEP was 1:2.58. The mixture was incubated at 4° C. in the dark for 5 hours with gentle shaking to reduce the interchain disulfide bonds of the antibody to obtain reaction solution 1.

[0650] 2. Conjugation of Antibodies to Linkers-Payloads: 2460 μL of a 10 mg / mL Linker-payload solution dissolved in 50% acetone / water solution was added to the reaction solution 1, so that the molar ratio of the antibody to the Linker-payload was 1:5.1. The mixture was incubated at 4°C in the dark for 40 min with gentle stirring to connect the antibody to the linker-payload, thereby obtaining a reaction solution 2.

[0651] 3. Coupling termination and purification: The reaction solution 2 was ultrafiltered with a pH 6.0 histidine buffer to obtain the anti-Trop-2 antibody drug conjugate TINA-DDDXd (3).

[0652] Referring to the method of Example 15-2, the DAR value of TINA-DDDXd(3) was measured to be 4.7.

[0653] The structure of TINA-DDDXd(3) is as follows:

[0654]

[0655] Example 14-11: Preparation of isotype control IgG-Eribulin (1)

[0656] Reagents:

[0657] The antibody was hIgG1 (Sino Biological, Catalog No.: HG1K), and the Linker-payload was MC-GGFG-Eribulin synthesized in Example 13-1.

[0658] Experimental process:

[0659] 1. Antibody reduction: Replace the antibody with histidine buffer at pH 6.0 and adjust the antibody concentration to about 10 mg / mL with histidine buffer (pH 6.0). Place the antibody solution in a light-proof glass bottle and add 0.3 M Na 2 HPO 4 The pH was adjusted to about 7.0, and 10 mM TCEP solution was added thereto so that the molar ratio of the antibody to TCEP was 1:2.58. The mixture was incubated at 4° C. in the dark for 5 hours with gentle shaking to reduce the interchain disulfide bonds of the antibody to obtain reaction solution 1.

[0660] 2. Conjugation of Antibodies to Linkers-Payloads: A linker-payload solution with a concentration of 10 mg / mL dissolved in 50% acetone / water solution was added to the reaction solution 1 so that the molar ratio of the antibody to the linker-payload was 1:5.1, and the reaction solution was incubated at 4°C in the dark for 40 min with gentle stirring to connect the antibody to the linker-payload to obtain a reaction solution 2.

[0661] 3. Coupling termination and purification: The reaction solution 2 was ultrafiltered with a pH 6.0 histidine buffer to obtain an isotype control IgG-Eribulin (1).

[0662] Referring to the method of Example 15-1, the DAR value of IgG-Eribulin (1) was measured to be 3.8.

[0663] The structure of IgG-Eribulin (1) is as follows:

[0664]

[0665] Example 14-12: Preparation of isotype control IgG-Eribulin (2)

[0666] Reagents:

[0667] The antibody was hIgG1 (Sino Biological, Catalog No.: HG1K), and the Linker-payload was MC-GGFG-Eribulin synthesized in Example 13-1.

[0668] Experimental process:

[0669] 1. Antibody reduction: Replace the antibody with histidine buffer at pH 6.0 and adjust the antibody concentration to 10.76 mg / mL with histidine buffer (pH 6.0). Place 1 mL of the antibody solution in a light-proof EP tube and add 0.3 M Na 2 HPO 4 The pH was adjusted to about 7.0, and 19 μL of 10 mM TCEP solution was added thereto so that the molar ratio of the antibody to TCEP was 1:2.58. The mixture was incubated at 4° C. in the dark for 5 hours with gentle shaking to reduce the interchain disulfide bonds of the antibody to obtain reaction solution 1.

[0670] 2. Conjugation of Antibodies to Linkers-Payloads: 46 μL of a 10 mg / mL Linker-payload solution dissolved in 50% acetone / water solution was added to the reaction solution 1, so that the molar ratio of the antibody to the Linker-payload was 1:5.1. The mixture was incubated at 4°C in the dark for 40 min with gentle stirring to connect the antibody to the linker-payload, thereby obtaining a reaction solution 2.

[0671] 3. Coupling termination and purification: The reaction solution 2 was ultrafiltered with a pH 6.0 histidine buffer to obtain an isotype control IgG-Eribulin (2).

[0672] Referring to the method of Example 15-1, the DAR value of IgG-Eribulin (2) was measured to be 4.3.

[0673] The structure of IgG-Eribulin (2) is as follows:

[0674]

[0675] Example 14-13: Preparation of isotype control IgG-Eribulin (3)

[0676] Reagents:

[0677] The antibody was hIgG1 (Sino Biological, Catalog No.: HG1K), and the Linker-payload was MC-GGFG-Eribulin synthesized in Example 13-1.

[0678] Experimental process:

[0679] 1. Antibody reduction: Replace the antibody with histidine buffer at pH 6.0 and adjust the antibody concentration to 10 mg / mL with histidine buffer (pH 6.0). Place 1 mL of the antibody solution in a light-proof glass bottle and add 0.3 M Na 2 HPO 4The pH was adjusted to about 7.0, and 10 mM TCEP solution was added thereto so that the molar ratio of the antibody to TCEP was 1:8. The mixture was incubated at 37° C. in the dark for 1 hour with gentle stirring to reduce the interchain disulfide bonds of the antibody, thereby obtaining reaction solution 1.

[0680] 2. Conjugation of Antibodies to Linkers-Payloads: A linker-payload solution dissolved in DMSO solution at a concentration of 10 mg / mL was added to the reaction solution 1 so that the molar ratio of the antibody to the linker-payload was 1:10, and the mixture was incubated at 37° C. in the dark for 1 hour with gentle stirring to connect the antibody to the linker-payload to obtain a reaction solution 2.

[0681] 3. Coupling termination and purification: The reaction solution 2 was ultrafiltered with a pH 6.0 histidine buffer to obtain an isotype control IgG-Eribulin (3).

[0682] Referring to the method of Example 15-1, the DAR value of IgG-Eribulin (3) was measured to be 7.2.

[0683] The structure of IgG-Eribulin (3) is as follows:

[0684]

[0685] Example 14-14: Preparation of isotype control IgG-Eribulin (4)

[0686] Reagents:

[0687] The antibody was IgG purchased from Sino Biological (Cat. No.: HG1K), and the linker-payload was MC-GGFG-Eribulin synthesized in Example 13-1.

[0688] Experimental process:

[0689] 1. Antibody reduction: Replace the antibody with histidine buffer at pH 6.0 and adjust the antibody concentration to 10.76 mg / mL with histidine buffer (pH 6.0). Place 1 mL of the antibody solution in a light-proof EP tube and add 0.3 M Na 2 HPO 4 The pH was adjusted to about 7.0, and 62 μL of 10 mM TCEP solution was added thereto so that the molar ratio of the antibody to TCEP was 1:8. The mixture was incubated at 37° C. in the dark for 1 hour with gentle stirring to reduce the interchain disulfide bonds of the antibody to obtain reaction solution 1.

[0690] 2. Conjugation of Antibodies to Linkers-Payloads:95 μL of a 10 mg / mL Linker-payload solution dissolved in DMSO was added to the reaction solution 1, so that the molar ratio of the antibody to the Linker-payload was 1:10. The mixture was incubated at 37° C. in the dark for 1 hour with gentle stirring to connect the antibody to the linker-payload, thereby obtaining a reaction solution 2.

[0691] 3. Coupling termination and purification: The reaction solution 2 was ultrafiltered with a pH 6.0 histidine buffer to obtain an isotype control IgG-Eribulin (4).

[0692] Referring to the method of Example 15-1, the DAR value of IgG-Eribulin (4) was measured to be 7.9.

[0693] The structure of IgG-Eribulin (4) is as follows:

[0694]

[0695] Example 15: Determination of DAR value of antibody drug conjugate

[0696] The DAR value of the antibody-drug conjugate was determined by the hydrophobic interaction chromatography (HIC) method. A neutral high-salt mobile phase was used to increase the hydrophobic properties of the protein molecules, thereby combining with the hydrophobic bonds in the chromatographic column. The salt concentration was then gradually reduced and the proportion of isopropanol was gradually increased to elute the substance. The less hydrophobic molecules were eluted first, and the more hydrophobic molecules were eluted later.

[0697] Example 15-1:

[0698] The components of the anti-Trop-2 antibody drug conjugate were separated using a butyl-bonded nonporous resin (NPR) filler. The chromatographic column specifications were TSKgel Butyl-NPR, 2.5 μm, 4.6×100 mm, and the column temperature was 25°C. The mobile phase A was 25 mM phosphate buffer-1.5 M ammonium sulfate, pH 7.0 (3.55 g of anhydrous disodium hydrogen phosphate and 198.21 g of ammonium sulfate were weighed, and about 700 mL of ultrapure water was added. After stirring until fully dissolved, the pH was adjusted to 7.0±0.1 with phosphoric acid, and the volume was fixed to 1 L with ultrapure water. After mixing, the mixture was filtered through a 0.22 μm filter membrane). Mobile phase B is 25mM phosphate buffer-25% isopropanol, pH 7.0 (weigh 3.55g of anhydrous disodium hydrogen phosphate, add about 800mL of ultrapure water, stir until fully dissolved, adjust to pH 7.0±0.1 with phosphoric acid, add ultrapure water to 1L, mix well, take 750mL, add 250mL of isopropanol, mix well, filter through a 0.22μm filter membrane). Dilute the sample 1 times with the initial proportion mobile phase as the test solution, adjust the injection volume according to the sample concentration, inject 50μg of protein, and detect at a wavelength of 280nm. The flow rate is 0.5mL / min, and the gradient elution parameters are as shown in Table 11-1.

[0699] Table 11-1. Gradient elution parameters

[0700] time Mobile phase A Mobile phase B 0min 85% 15% 15min 20% 80% 20min 20% 80% 20.1min 85% 15% 30min 85% 15%

[0701] Example 15-2:

[0702] The components of the anti-Trop-2 antibody drug conjugate were separated using a butyl-bonded nonporous polystyrene / divinylbenzene (PS / DVB) filler. The chromatographic column specifications were Sepax HIC-Butyl, 4.6×100mm, 5μm, and the column temperature was 25°C. The mobile phase A was 25mM phosphate buffer-2M ammonium sulfate, pH 7.0 (3.55g of anhydrous disodium hydrogen phosphate and 264.28g of ammonium sulfate were weighed, and about 800mL of ultrapure water was added. After stirring until fully dissolved, the pH was adjusted to 7.0±0.1 with phosphoric acid, and the volume was fixed to 1L with ultrapure water. After mixing, it was filtered through a 0.22μm filter membrane). Mobile phase B is 25mM phosphate buffer, pH 7.0 (weigh 3.55g of anhydrous disodium hydrogen phosphate, add about 800mL of ultrapure water, stir until fully dissolved, adjust to pH 7.0±0.1 with phosphoric acid, add ultrapure water to 1L, mix well and filter through a 0.22μm filter membrane). Mobile phase C is 100% isopropanol. Dilute the sample 1 times with the initial proportion mobile phase as the test solution, adjust the injection volume according to the sample concentration, inject 50μg of protein, and detect at a wavelength of 280nm. The flow rate is 0.5mL / min, and the gradient elution parameters are shown in Table 11-2.

[0703] Table 11-2. Gradient elution parameters

[0704] time Mobile phase A Mobile phase B Mobile phase C 0min 75% 25% 0% 15min 10% 65% 25% 15.1min 0% 100% 0% 20min 0% 100% 0% 20.1min 75% 25% 0% 30min 75% 25% 0%

[0705] Data processing, using area normalization method for quantitative analysis of the results. Calculate the peak area percentages of ADCs containing 0, 1, 2, 3, 4, 5, 6, 7 and 8 cytotoxic drugs, and calculate the DAR value results. The calculation formula is: DAR value = (peak area percentage of ADC containing 0 cytotoxic drugs × 0 + peak area percentage of ADC containing 1 cytotoxic drug × 1 + peak area percentage of ADC containing 2 cytotoxic drugs × 2 + peak area percentage of ADC containing 3 cytotoxic drugs × 3 + peak area percentage of ADC containing 4 cytotoxic drugs × 4 + peak area percentage of ADC containing 5 cytotoxic drugs × 5 + peak area percentage of ADC containing 6 cytotoxic drugs × 6 + peak area percentage of ADC containing 7 cytotoxic drugs × 7 + peak area percentage of ADC containing 8 cytotoxic drugs × 8) / 100%.

[0706] Example 16: Aggregation Validation of Anti-Trop-2 Antibody Drug Conjugate

[0707] A gel chromatography column was used to separate the components of the anti-Trop-2 antibody drug conjugate. A neutral pH buffer with 10% isopropanol was used as the mobile phase for elution, and the components were eluted in descending order of molecular weight. The chromatographic column is ACQUITY UPLC Protein BEH SEC Column 1.7μm, 4.6×300mm gel chromatography column, column temperature 25℃. Mobile phase is 50mM phosphate buffer-200mM sodium chloride-10% isopropanol, pH 7.0 (weigh 12.53g disodium hydrogen phosphate dodecahydrate, 2.33g sodium dihydrogen phosphate dihydrate, 11.69g sodium chloride, add about 800mL ultrapure water, stir until fully dissolved, add ultrapure water to 1L, mix well, take 900mL, add 100mL isopropanol, mix well, filter through 0.22μm filter membrane to obtain). Accurately take 20μg of anti-Trop-2 antibody conjugate and inject it into liquid chromatograph, detect at 280nm wavelength. Flow rate is 0.3mL / min, isocratic elution for 15min.

[0708] Data processing, the results were quantitatively analyzed using the area normalization method. The peak area percentages of aggregates, monomers and low molecular weight impurities of the anti-Trop-2 antibody drug conjugate were calculated respectively, where the aggregates before the main peak, the monomers during the main peak, and the low molecular weight impurities after the main peak. The content ratios of monomers, aggregates and low molecular weight impurities of the anti-Trop-2 antibody drug conjugate are shown in Table 12 below.

[0709] Table 12. Monomer, aggregate and low molecular weight impurity content of anti-Trop-2 antibody drug conjugate

[0710]

[0711] Example 17: Affinity of anti-Trop-2 antibody drug conjugates to Trop-2

[0712] The affinity of anti-Trop-2 antibody-drug conjugate to Trop-2 was tested using a biomolecular interaction analysis system (GE, Biacore 8K), and anti-Trop-2 antibody hz-Ab35-1.3 was set as a control. Amino-coupled Anti-hIgG (Fc) antibody (GE, catalog No. BR-1008-39) was attached to a CM5 sensor chip and run in a buffer (437 mM NaCl, 2.7 mM KCl, 10 mM Na 2 HPO 4 12H 2 O, 1.8 mM KH 2 PO 4 , 0.05% surfactant P-20 (w / v), pH 7.4) to dilute the antibody and antibody drug conjugate to 2μg / mL, and capture through the experimental channel at a flow rate of 30μL / min. Trop-2 (Acro biosystems, catalog number TR2-H5223) was diluted to 50nM, 25nM, 12.5nM, 6.25nM, 3.125nM and 1.5625nM using running buffer, and bound at a flow rate of 50μL / min. The binding time was set to 180s, after which the injection was stopped for dissociation, and the dissociation time was set to 500s. The software Biacore 8K Control Software 3.0 collected data signals in real time, and the software BiacoreInsight Evaluation Software 3.0 analyzed the data. The Langmuir 1:1 model was used for fitting and the binding rate constant k was calculated. a (1 / Ms), dissociation rate constant k d (1 / s), equilibrium dissociation constant K D (M) values ​​are shown in Table 13.

[0713] Table 13. Affinity of Antibodies or Antibody Drug Conjugates for Trop-2

[0714] Sample name <![CDATA[k a (1 / Ms)]]> <![CDATA[k d (1 / s)]]> <![CDATA[K D (M)]]> hz-Ab35-1.3-Eribulin(1) 1.75E+05 2.91E-04 1.66E-09 TINA-DDDXd(1) 4.18E+05 3.17E-03 7.57E-09 hz-Ab35-1.3 2.17E+05 2.93E-04 1.35E-09

[0715] Example 18: Cell Binding Activity of Anti-Trop-2 Antibody Drug Conjugates

[0716] Flow cytometry was used to detect the cell binding activity of anti-Trop-2 antibody-drug conjugates. NCI-H292, HCC38, NCI-H322, HCC1806, Capan-1, BT474, OVCAR-3, PC-3, and AC16 cell lines with different Trop-2 expression levels were diluted to 1×10 6 100 μL / well was added to a 96-well plate, and FACS buffer (Miltenyi Biotec, catalog number 130-091-221) was added with gradient dilutions of anti-Trop-2 antibody drug conjugates (for NCI-H292 and NCI-H322 cells, the final concentration in the plate was 100 nM as the starting concentration, 5-fold gradient dilutions, a total of 9 concentrations; for HCC38, HCC1806 and OVCAR3, the final concentration in the plate was 300 nM as the starting concentration, 4-fold gradient dilutions, a total of 9 concentrations; for Capan-1, BT474, PC3 and AC16 cells, the final concentration in the plate was 67 nM as the starting concentration, 4-fold gradient dilutions, a total of 9 concentrations), incubated at 4°C for 60 minutes, centrifuged at 1000 rpm for 5 minutes, the supernatant was discarded, washed three times with pre-cooled PBS (pH 7.4), and goat-anti-human IgG diluted at 1:200 (v / v) was added Fcγ-PE secondary antibody (Jackson immunoresearch, catalog number 109-116-170), 100 μL / well, incubate at 4°C for 30 minutes. Wash 3 times with pre-cooled PBS (pH 7.4), resuspend with 100 μL PBS (pH 7.4), and then use flow cytometry (Sartorius, iQUE) to analyze and detect the fluorescence signal. The binding activity of the anti-Trop-2 antibody drug conjugate to the cells is indicated by the mean fluorescence intensity (MFI) of the staining. The results are shown in Figure 7A-Figure 7I As shown, the calculated EC 50 The maximum binding (Top) is shown in Tables 14-1 to 14-3 below. The results show that hz-Ab35-1.3-Eribulin (2), hz-Ab35-1.3-Eribulin (4), hz-Ab35-1.3-Eribulin (6) and hz-Ab35-1.3-Eribulin (7) can effectively bind to Trop-2 expressing cells.

[0717] Table 14-1. EC binding of antibodies or antibody drug conjugates to Trop-2 expressing cells 50 and the maximum combined MFI

[0718]

[0719] Table 14-2. EC binding of antibodies or antibody drug conjugates to Trop-2 expressing cells 50 and the maximum combined MFI

[0720]

[0721] Table 14-3. EC binding of antibodies or antibody drug conjugates to Trop-2 expressing cells 50 and the maximum combined MFI

[0722]

[0723]

[0724] Example 19: Cellular endocytosis experiment of anti-Trop-2 antibody drug conjugate

[0725] Flow cytometry was used to detect the endocytosis of anti-Trop-2 antibody-drug conjugates in cells with different Trop-2 expression levels. The concentration of NCI-H292, HCC38, NCI-H322, Capan-1, BT474, OVCAR-3, and PC-3 cells with different Trop-2 expression levels was adjusted to 1×10 6 / mL, 50μL / well in a 96-well plate. Refer to Table 1, dilute the antibody or antibody-drug conjugate with the corresponding culture medium for different cells, add the gradient diluted antibody or antibody-drug conjugate (the final concentration in the plate is 68nM as the starting concentration, 4-fold gradient dilution, a total of 9 concentrations) to the cell plate, add 50μL to each well, and incubate at 4℃ for 30min. After the incubation, take out the 96-well cell culture plate, place it at 4℃, 400g, centrifuge for 4min, and discard the supernatant. Dilute pHrodo at 1:200 (v / v) TM Dyes for Amine Labeling (Invitrogen, Catalog No.: P35358) labeled AffiniPure Goat Anti-Human IgG, Fcγfragment specific (Goat anti-human IgG, Fc fragment specific antibody; Jackson Immuno; Catalog No.: 109-005-190), mix well, add 50 μL to each well and incubate at 4°C. Wash the plate after 30 minutes, add 50 μL of cell culture medium to each well, mix well, place in a 37°C incubator for 2 hours, place in a flow cytometer (Sartorius, iQUE), and measure the fluorescence value of the RL1 channel. The results are shown in the figure. Figures 8A-8G As shown, the calculated EC 50The results are shown in Tables 15-1 to 15-3 below. The results showed that hz-Ab35-1.3-Eribulin (2), hz-Ab35-1.3-Eribulin (4) and hz-Ab35-1.3-Eribulin (7) were able to effectively perform endocytosis in cells expressing Trop-2.

[0726] Table 15-1. ECs internalized by antibodies or antibody drug conjugates in cells expressing Trop-2 50 and maximum MFI

[0727]

[0728] Table 15-2. ECs internalized by antibodies or antibody drug conjugates in cells expressing Trop-2 50 and maximum MFI

[0729]

[0730] Table 15-3. ECs internalized by antibodies or antibody drug conjugates in cells expressing Trop-2 50 and maximum MFI

[0731]

[0732] Example 20: Anti-Trop-2 Antibody Drug Conjugate Kills Tumor Cells

[0733] To detect the killing effect of anti-Trop-2 antibody-drug conjugates on Trop-2 positive tumor cells, the killing activity of NCI-H292, HCC38, NCI-H322 and HCC1806 cells with different Trop-2 expression levels were tested.

[0734] Take cells in the logarithmic growth phase and adjust the cell density to 2×10 4 100 μL / well of the plate was added to a 96-well plate and incubated at 37°C and 5% CO 2Adhesion overnight culture. Referring to Table 1, the anti-Trop-2 antibody drug conjugate was diluted with the corresponding culture medium for different cells, with 32 nM (final concentration in the plate) as the starting concentration, 4-fold gradient dilution, and a total of 9 concentrations. Take out the cells that have been cultured overnight, add 50 μL / well of the diluted anti-Trop-2 antibody drug conjugate to the experimental group, and add 50 μL / well of complete medium containing 10% (v / v) FBS to the negative control group. Continue to culture for 96h, 120h or 144h, and then use the CellTiter-GloLuminescent Cell Kit (Promega, Catalog No.: G7572) for detection. Specifically, take out the 96-well plate, add 75 μL of CTG detection solution (Promega, Catalog No.: G7572) to each well, shake and mix, incubate at room temperature and avoid light for 10 minutes, then transfer 180 μL from each well to an opaque white plate, remove bubbles, read the chemiluminescence value, and calculate the killing rate of the anti-Trop-2 antibody drug conjugate on the cells. The calculation formula is as follows:

[0735]

[0736] The results are as follows Figure 9A-9D , as shown in Table 16-1 and Table 16-2, the calculated EC 50 The results are shown in the table below. The results show that hz-Ab35-1.3-Eribulin (3), hz-Ab35-1.3-Eribulin (4) and hz-Ab35-1.3-Eribulin (7) can effectively kill tumor cells expressing different Trop-2.

[0737] Table 16-1. Cytotoxicity of anti-Trop-2 antibody-drug conjugates against tumor cells

[0738]

[0739] Table 16-2. Cytotoxicity of anti-Trop-2 antibody-drug conjugates against tumor cells

[0740]

[0741] Example 21: Bystander effect of anti-Trop-2 antibody drug conjugate on tumor cells

[0742] To detect the bystander effect of anti-Trop-2 antibody drug conjugates, NCI-H322 cells were used as positive cells and Jurkat cells were used as negative cells. The FACS-based method was used to detect the bystander effect of anti-Trop-2 antibody drug conjugates. NCI-H322 and Jurkat cells in the logarithmic growth phase were taken and the viable cell density was adjusted to 8×10 4 / mL and 4×10 41 mL of each type of cell was added to each well of a 6-well cell culture plate and placed in a 37°C, 5% CO 2 Culture overnight in a carbon dioxide cell culture incubator. After overnight, add the anti-Trop-2 antibody-drug conjugate to the cell plate in the order of the well plate (the final concentration in the plate is 0.032nM); at the same time, set up a blank control group without antibody-drug conjugate. After incubation for 5 days, take the cells from the 6-well plate, digest and count them with trypsin, collect cells from different sample wells, and adjust the cell density to 1×10 with Running buffer (Miltenyi Biotec, catalog number: 130-091-221). 6 100 μL / well was added to a 96-well V-bottom plate. Directly labeled antibody (PE anti-Human Trop-2, Abcam, Catalog No.: Ab275728) was added to the 96-well plate and incubated at 4°C for 60 min. After incubation, the cells were washed twice, resuspended in the Running buffer solution, and flow cytometry ( NxT) detection signal. The result is as follows Fig.10 As shown, hz-Ab35-1.3-Eribulin (5) and hz-Ab35-1.3-Eribulin (6) both have bystander effects and are superior to the control TINA-DDDXd (3).

[0743] Example 22: Anti-Trop-2 Antibody Drug Conjugates in NCI-H292 Human Lung Cancer Cell Nude Mouse Xenograft Tumor Model Pharmacodynamic evaluation in

[0744] NCI-H292 human lung cancer cells were subcutaneously inoculated in the right axilla of SPF female nude mice (source: Jiangsu Huachuang Xinnuo Pharmaceutical Technology Co., Ltd.) at 5×10 6 When the average tumor volume reaches 100mm 3 At about 1:10 pm, the animals were divided into 7 groups, 5 in each group. The specific grouping and dosing schedule are shown in Table 17:

[0745] Table 17. Grouping and dosing regimen

[0746] Group drug ADC dose (mg / kg) 1 Solvent control N / A 2 TINA-DDDXd(3) 1.5 3 TINA-DDDXd(3) 3.0 4 hz-Ab35-1.3-Eribulin(3) 0.5 5 hz-Ab35-1.3-Eribulin(3) 1.5 6 hz-Ab35-1.3-Eribulin(7) 0.3 7 hz-Ab35-1.3-Eribulin(7) 0.9

[0747] “N / A” means not applicable.

[0748] The day of grouping was designated as day 0, and the drug was administered once through the tail vein on the day of grouping. The tumor volume was measured twice a week, and the mice were weighed and the data were recorded; the general performance of the mice was observed and recorded daily. After the experiment, the tumor was removed, weighed, and photographed.

[0749] The detection indicators and calculation formula are as follows:

[0750] Tumor volume, TV (mm 3 )=1 / 2×(a×b 2), where a is the long diameter of the tumor and b is the short diameter of the tumor.

[0751] Relative tumor volume, RTV = TV t / TV 0 Among them, TV 0 is the tumor volume on day 0, TV t is the tumor volume at each measurement.

[0752] Relative tumor proliferation rate, T / C (%) = T RTV / C RTV ×100%; where T RTV RTV for the treatment group, C RTV The solvent control group RTV.

[0753] Tumor growth inhibition rate, TGI (%) = (1-TW / TW 0 )×100%; TW is the tumor weight of the treatment group, TW 0 is the tumor weight of the vehicle control group.

[0754] Body weight change rate, WCR (%) = (Wt t -Wt 0 ) / Wt 0 ×100%; where Wt 0 is the weight of mice on day 0, Wt t is the weight of the mice at each measurement.

[0755] The results of the test indicators on the 17th day are shown in Table 18 below. Both hz-Ab35-1.3-Eribulin (3) and hz-Ab35-1.3-Eribulin (7) had no obvious toxicity and had inhibitory activity against NCI-H292 human lung cancer xenograft tumors in nude mice. The efficacy of hz-Ab35-1.3-Eribulin (3) and hz-Ab35-1.3-Eribulin (7) was better than that of TINA-DDDXd (3).

[0756] Table 18. Effects of anti-Trop-2 antibody drug conjugates on various parameters in the NCI-H292 human lung cancer cell subcutaneous xenograft model in nude mice

[0757]

[0758] Note: Compared with the vehicle control group, *p<0.05, **p<0.01

[0759] The sequence information of the present disclosure is summarized in Table S2 below.

[0760] Table S2. Sequence information

[0761]

[0762]

[0763]

[0764]

[0765]

[0766]

[0767]

[0768] All patents, patent applications and other identified publications are expressly incorporated herein by reference for the purposes of description and disclosure. These publications are provided solely because their disclosure predates the filing date of the present disclosure. All statements regarding the dates of these documents or representations of the contents of these documents are based on the information available to the applicant and do not constitute any admission as to the correctness of the dates of these documents or the contents of these documents. Furthermore, any reference to these publications herein does not constitute an admission that the publications become part of the common general knowledge in the art in any country.

[0769] Although the present disclosure has been described in detail above with general descriptions and specific implementation schemes, it is obvious to those skilled in the art that some modifications or improvements can be made to the present disclosure. Therefore, these modifications or improvements made without departing from the spirit of the present disclosure are within the scope of protection claimed by the present disclosure.

Claims

1. An antibody-drug conjugate, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a solvate of the antibody-drug conjugate, its stereoisomer, or a pharmaceutically acceptable salt thereof, comprising an anti-Trop-2 antibody or an antigen-binding fragment thereof, wherein the anti-Trop-2 antibody or the antigen-binding fragment thereof comprises: a HCDR1 comprising the amino acid sequence of SEQ ID NO: 17, 5, 11 or 48, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 18, 6, 12, 31, 32, 49 or 62, a HCDR3 comprising the amino acid sequence of SEQ ID NO: 19, 7 or 13, a LCDR1 comprising the amino acid sequence of SEQ ID NO: 20, 8, 14 or 33, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 21, 9, 15 or 34, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 22, 10, 16 or 35.

2. The antibody-drug conjugate, its stereoisomer, its pharmaceutically acceptable salt, or a solvate of the antibody-drug conjugate, its stereoisomer, or its pharmaceutically acceptable salt according to claim 1, wherein: The anti-Trop-2 antibody or antigen-binding fragment thereof comprises: (1) a HCDR1 comprising the amino acid sequence of SEQ ID NO:5, a HCDR2 comprising the amino acid sequence of SEQ ID NO:6, a HCDR3 comprising the amino acid sequence of SEQ ID NO:7, a LCDR1 comprising the amino acid sequence of SEQ ID NO:8, a LCDR2 comprising the amino acid sequence of SEQ ID NO:9, and a LCDR3 comprising the amino acid sequence of SEQ ID NO:10; (2) a HCDR1 comprising the amino acid sequence of SEQ ID NO:5, a HCDR2 comprising the amino acid sequence of SEQ ID NO:31, a HCDR3 comprising the amino acid sequence of SEQ ID NO:7, a LCDR1 comprising the amino acid sequence of SEQ ID NO:8, a LCDR2 comprising the amino acid sequence of SEQ ID NO:34, and a LCDR3 comprising the amino acid sequence of SEQ ID NO:10; (3) a HCDR1 comprising the amino acid sequence of SEQ ID NO:5, a HCDR2 comprising the amino acid sequence of SEQ ID NO:32, a HCDR3 comprising the amino acid sequence of SEQ ID NO:7, a LCDR1 comprising the amino acid sequence of SEQ ID NO:8, a LCDR2 comprising the amino acid sequence of SEQ ID NO:34, and a LCDR3 comprising the amino acid sequence of SEQ ID NO:10; (4) a HCDR1 comprising the amino acid sequence of SEQ ID NO:5, a HCDR2 comprising the amino acid sequence of SEQ ID NO:31, a HCDR3 comprising the amino acid sequence of SEQ ID NO:7, a LCDR1 comprising the amino acid sequence of SEQ ID NO:33, a LCDR2 comprising the amino acid sequence of SEQ ID NO:34, and a LCDR3 comprising the amino acid sequence of SEQ ID NO:35; (5) a HCDR1 comprising the amino acid sequence of SEQ ID NO:5, a HCDR2 comprising the amino acid sequence of SEQ ID NO:32, a HCDR3 comprising the amino acid sequence of SEQ ID NO:7, a LCDR1 comprising the amino acid sequence of SEQ ID NO:33, a LCDR2 comprising the amino acid sequence of SEQ ID NO:34, and a LCDR3 comprising the amino acid sequence of SEQ ID NO:35; (6) a HCDR1 comprising the amino acid sequence of SEQ ID NO:11, a HCDR2 comprising the amino acid sequence of SEQ ID NO:12, a HCDR3 comprising the amino acid sequence of SEQ ID NO:13, a LCDR1 comprising the amino acid sequence of SEQ ID NO:14, a LCDR2 comprising the amino acid sequence of SEQ ID NO:15, and a LCDR3 comprising the amino acid sequence of SEQ ID NO:16; (7) a HCDR1 comprising the amino acid sequence of SEQ ID NO:48, a HCDR2 comprising the amino acid sequence of SEQ ID NO:49, a HCDR3 comprising the amino acid sequence of SEQ ID NO:13, a LCDR1 comprising the amino acid sequence of SEQ ID NO:14, a LCDR2 comprising the amino acid sequence of SEQ ID NO:15, and a LCDR3 comprising the amino acid sequence of SEQ ID NO:16; (8) a HCDR1 comprising the amino acid sequence of SEQ ID NO:48, a HCDR2 comprising the amino acid sequence of SEQ ID NO:12, a HCDR3 comprising the amino acid sequence of SEQ ID NO:13, a LCDR1 comprising the amino acid sequence of SEQ ID NO:14, a LCDR2 comprising the amino acid sequence of SEQ ID NO:15, and a LCDR3 comprising the amino acid sequence of SEQ ID NO:16; (9) a HCDR1 comprising the amino acid sequence of SEQ ID NO: 17, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 18, a HCDR3 comprising the amino acid sequence of SEQ ID NO: 19, a LCDR1 comprising the amino acid sequence of SEQ ID NO: 20, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 21, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 22; or (10) A HCDR1 comprising the amino acid sequence of SEQ ID NO: 17, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 62, a HCDR3 comprising the amino acid sequence of SEQ ID NO: 19, a LCDR1 comprising the amino acid sequence of SEQ ID NO: 20, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 21, and a LCDR3 comprising the amino acid sequence of SEQ ID NO:

22.

3. An antibody-drug conjugate, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a solvate of the antibody-drug conjugate, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, comprising an anti-Trop-2 antibody or an antigen-binding fragment thereof, wherein the anti-Trop-2 antibody or the antigen-binding fragment thereof comprises: HCDR1, HCDR2 and HCDR3 in the heavy chain variable region of the amino acid sequence as shown in SEQ ID NO: 27, 63, 64, 65, 23, 25, 36, 37, 38, 39, 50, 51, 52 or 53, and LCDR1, LCDR2 and LCDR3 in the light chain variable region of the amino acid sequence as shown in SEQ ID NO: 28, 66, 67, 24, 26, 40, 41, 54 or 55.

4. The antibody-drug conjugate, its stereoisomer, its pharmaceutically acceptable salt, or a solvate of the antibody-drug conjugate, its stereoisomer, or its pharmaceutically acceptable salt according to claim 3, wherein: The anti-Trop-2 antibody or antigen-binding fragment thereof comprises: (1) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence shown in SEQ ID NO: 23, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence shown in SEQ ID NO: 24; (2) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence set forth in SEQ ID NO:25, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence set forth in SEQ ID NO:26; (3) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence set forth in SEQ ID NO:27, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence set forth in SEQ ID NO:28; (4) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence set forth in SEQ ID NO:36, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence set forth in SEQ ID NO:40; (5) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence set forth in SEQ ID NO:37, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence set forth in SEQ ID NO:40; (6) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence set forth in SEQ ID NO:38, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence set forth in SEQ ID NO:40; (7) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence shown in SEQ ID NO:39, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence shown in SEQ ID NO:40; (8) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence shown in SEQ ID NO:36, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence shown in SEQ ID NO:41; (9) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence shown in SEQ ID NO:37, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence shown in SEQ ID NO:41; (10) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence shown in SEQ ID NO:38, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence shown in SEQ ID NO:41; (11) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence shown in SEQ ID NO:39, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence shown in SEQ ID NO:41; (12) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence shown in SEQ ID NO:50, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence shown in SEQ ID NO:54; (13) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence shown in SEQ ID NO:51, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence shown in SEQ ID NO:54; (14) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence shown in SEQ ID NO:52, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence shown in SEQ ID NO:54; (15) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence shown in SEQ ID NO:53, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence shown in SEQ ID NO:54; (16) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence shown in SEQ ID NO:50, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence shown in SEQ ID NO:55; (17) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence shown in SEQ ID NO:51, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence shown in SEQ ID NO:55; (18) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence shown in SEQ ID NO:52, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence shown in SEQ ID NO:55; (19) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence shown in SEQ ID NO:53, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence shown in SEQ ID NO:55; (20) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence shown in SEQ ID NO:63, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence shown in SEQ ID NO:66; (21) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence shown in SEQ ID NO:64, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence shown in SEQ ID NO:66; (22) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence shown in SEQ ID NO:65, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence shown in SEQ ID NO:66; (23) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence shown in SEQ ID NO:63, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence shown in SEQ ID NO:67; (24) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region with the amino acid sequence of SEQ ID NO:64, and LCDR1, LCDR2 and LCDR3 in the light chain variable region with the amino acid sequence of SEQ ID NO:67; or (25) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region whose amino acid sequence is shown in SEQ ID NO:65, and LCDR1, LCDR2 and LCDR3 in the light chain variable region whose amino acid sequence is shown in SEQ ID NO:

67.

5. The antibody-drug conjugate, its stereoisomer, its pharmaceutically acceptable salt, or a solvate of the antibody-drug conjugate, its stereoisomer, or its pharmaceutically acceptable salt according to any one of claims 1 to 4, wherein: The anti-Trop-2 antibody or antigen-binding fragment thereof comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:23, 25, 27, 36, 37, 38, 39, 50, 51, 52, 53, 63, 64 or 65, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:24, 26, 28, 40, 41, 54, 55, 66 or 67.

6. The antibody-drug conjugate, its stereoisomer, its pharmaceutically acceptable salt, or a solvate of the antibody-drug conjugate, its stereoisomer, or its pharmaceutically acceptable salt according to any one of claims 1 to 5, wherein: The anti-Trop-2 antibody or antigen-binding fragment thereof comprises: (1) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:23, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:24; (2) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:25, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:26; (3) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:27, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:28; (4) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:36, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:40; (5) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:37, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:40; (6) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:38, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:40; (7) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:39, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:40; (8) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:36, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:41; (9) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:37, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:41; (10) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:38, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:41; (11) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:39, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:41; (12) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:50, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:54; (13) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:51, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:54; (14) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:52, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:54; (15) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:53, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:54; (16) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:50, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:55; (17) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:51, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:55; (18) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:52, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:55; (19) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:53, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:55; (20) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:63, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:66; (21) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:64, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:66; (22) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:65, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:66; (23) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:63, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:67; (24) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:64, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:67; or (25) a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:65, and a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:

67.

7. The antibody-drug conjugate, its stereoisomer, its pharmaceutically acceptable salt, or a solvate of the antibody-drug conjugate, its stereoisomer, or its pharmaceutically acceptable salt according to any one of claims 1 to 6, wherein: The anti-Trop-2 antibody or antigen-binding fragment thereof comprises: (1) a heavy chain variable region having an amino acid sequence as shown in SEQ ID NO: 23, and a light chain variable region having an amino acid sequence as shown in SEQ ID NO: 24; (2) a heavy chain variable region having an amino acid sequence as shown in SEQ ID NO: 25, and a light chain variable region having an amino acid sequence as shown in SEQ ID NO: 26; (3) a heavy chain variable region having an amino acid sequence as shown in SEQ ID NO: 27, and a light chain variable region having an amino acid sequence as shown in SEQ ID NO: 28; (4) a heavy chain variable region having an amino acid sequence as shown in SEQ ID NO:36, and a light chain variable region having an amino acid sequence as shown in SEQ ID NO:40; (5) a heavy chain variable region having an amino acid sequence as shown in SEQ ID NO:37, and a light chain variable region having an amino acid sequence as shown in SEQ ID NO:40; (6) a heavy chain variable region having an amino acid sequence as shown in SEQ ID NO:38, and a light chain variable region having an amino acid sequence as shown in SEQ ID NO:40; (7) a heavy chain variable region having an amino acid sequence as shown in SEQ ID NO:39, and a light chain variable region having an amino acid sequence as shown in SEQ ID NO:40; (8) a heavy chain variable region having an amino acid sequence as shown in SEQ ID NO:36, and a light chain variable region having an amino acid sequence as shown in SEQ ID NO:41; (9) a heavy chain variable region having an amino acid sequence as shown in SEQ ID NO:37, and a light chain variable region having an amino acid sequence as shown in SEQ ID NO:41; (10) a heavy chain variable region having an amino acid sequence as shown in SEQ ID NO:38, and a light chain variable region having an amino acid sequence as shown in SEQ ID NO:41; (11) a heavy chain variable region having an amino acid sequence as shown in SEQ ID NO:39, and a light chain variable region having an amino acid sequence as shown in SEQ ID NO:41; (12) a heavy chain variable region having an amino acid sequence as shown in SEQ ID NO:50, and a light chain variable region having an amino acid sequence as shown in SEQ ID NO:54; (13) a heavy chain variable region having an amino acid sequence as shown in SEQ ID NO:51, and a light chain variable region having an amino acid sequence as shown in SEQ ID NO:54; (14) a heavy chain variable region having an amino acid sequence as shown in SEQ ID NO:52, and a light chain variable region having an amino acid sequence as shown in SEQ ID NO:54; (15) a heavy chain variable region having an amino acid sequence as shown in SEQ ID NO:53, and a light chain variable region having an amino acid sequence as shown in SEQ ID NO:54; (16) a heavy chain variable region having an amino acid sequence as shown in SEQ ID NO:50, and a light chain variable region having an amino acid sequence as shown in SEQ ID NO:55; (17) a heavy chain variable region having an amino acid sequence as shown in SEQ ID NO:51, and a light chain variable region having an amino acid sequence as shown in SEQ ID NO:55; (18) a heavy chain variable region having an amino acid sequence as shown in SEQ ID NO:52, and a light chain variable region having an amino acid sequence as shown in SEQ ID NO:55; (19) a heavy chain variable region having an amino acid sequence as shown in SEQ ID NO:53, and a light chain variable region having an amino acid sequence as shown in SEQ ID NO:55; (20) a heavy chain variable region having an amino acid sequence as shown in SEQ ID NO:63, and a light chain variable region having an amino acid sequence as shown in SEQ ID NO:66; (21) a heavy chain variable region having an amino acid sequence as shown in SEQ ID NO:64, and a light chain variable region having an amino acid sequence as shown in SEQ ID NO:66; (22) a heavy chain variable region having an amino acid sequence as shown in SEQ ID NO:65, and a light chain variable region having an amino acid sequence as shown in SEQ ID NO:66; (23) a heavy chain variable region having an amino acid sequence as shown in SEQ ID NO:63, and a light chain variable region having an amino acid sequence as shown in SEQ ID NO:67; (24) the heavy chain variable region of the amino acid sequence shown in SEQ ID NO: 64, and the light chain variable region of the amino acid sequence shown in SEQ ID NO: 67; or (25) a heavy chain variable region having the amino acid sequence shown in SEQ ID NO:65, and a light chain variable region having the amino acid sequence shown in SEQ ID NO:

67.

8. The antibody-drug conjugate, its stereoisomer, its pharmaceutically acceptable salt, or a solvate of the antibody-drug conjugate, its stereoisomer, or its pharmaceutically acceptable salt according to any one of claims 1 to 7, wherein: The anti-Trop-2 antibody is of IgG1, IgG2, IgG3 or IgG4 isotype.

9. The antibody drug conjugate, its stereoisomer, its pharmaceutically acceptable salt, or a solvate of the antibody drug conjugate, its stereoisomer, or its pharmaceutically acceptable salt according to any one of claims 1 to 8, wherein: The anti-Trop-2 antibody further comprises a heavy chain constant region and a light chain constant region, the heavy chain constant region comprising the amino acid sequence shown in SEQ ID NO:29 or an amino acid sequence having 1, 2, 3, 4 or 5 amino acid substitutions, deletions or insertions compared to the amino acid sequence shown in SEQ ID NO:29, and the light chain constant region comprising the amino acid sequence shown in SEQ ID NO:30 or an amino acid sequence having 1, 2, 3, 4 or 5 amino acid substitutions, deletions or insertions compared to the amino acid sequence shown in SEQ ID NO:

30.

10. An antibody-drug conjugate, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a solvate of the antibody-drug conjugate, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, comprising an anti-Trop-2 antibody, wherein: The anti-Trop-2 antibody comprises a heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:70, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:71; and the anti-Trop-2 antibody comprises a HCDR1 of the amino acid sequence of SEQ ID NO:17, a HCDR2 of the amino acid sequence of SEQ ID NO:18, a HCDR3 of the amino acid sequence of SEQ ID NO:19, a LCDR1 of the amino acid sequence of SEQ ID NO:20, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: LCDR2 comprising the amino acid sequence shown in SEQ ID NO:21, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO:22.